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3 Summary 
 
Technology: Infliximab and comparator biologicals such as abatacept, adalimumab, 
certolizumab, etanercept, golimumab, rituximab and tocilizumab. 
 
Conditions: Rheumatoid Arthritis (RA). 
 
Issue: Infliximab is registered to be used in patients with RA. The aim of the Report is to evaluate 
the clinical efficacy and safety of infliximab and comparator biologicals. 
 
Methods: Systematic literature review and analysis as well as meta-analysis of published randomised 
controlled clinical trials (RCT) were performed, all relevant health economics literature were 
identified ad analysed.  
 
Results: 338 potentially relevant citations were retrieved and finally after exclusions 40 original 
RCTs were included in current review. Clinical efficacy of infliximab and comparator biologicals is 
proved by the available RCTs. Biologics show similar clinical efficacy and safety profile with 
respect to ACR20, ACR50 and ACR70. Thirty-six cost-utility studies were identified and 
analysed. Most of the cost-utility analyses were performed in the US (n=8), Northern Europe 
(n=10) and UK (n=6). These countries differ considerably from Central and Eastern European 
countries, thus the transferability of these health economic results to jurisdictions of Central 
and Eastern Europe is rather limited. 
 
Implications for decision making: Scientific evidence suggests that infliximab and comparator 
biologicals can improve the symptoms of the RA in all important outcomes. Safety profile of these 
biologicals are rather similar and tolerable. There is a shortage of cost-utility studies published in 
Central and Eastern European countries, however local data and local study results are more and more 
required in all CEE countries by the funders. More data about budget impact, costs, outcomes and 
cost-utility is crucial in order to have better patient access to modern RA therapy. 
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4 Epidemiology, quality of life and costs in rheumatoid arthritis 
(Péntek M, Gulácsi L) 
 
4.1 Description of the health problem 
 
Rheumatoid arthritis (RA) is a chronic inflammatory arthropaty associated with articular 
damage and comorbidities, particularly in the cardiovascular system, and with increasing 
disability and socioeconomic decline.
74
  
RA is thought to result from a combination of genetic susceptibility and exposure to an 
appropriate environmental trigger. 
RA is more common in women than in men and is characterised, pathologically, by an 
inflammatory reaction and increased cellularity of the lining layer of synovial joints. RA 
causes pain, swelling and stiffness of affected joints, patients commonly experience joint 
destruction and fatigue. Productivity loss and work disability is a major problem in RA even 
today.
107
 
 
The vasculature plays a crucial role in inflammation, angiogenesis, and atherosclerosis 
associated with the pathogenesis of the disease.
112
 As a consequence, patients are at increased 
risks of myocardial infarction and stroke, both accounts for the observed increased mortality 
in individuals with RA.
77, 88, 111
 
RA patients show a wide spectrum both in terms of disease progression and clinical 
manifestations.
82
 Besides the diversity in natural progression of the disease the burden of RA 
appears to correlate substantially with socioeconomic and health care system related factors, 
i.e. GDP and access to treatment in a specific country.
67, 83
 
 
RA related costs are substantial. Healthcare cost is more than €4,000 per patient per year in 
Western European countries, the cost to patients and families is more than €2,000 yearly.17 In 
studies of anti-TNF therapies, the drug costs were higher but the overall costs were lower with 
these agents. Costs related to lost productivity (indirect costs) highly depend on the 
methodological approach used however this can be 50% higher than direct costs even if using 
conservative estimates.
87
 Hidden cost (preseenteism, quality of life loss related costs) are 
often missed in cost-of-illness studies as these are more difficult to measure and evaluate. 
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4.2 Classification criteria 
 
In the past decades the diagnosis of RA relied on the classification system established by the 
American College of Rheumatology (ACR) revised criteria from 1987. The criteria were as 
follows: 1) morning stiffness in and around joints lasting at least 1 hour before maximal 
improvement; 2) soft tissue swelling (arthritis) of 3 or more joint areas observed by a 
physician; 3) swelling (arthritis) of the proximal interphalangeal, metacarpophalangeal, or 
wrist joints; 4) symmetric swelling (arthritis); 5) rheumatoid nodules; 6) the presence of 
rheumatoid factor; and 7) radiographic erosions and/or periarticular osteopenia in hand and/or 
wrist joints. Criteria 1 through 4 must have been present for at least 6 weeks. Rheumatoid 
arthritis is defined by the presence of 4 or more criteria
i
, and no further qualifications (classic, 
definite, or probable) or list of exclusions are required.
8
 
 
The importance of early diagnosis and early aggressive treatment of RA became evident in 
the past years.
91
 Therefore, the 1987 ACR criteria have been criticized, because they are not 
equipped to diagnose early RA. The American College of Rheumatology (ACR)/European 
League Against Rheumatism (EULAR) collaboration developed new classification criteria for 
RA. It aims to arrive at homogeneous groups of patients in order to compare the results of 
clinical or experimental studies including early RA cases. 
 
In the new criteria set, classification as "definite RA" is based on the confirmed presence of 
synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the 
synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the 
individual scores in 4 domains: number and site of involved joints (score range 0-5), serologic 
abnormality (score range 0-3), elevated acute-phase response (score range 0-1), and symptom 
duration (2 levels; range 0-1).
4
 Nevertheless, it has been repeatedly shown that the sensitivity 
of the 2010 criteria increased compared with the 1987 criteria, but the specificity decreased.
118
 
 
                                                 
i
 These particular criteria are appropriate for established disease, and are not sensitive to early disease. 
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4.3 Epidemiology 
 
The occurrence of RA varies among countries and areas of the world. The median prevalence 
estimate for the total population in south European countries is 3.3 (range 3.1 to 5.0) cases per 
10
3
, for north European countries 5.0 (range 4.4 to 8.0). The median annual incidence for the 
total population observed in south European countries is 16.5 (range 9 to 24) cases per 10
5
. 
For north European countries the median annual incidence observed was 29 (range 24 to 36).
2
 
The prevalence of RA among individuals aged 14-65 years was 0.37% in Hungary according 
to a population based survey.
53
 In the Czech Republic (2002-2003) the prevalence of RA was 
610/100,000 (95% CI 561 to 658/100,000) and the total annual incidence of RA was 
31/100,000 in the adult population aged 16 years and more (95% CI 20 to 42/100,000).
43
 
 
 
4.4 Health status assessment in RA 
 
Disease activity, functional disability and radiographic damage are the most studied outcomes 
in RA. 
 
4.4.1 Disease activity 
 
Several validated measures are available to assess disease activity on RA in clinical practice 
(Clinical Disease Activity Index, Disease Activity Score with 28-joint counts (DAS28), 
Patient Activity Scale (PAS), PAS-II, Routine Assessment of Patient Index Data with 3 
measures, and Simplified Disease Activity Index).
7
  
 
The DAS28 is a combined index which probably the most widely used and has been 
extensively validated for its use in clinical trials. The DAS28 uses either the erythrocyte 
sedimentation rate or the C-reactive protein, tender and swollen joint count of 28 joints (arms, 
hands and knees) and a patient reported global assessment on a visual analogue scale (VAS). 
(http://www.das-score.nl/)  
 
The DAS28 can be used to assess whether an individual patient has a significant improvement 
of the disease activity, compared to baseline. It is also possible to choose a baseline 
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independent absolute level of disease activity as goal for your therapeutic intervention. A 
DAS28 value of 5.1 (high disease activity) 3.2 (low disease activity) or even 2.6 (remission) 
are often selected as threshold. The DAS28 plays also crucial role in the assessment of 
remission.
38
 
 
4.4.2 Functional and health status 
 
4.4.2.1 Health Assessment Questionnaire (HAQ) 
 
The Health Assessment Questionnaire (HAQ) is a valuable, effective, and sensitive tool for 
measurement of functional status in RA. It is available in more than 60 languages and is 
supported by a bibliography of more than 500 references.
26
 It was developed in 1978 by 
James F. Fries, MD, and colleagues at Stanford University and it was one of the first self-
report functional status (disability) measures. HAQ has become the dominant instrument in 
RA.  
 
The disability assessment component of the HAQ, the HAQ-DI, assesses a patient's level of 
functional ability and includes questions of fine movements of the upper extremity, locomotor 
activities of the lower extremity, and activities that involve both upper and lower extremities. 
There are 20 questions in eight categories of functioning which represent a comprehensive set 
of functional activities – dressing, rising, eating, walking, hygiene, reach, grip, and usual 
activities. The stem of each item asks over the past week "Are you able to …" perform a 
particular task. The patient's responses are made on a scale from zero (no disability) to three 
(completely disabled). The HAQ-DI score range is between 0-3, the higher score reflects a 
worse status. HAQ-DI correlates with disease duration and also with disease progression 
especially in later stages of the disease.  
 
4.4.2.2 EQ-5D 
 
EQ-5D is a standardised instrument for use as a measure of health outcome which was 
introduced in 1990. Applicable to a wide range of health conditions and treatments, it 
provides a simple descriptive profile and a single index value for health status 
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(http://www.euroqol.org). The EQ-5D consists of 2 pages - the EQ-5D descriptive system and 
the EQ visual analogue scale (EQ VAS). The EQ-5D descriptive system comprises the 
following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme 
problem. (A new version has been launched recently with 5 levels.) An EQ-5D health state 
may be converted to a single summary index by applying a formula that essentially attaches 
weights to each of the levels in each dimension. This formula is based on the valuation of EQ-
5D health states from general population samples thus EQ-5D index reflects the utility of a 
health status from the societal point of view. The EQ-5D index ranges between (-0.594) – 1.0, 
the higher the score, the better the health state is. The EQ-5D is one of the most extensively 
studied instruments and shows validity and responsiveness for use in RA.
44
 
 
4.4.2.3 HAQ and EQ-5D in economic evaluations 
 
Several studies in various countries confirmed that HAQ correlates not only with disease 
progression but also with disease related costs in RA.
36, 87
 Furthermore, a strong relationship 
has been proved between HAQ and EQ-5D.
65
 Therefore, HAQ has an outlying importance in 
health economic evaluations. HAQ has been widely used in RA health economic studies to 
model disease progression, related costs and utilities.
54
 
 
4.4.3 Radiologic measures 
 
Joint damage visualized on radiographs is still the hallmark of RA although there is a growing 
interest in the use of new imaging techniques (ultrasound, magnetic resonance - MR).
117
 
Several studies, in pure undifferentiated arthritis and mixed populations, clearly demonstrate 
that conventional radiographs are helpful in predicting future diagnosis of RA or worse 
prognosis. However, absence of abnormalities on conventional radiographs does not 
sufficiently exclude RA or other unfavourable outcome.
60
  
Because of the importance of radiographic progression in determining long term outcomes, a 
standardised, systematic method to evaluate and quantify the amount and progression of 
radiographic damage caused by RA is desirable. The scoring systems that have been designed 
to evaluate radiographic changes in RA can be divided into two main groups, global and 
detailed. The most widely used detailed scoring system is the modified Sharp method and its 
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variations, and the most widely used global scoring system is the Scott modification of the 
Larsen score.
84
 
 
4.5 Assessment of treatment response in RA – the ACR response criteria 
 
The ACR developed a core set for of disease activity measures for RA clinical trials. The core 
set consists of a tender joint count, swollen joint count, patient's assessment of pain, patient's 
and physician's global assessments of disease activity, patient's assessment of physical 
function (HAQ), and laboratory evaluation of 1 acute-phase reactant.
37
 ACR criteria are 
indicated as ACR20, ACR50, and ACR70 reflecting 20%, 50%, or 70% relative improvement 
compared to baseline. Clinical trials report the percentage of study participants who achieve 
ACR20, ACR50, and ACR70. 
More recently, the EULAR/ACR collaboration developed recommendations on how to report 
disease activity in clinical trials of RA. The recommendation include the following criteria: 1) 
disease activity response and disease activity states; 2) appropriate descriptive statistics of the 
baseline, the endpoints and change of the single variables included in the core set; 3) baseline 
disease activity levels (in general); 4) the percentage of patients achieving a low disease 
activity state and remission; 5) time to onset of the primary outcome; 6) sustainability of the 
primary outcome; 7) fatigue.
3
 
 
4.6 Treatment goal in RA 
 
The therapeutic goal in RA should be remission which can be defined in general ‘the state of 
absence of disease activity in patients with a chronic illness, with the possibility of return of 
disease activity’ (the treat-to-target concept). Remission is associated with less radiological 
progression and better functional outcome.
105
 
 
4.7 Drug treatment of RA 
 
Drug treatment of RA comprises three main modalities: disease-modifying antirheumatic 
drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids 
(GCs). A significant proportion of RA patients can attain a state of very low disease activity 
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or remission with traditional DMARDs (also called conventional and/or synthetic DMARDs) 
such as methotrexate (MTX) and leflunomide (LEF), especially if applied in early stage of the 
disease.  
New and highly effective DMARDs have continued to emerge, in particular, biological agents 
(also called biological DMARDs or Biological Response Modifier Drugs – BRMD) which 
target tumour necrosis factor, the interleukin 1 (IL-1) receptor, the IL-6 receptor, B 
lymphocytes and T-cell co-stimulation. Currently eight biological drugs are registered by the 
European Medicines Agency (EMA) for the treatment of RA: abatacept, adalimumab, 
certolizumab pegol, etanercept, golimumab, infliximab, tocilizumab and rituximab (anakinra 
is registered but available only in few countries, http://www.ema.europa.eu/ema/) 
Randomized controlled trials (RCTs) have demonstrated the efficacy of biologic agents in 
treatment of RA. In the past decade various observational cohorts and registries have been 
created to analyse the effectiveness and safety of biological drugs. Well-designed registries 
can offer important complementary information to RCTs from real world experience not only 
in terms of effects and side-effects but also about persistence and costs which are crucial for 
health economic evaluations.
29
 
Treatment strategies have also changed in the past years. Early referral, early institution of 
DMARD treatment, the treat-to-target concept, tight control using composite measures of 
disease activity and appropriate switching of drug treatment have been proved to be highly 
efficacious approaches.
105
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5 Clinical efficacy and safety of biological medications of rheumatoid 
arthritis (Baji P, Balogh O, Brodszky V) 
 
Summary 
Our systematic review – based on fourty randomized controlled trials – showed similar 
clinical efficacy and safety profile of biologics. All biologics demonstrated statistically 
significant improvements compared to placebo with respect to ACR20, ACR50 and ACR70 
improvements. Among RA patients who took infliximab, etanercept, adalimumab, abatacept, 
golimumab or rituximab there was no statistically significant difference in ‘any adverse 
events’, ‘serious adverse events’ and ‘serious infections’ compared to those who received 
placebo. All three safety endpoints were experienced significantly more frequently with 
certolizumab compared to placebo and ‘any adverse events’ was experienced significantly 
more frequently with tocilizumab. 
 
5.1 Objectives 
 
The main aims of this systematic review were: 
1. to identify all relevant literature on clinical efficacy and safety evidence for infliximab 
and comparator biological medications
i
 for rheumatoid arthritis 
2. to conduct an up-to-date meta-analysis on clinical efficacy and safety outcomes, and 
3. to generate an overview of recently published systematic reviews. 
 
Methods used in this analysis were fully corresponding to NICE Decision Support Unit’s 
recommendations
33
 about the evidence synthesis and to Cochrane Handbook’s45 
recommendations. 
 
                                                 
i
 In this report the following terminology are used interchangeably as synonyms: biologic response 
modifiers, biological, biological medications, biologics, biologic, biologic agent 
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5.2 Methods 
 
5.2.1 Comparators 
 
The following comparators were considered for this analysis: abatacept, adalimumab, 
certolizumab, etanercept, golimumab, infliximab, rituximab and tocilizumab.  
The analysis compares each biological DMARD at licensed dose with placebo both combined 
with conventional DMARD using follow-up data available at the end of the randomized, 
double-blind controlled period of the trial. The doses included in the analysis are as follows:  
1. Abatacept: 10mg/kg at days 1, 15 and 30 and monthly thereafter, or by patient groups 
based on patient weight < 60kg, 500 mg; 60 – 100kg, 750 mg; > 100kg, 1000mg.  
2. Adalimumab: 40 mg every other week 
3. Certolizumab: 400 mg at 0, 2, 4 weeks and then 200 mg at every 2 weeks 
4. Etanercept: 25 mg twice weekly, 50 mg once weekly 
5. Golimumab: 50 mg once a month 
6. Infliximab: 3 mg/kg at 0, 2, 6 weeks and then every 4 or 8 weeks, 6 mg/kg at 0, 2, 6 
weeks and then every 8 weeks 
7. Rituximab: 1000 mg on days 1 and 15 
8. Tocilizumab: 8 mg/kg once every 4 weeks 
 
 
5.2.2 Search strategies 
 
Electronic databases (Medline and Cochrane Library) as well as references of retrieved 
articles were searched. The search was not restricted by publication date. The Cochrane 
Highly Sensitive Search Strategy
45
 was applied to identify randomized controlled publications 
and was combined with ‘arthritis, rheumatoid’ Medical Subject Headings (MeSH) terms and 
drug names. Meta-analyses were identified by applying the relevant publication type limit. 
Exact search terms are presented in Appendix 8.1. The search dates were November 1st 2009 
to March 31st 2012. References of RCTs from earlier time period were taken from our 
previous systematic review
19
. 
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5.2.3 Inclusion and exclusion criteria 
 
5.2.3.1 Inclusion criteria 
 
 Randomized controlled clinical trials (RCT) where the full paper can be obtained 
(studies with only abstracts available were excluded) 
 Patients in at least one arm of the trial must receive one of the following treatments: 
abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab 
and tocilizumab 
 Head-to-head trials will also be included.  
 The patients of interest are adults with moderate-to-severe RA. 
 
5.2.3.2 Exclusion criteria 
 
 Nonrandomized or uncontrolled studies, observational studies, case series, letters to 
editor, studies with no abstracts or with conference abstracts only. 
 Trials in diseases other than rheumatoid arthritis. 
 Studies reporting solely on laboratory measures aimed at investigating disease, or 
treatment mechanisms and which do not report relevant clinical outcomes. 
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5.2.4 Data abstraction 
 
Data was extracted and analysed by two independent persons and checked by a third reviewer. 
Any disagreement was resolved through discussion until consensus was reached. Data on the 
following outcome measures were included: 
 
Trial characteristics 
 Trial/Reference 
 Population (description) 
 Mean age (years) 
 Mean disease duration (years) 
 Mean baseline HAQ score (0 to 3) 
 Mean baseline DAS28 (scale 0-10) 
 Swollen joint count 
 Tender joint count 
 Trial Duration (weeks) 
 Treatment 
 Comparator 
 Rescue therapy 
 
Clinical Efficacy Measures 
 ACR20 (n) 
 ACR50 (n) 
 ACR70 (n) 
Tolerability Measures 
 Withdrawals due to adverse events (n) 
 Withdrawals for any reason (n) 
Safety Measures 
 Serious adverse events (n) 
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 Serious infection (n) 
 Any infection (n) 
 
5.2.5 Quality assessment 
 
The quality of selected studies was measured using the Jadad-score.
46
 This score is the most 
frequently used scale in quality assessment of clinical trials.
81
 The Jadad scale assesses the 
quality of published clinical trials based methods relevant to random assignment, double 
blinding, and the withdrawals and dropout of patients. Jadad score ranges from zero to five. 
Detailed description of scoring can be found in Appendices (Appendix 8.3). 
 
5.2.6 Comparisons 
 
Combining RA trials in a meta-analysis is quite a challenging task. Patient population 
(previous conventional DMARD history of patients) and administration might differ across 
trials. There are trials including MTX naïve patients, patients with prior inadequate response 
to conventional DMARD or patients with prior inadequate response to biologics. Besides, in 
some trials biologics are used as monotherapy, in other trials they are used in combination 
with regular DMARD.  
 
Infliximab can be administered only in combination with MTX, therefore only combination 
therapies were compared in this systematic review.  
 
Two comparisons were done. Firstly, we applied rigorous inclusion criteria and trials 
comprising patients with prior inadequate response to conventional DMARD were included. 
Secondly, we applied less rigorous inclusion criteria and trials regardless of patients’ 
DMARD history were included.  
 
5.2.7 Meta-analysis 
 
We have conducted a meta-analysis to compare the efficacy and safety of included 
biologicals. Two specific analyses were performed for this meta-analysis:  
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1. direct comparison: a frequentist meta-analysis of study outcomes 
2. a mixed treatment comparisons: combining direct and indirect evidence 
 
5.2.7.1 Direct comparison 
 
Data were analysed using Review Manager 5 software. The Relative Risk (RR), Rate 
difference (RD) and appropriate 95% CI were derived for each study according to the number 
of events reported in the original studies. Intention-to-treat analysis was conducted. The 
denominators were the total number of patients randomized; missing values were considered 
treatment failures. The pooled RR and RD and 95% CI were calculated using a fixed effect 
model since no significant heterogeneity was detected. The chi-square test for heterogeneity 
was computed with a P-value set to 0.10 to determine statistical significance. In case of 
significant heterogeneity random effect model was applied. 
 
5.2.7.2 Mixed treatment comparison 
 
Traditional methods of meta-analysis do not permit indirect comparisons between drugs 
because they only allow us to pool studies with the same comparators. For our second 
analysis, we examined the relative effectiveness of each individual treatment using the Lu’s 
method for combining direct and indirect evidence in mixed treatment comparisons, a 
Bayesian approach. Statistical models developed by NICE Decision Support Unit (DSU) were 
used. We estimated the posterior densities for all unknown parameters using MCMC (Markov 
chain Monte Carlo) for each model in WinBUGS version 1.4.3. Each outcome measure was 
analysed using random effects models, which allowed for studies with 3 or more arms. 
All MTC models used the odds ratio as the measure of relative treatment effect and assumed 
that treatment effects on the odds-ratio scale were multiplicative and exchangeable between 
trials. 
 
Differences between treatments were considered significant at the 0.05 level if the 95% 
confidence interval around the odds ratio did not cross 1. 
 
Detailed description of methods and WinBUGS codes are provided in Appendix 8.4. 
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5.2.7.3 Presentation of results 
 
We give a detailed description of the infliximab trials identified in the literature and also 
about the quality assessment of each trial. Outcomes of all published infliximab RCT trials 
will be analysed and combined in one meta-analysis – in this way the key parameters of the 
“statistical infliximab trial” will be provided. Detailed descriptions of biologics’ trials appear 
in Appendices. Results of the classical meta-analysis will then be summarized. In Appendices, 
the detailed results from classical meta-analysis will be presented as forest plots diagrams. 
The Bayesian mixed treatment comparison will be introduced separately since it includes 
indirect comparisons of biologics. Results will be presented by outcome (e.g., ACR20, 
ACR50, ACR70, serious adverse effect etc.). 
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5.3 Results: meta-analysis of randomized controlled trials 
 
5.3.1 Included studies 
 
The search in MEDLINE (01.11.2009-31.03.2012) yielded 338 potential citations for 
randomized controlled trials examining the biological treatment of rheumatoid arthritis. 
Eighteen RCT reports in rheumatoid arthritis were amongst them from which 12 trials were 
excluded because they did not meet our inclusion criteria (See Figure 1). In addition, thirty-
four references of trials were taken from our previous systematic review.
19
 Altogether 40 
RCTs were included. The number of trials in given comparisons might be different because of 
the specific inclusion criteria for each comparison and the distinct endpoints reporting across 
trials. Detailed descriptions of included studies are provided in Appendices. 
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Figure 1 Quorum chart for identification of studies in the systematic review 
 
 
*Detailed explanation for exclusion: 
Abatacept: Schiff 2009 ARRIVE
97
 – excluded because of open label design; Westhovens 
2009
124
 - included; Kaine 2012
49
 - excluded because of sub cutaneous administration. 
Adalimumab: van Vollenhoven 2012
120
 - excluded because of open label design; Soubrier 
2009 GEUPARD
108
 excluded because of open label design. 
Etanercept: Kameda 2010
51
 – excluded, etanercept in each arm; Kameda 201150 – excluded, 
etanercept in each arm; Golimumab: Kremer 2010
62
 - included; Østergaard 201185 - excluded, 
no ACR and safety endpoints. 
Infliximab: Takeuchi 2011
114
 – excluded, infliximab in each arms; Gao 201039 – excluded, 
Chinese language.  
Rituximab: Emery 2010
35
 - included; Mease 2010
75
 – excluded, rituximab retreatment; Rigby 
2011
92
 – excluded, ACR and safety outcomes not reported; Rubbert-Roth 201093 – excluded, 
rituximab in each arms; Tak 2011
113
 – included.  
Tocilizumab: Yacizi 2012
129
 - included; Jones 2010
48
 – included. 
  
338 potentially relevant citations 
retrieved 
18 articles remaining for more 
detailed evaluation 
320 irrelevant citations were excluded 
from the study (reviews, studies with 
different diseases, nonrandomized trials) 
40 original RCTs were included in 
current review 
12 articles were excluded*: 
-open label (n=3) 
-off-label administration (n = 1) 
-same biologic in each arms (n=4) 
-article published in Chinese (n=1) 
-ACR and safety outcomes not reported 
(n=2) 
-retreatment (n=1) 
34 articles were taken from our previous 
review 
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5.3.2 Description of infliximab studies 
 
Four RCTs with infliximab encompassing at total of 2,992 patients were included in this 
review. The following published papers reported originally these RCTs: Maini 1999 
ATTRACT study
68
, Clair 2004 ASPIRE study
110
, Westhovens 2006 START study
125
 and 
Schiff 2008 ATTEST study
96
. A list of these trials, including comparators, endpoints and 
baseline patient characteristics are shown in Table 1. Detailed description of infliximab 
studies are presented in Appendix 8.5. In this section, we will give a short description about 
study characteristics. 
 
5.3.2.1 Maini 1999 – ATTRACT study 
 
ATTRACT trial
68
 was a 30-week, double-blind, multicentre, placebo-controlled RCT that 
evaluated the effects of infliximab in patients with persistent, active RA despite MTX. Four 
hundred twenty-eight patients were randomized to receive 3 mg/kg/every 4 weeks or 3 
mg/kg/every 8 weeks or 10 mg/kg/every 4 weeks or 10 mg/kg/every 8 weeks infliximab or 
placebo. All patients received their baseline dose of MTX. Prior to enrolment, patients were 
required to have ≥ 6 swollen and tender joints, and CRP ≥ 2 mg/dL. Patients were required to 
have been treated for MTX for at least 3 months with a stable dose of 12.5 mg/week or more, 
for at least four weeks before screening. The primary endpoint was ACR20 at 30 weeks. 
 
5.3.2.2 Claire 2004 – ASPIRE study 
 
ASPIRE trial
110
 was a 54 week randomized, placebo controlled study. The analysis compared 
the benefits of treatment with MTX and infliximab or treatment with methotrexate alone in 
patients with rheumatoid arthritis. One thousand forty-nine patients were randomized to 
receive MTX–placebo or MTX–3 mg/kg infliximab or MTX–6 mg/kg infliximab. Patients 
were excluded if they had any prior treatment with MTX or other DMARDs within 4 weeks 
of entry or had been treated with infliximab, etanercept, adalimumab or other anti-TNF agent
i
. 
Prior to enrolment, patients were required to have 10 swollen and 12 tender joints and CRP 
                                                 
i
 In this report the following terminology are used interchangeably as synonyms: anti-TNFalpha 
therapy; anti-TNF agent, TNF-blockers; TNF-α blockers 
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2.0 mg/dL. The primary endpoint was the percentage of ACR improvement (ACR-N) from 
baseline to week 54. 
 
5.3.2.3 Westhovens 2006 – START study 
 
START study
125
 was a 22 week randomized, placebo-controlled trial that assessed the risk of 
serious infections of infliximab therapy. One thousand eighty-four patients were randomly 
assigned to receive placebo or 3mg/kg infliximab or 10mg/kg infliximab at weeks 0, 2, 6, 14. 
All patients had to be received MTX for at least 3 months prior to randomization and had to 
have active disease in spite of receiving it. The MTX dose must have been stable for at least 4 
weeks prior to randomization. Prior to enrolment patients had to have 6 swollen and 6 tender 
joints. The primary endpoint was the occurrence of serious infections through week 22. 
 
5.3.2.4 Schiff 2008 – ATTEST study 
 
ATTEST trial
96
 was a 52 week phase III, randomised, double-blind, double-dummy, placebo- 
and active (infliximab) controlled multi-centre study that evaluated the efficacy and safety of 
abatacept or infliximab vs. placebo. Four hundred thirty-one patients were randomised to 
abatacept 10 mg/kg every 4 weeks or infliximab 3 mg/kg every 8 weeks or placebo every 4 
weeks and background MTX. Patients were required to have ≥ 10 swollen and ≥ 12 tender 
joints and CRP ≥ 1 mg/dL. Patients had to have RA for at least 1 year and had to have an 
inadequate response to MTX. The primary endpoint was to evaluate a reduction in disease 
activity, measured by Disease Activity Score 28 with abatacept vs. placebo at 6 months. 
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Table 1 Characteristics of infliximab RCTs 
Author – 
Study name 
Study 
duration 
(weeks) 
Patients 
included* 
Treatments Number 
of patient 
Mean 
age 
Disease 
duration 
Baselin
e HAQ 
Endpoints 
Maini 1999 - 
ATTRACT 
30 DMARD 
IR 
INF 3 mg/kg/every 8 weeks+MTX 
INF 3 mg/kg/every 4 weeks+MTX 
INF10mg/kg/every 8 weeks+MTX 
INF10 mg/kg/every 4 weeks+MTX 
placebo + MTX 
86 
86 
87 
81 
88 
56 
51 
55 
52 
51 
8.4 
7.2 
9 
8.7 
8.9 
1.8 
1.8 
1.8 
1.5 
1.8 
ACR20, ACR 50, ACR70,  
Clair 2004 - 
ASPIRE 
54 MTX 
naïve 
INF 3mg/kg + MTX 0, 2, and 6, and every 8 
weeks thereafter through week 46 
INF 6mg/kg + MTX 0, 2, and 6, and every 8 
weeks thereafter through week 46 
placebo + MTX 0, 2, and 6, and every 8 
weeks thereafter through week 46 
373 
 
378 
 
298 
51 
 
50 
 
50 
0.8 
 
0.9 
 
0.9 
1.5 
 
1.5 
 
1.5 
ACR-N, change in total Sharp score, 
HAQ 
Westhovens 
2006 - 
START 
22 DMARD 
IR 
INF 3 mg/kg+ MTX at weeks 0, 2, 6, and 14 
INF 10mg/kg + MTX at weeks 0, 2, 6, and 
14 
placebo + MTX at weeks 0, 2, 6, and 14 
360 
361 
363 
53 
52 
52 
7.8 
6.3 
8.4 
1.5 
1.5 
1.5 
occurrence of serious infections, 
ACR20, ACR50, ACR70, DAS28 
Schiff 2008 - 
ATTEST 
52 DMARD 
IR 
ABATACEPT 10mg/kg + MTX 
INF 3mg/kg every 8 weeks + MTX 
placebo + MTX 
156 
165 
110 
49 
49.1 
49.4 
7.9 
7.3 
8.4 
1.8 
1.7 
1.8 
DAS28 with abatacept vs. placebo, 
DAS28 with inf. vs. placebo; DAS28 
with abatacept vs. inf.; EULAR; 6 low 
disease activity score, HAQ-DI; 
response rates and mean changes in the 
physical and mental component 
summary scores; and eight subscales of 
the SF-36 
DMARD IR: inadequate response to DMARD; MTX=methotrexate 
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5.3.2.5 Results from infliximab studies 
 
5.3.2.5.1 Efficacy 
 
There was a significant difference at 24 weeks in favour of the infliximab group compared to 
the placebo group with respect to the ACR20, ACR50 and ACR70 response (See Figure 2, 
Figure 3 and Figure 4). The NNTs were 5 (3-10), 5 (4-7) and 10 (8-14) treated patients to 
achieve one ACR20, ACR50 and ACR70 response, respectively.  
 
Figure 2 Efficacy of infliximab 3 mg/kg on ACR20 response at six month 
 
Figure 3 Efficacy of infliximab 3 mg/kg on ACR50 response at six month 
 
Figure 4 Efficacy of infliximab 3 mg/kg on ACR70 response at six month 
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5.3.2.5.2 Tolerability and safety of infliximab treatment 
 
There were no significant differences between infliximab and placebo groups with respect to 
withdrawals due to any reason (Figure 5). There was a significant difference between the two 
groups with respect to withdrawal due to any adverse events (RR 2.16, 95% CI: 1.18-3.95) in 
favour of placebo treated patients (Figure 6). There were no significant differences between 
infliximab and placebo treatment with respect to any AE, serious AE and serious infections 
(See Figure 7, Figure 8 and Figure 9). 
The NNH (number needed to harm) was 25 (17-50) treated patients to cause one withdrawal 
due to adverse events. Similarly, NNHs were 50 (17-∞), 100 (33--∞) and 100 (33--∞) patients 
to cause one AE, serious AE and serious infection, respectively. There were no significant 
differences for safety endpoint of NNH between infliximab and placebo groups. 
 
Figure 5 Tolerability of infliximab 3 mg/kg, withdrawal due to any reason at six month 
 
 
Figure 6 Tolerability of infliximab 3 mg/kg, withdrawal due to adverse events at six 
month 
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Figure 7 Safety of infliximab 3 mg/kg, any adverse events at six month 
 
 
Figure 8 Safety of infliximab 3 mg/kg, serious adverse events at six month 
 
 
Figure 9 Safety of infliximab 3 mg/kg, serious infections at six month 
 
 
 
5.3.3 Classical meta-analysis: efficacy and safety of combination therapy 
 
In total of 31 RCTs were included in current meta-analysis of combination therapy. However, 
the number of trials in given comparisons might be different because of the special inclusion 
criteria for a given comparison. 
 
In this section we will present three comparisons with different inclusion criteria and patient 
population: 
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1. Biologic + conventional DMARD vs. placebo + conventional DMARD and no 
restriction on population: In this comparison efficacy endpoints from studies with 
prior inadequate response to DMARD population, prior inadequate response to 
biologics population and DMARD naïve population were combined. 
2. Biologic + conventional DMARD vs. placebo + conventional DMARD and no 
restriction on population: In this comparison efficacy endpoints from studies merely 
with prior inadequate response to DMARD population were combined. 
3. Safety and tolerability endpoints: In this comparison safety and tolerability endpoints 
from studies with prior inadequate response to conventional DMARD population, 
prior inadequate response to biologics population and DMARD naïve population were 
combined. 
 
5.3.3.1 Biologic + DMARD vs. placebo + DMARD and no restriction on previous 
treatment 
 
Thirty-one trials were included in this comparison. Among the 9 excluded trials, only 
monotherapy was used in 8 trials and efficacy endpoints were not reported in 1 trial. 
 
Each biologic showed significantly more favourable effect than placebo with respect to any 
ACR response (Table 2). 
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Table 2 Efficacy of label dose of biologics in combination with conventional DMARD; no 
restriction on previous treatments 
Outcome Stu-
dies 
Partici-
pants 
RR (random 
effect, 95% CI) 
NNT (random 
effect, 95% CI) 
ACR20 30* 12716 1.93 [1.68, 2.21] 4 [3, 5] 
abatacept 10mg/kg 4 1543 1.79 [1.51, 2.11] 4 [3, 4] 
adalimumab 40 mg eow. 5 1825 1.82 [1.29, 2.55] 4 [3, 7] 
certolizumab 200mg eow. 2 965 5.04 [3.38, 7.52] 2 [2, 2] 
etanercept 2x25 mg ew. 3 1090 1.32 [1.06, 1.66] 5 [3, 13] 
golimumab 50mg em. 4 1107 1.65 [1.23, 2.21] 6 [4, 10] 
infliximab 3 mg/kg e 8w 4 1843 1.71 [1.16, 2.51] 5 [3, 10] 
rituximab 2x1000mg 5 1763 1.85 [1.25, 2.73] 4 [3, 7] 
tocilizumab 8mg/mg 4 2580 2.45 [1.80, 3.34] 3 [2, 4] 
ACR50 31 13225 2.67 [2.23, 3.20] 5 [4, 5] 
abatacept 10mg/kg 5 2052 2.31 [1.51, 3.54] 5 [4, 6] 
adalimumab 40 mg eow. 5 1825 2.94 [1.59, 5.43] 4 [3, 6] 
certolizumab 200mg eow. 2 965 6.32 [3.15, 12.66] 3 [3, 4] 
etanercept 2x25 mg ew. 3 1090 1.50 [1.19, 1.90] 4 [3, 7] 
golimumab 50mg em. 4 1107 2.14 [1.35, 3.38] 8 [5, 13] 
infliximab 3 mg/kg e 8w 4 1843 2.39 [1.39, 4.09] 5 [4, 7] 
rituximab 2x1000mg 5 1763 2.62 [1.56, 4.39] 5 [4, 7] 
tocilizumab 8mg 4 2580 3.97 [2.90, 5.45] 4 [3, 5] 
ACR70 31 13225 3.27 [2.62, 4.09] 8 [7, 8] 
abatacept 10mg/kg 5 2052 2.90 [1.61, 5.23] 8 [7, 11] 
adalimumab 40 mg eow 5 1825 3.76 [1.77, 7.99] 6 [5, 8] 
certolizumab 200mg eow 2 965 8.24 [3.89, 17.44] 6 [5, 8] 
etanercept 2x25 mg ew 3 1090 1.98 [1.50, 2.61] 5 [4, 7] 
golimumab 50mg em 4 1107 2.36 [1.39, 4.00] 13 [8, 33] 
infliximab 3 mg/kg e 8w 4 1843 2.35 [1.41, 3.93] 10 [8, 14] 
rituximab 2x1000mg 5 1763 2.82 [1.61, 4.92] 8 [6, 17] 
tocilizumab 8mg 4 2580 8.44 [5.52, 12.91] 6 [5, 8] 
*One trial (Westhovens 2009): ACR20 endpoint not reported eow=every other week, 
ew=every week, em=every month 
 
  
25 
Clinical efficacy and safety of biological medications of rheumatoid arthritis (Baji P, 
Balogh O, Brodszky V) 
5.3.3.2 Biologic + DMARD vs. placebo + DMARD and prior inadequate response to 
conventional DMARD 
 
Twenty-one trials were included in this comparison. Among the 19 excluded trials, only 
monotherapy was used in 8 trials, efficacy endpoints were not reported in 1 trial, MTX naïve 
population were enrolled in 6 trials, patients with prior inadequate response to biologics were 
enrolled in 4 trials. 
 
Each biologic showed significantly more favourable effect than placebo with respect to any 
ACR response in patients with inadequate response to previous conventional DMARD 
therapy (Table 3). Biologics were associated with a number needed to treat of 3 to 5 patients 
for ACR20 improvement. NNTs for ACR50 and ACR70 were between 3-6 and 6-13, 
respectively. 
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Table 3 Efficacy of label dose of biologics in combination with conventional DMARD; 
patient with previous inadequate response to conventional DMARD  
Outcome Studies Parti-
cipants 
RR (random 
effect, 95% CI) 
NNT (random 
effect, 95% CI) 
ACR20 20 8168 2.07 [1.82, 2.36] 3 [3, 4] 
abatacept 10mg/kg 3 1152 1.68 [1.47, 1.90] 4 [3, 5] 
adalimumab 40 mg eow. 4 1300 2.05 [1.46, 2.87] 3 [2, 6] 
certolizumab 200mg eow. 2 965 5.04 [3.38, 7.52] 2 [2, 2] 
etanercept 2x25 mg ew. 1 89 2.67 [1.44, 4.94] 2 [2, 4] 
golimumab 50mg em. 2 480 1.82 [1.28, 2.57] 5 [2, 33] 
infliximab 3 mg/kg e 8w 3 1172 1.95 [1.36, 2.80] 4 [3, 6] 
rituximab 2x1000mg 3 765 1.87 [1.49, 2.34] 4 [3, 10] 
tocilizumab 8mg/mg 3 2245 2.11 [1.69, 2.62] 3 [3, 5] 
ACR50 21 8677 3.05 [2.43, 3.83] 4 [4, 5] 
abatacept 10mg/kg 4 1661 2.04 [1.37, 3.03] 5 [4, 6] 
adalimumab 40 mg eow. 4 1300 3.49 [2.40, 5.08] 3 [2, 6] 
certolizumab 200mg eow. 2 965 6.32 [3.15, 12.66] 3 [3, 4] 
etanercept 2x25 mg ew. 1 89 11.69 [1.66, 82.47] 3 [2, 5] 
golimumab 50mg em. 2 480 2.43 [1.63, 3.63] 6 [3, 50] 
infliximab 3 mg/kg e 8w 3 1172 2.92 [1.69, 5.05] 5 [4, 6] 
rituximab 2x1000mg 3 765 2.50 [1.77, 3.54] 6 [4, 13] 
tocilizumab 8mg 3 2245 3.67 [2.78, 4.84] 4 [3, 5] 
ACR70 21 8677 4.19 [2.99, 5.85] 8 [6, 9] 
abatacept 10mg/kg 4 1661 2.57 [1.44, 4.59] 7 [6, 10] 
adalimumab 40 mg eow 4 1300 4.91 [3.18, 7.58] 7 [5, 10] 
certolizumab 200mg eow 2 965 8.24 [3.89, 17.44] 6 [5, 8] 
etanercept 2x25 mg ew 1 89 9.82 [0.59, 163.15] 7 [4, 20] 
golimumab 50mg em 2 480 3.09 [1.57, 6.09] 11 [5, 0] 
infliximab 3 mg/kg e 8w 3 1172 2.97 [1.97, 4.50] 10 [8, 17] 
rituximab 2x1000mg 3 765 2.57 [1.50, 4.41] 13 [8, 33] 
tocilizumab 8mg 3 2245 8.30 [5.32, 12.95] 6 [5, 7] 
ew=every week, eow=every other week, em=every month 
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5.3.3.3 Safety and tolerability of combination therapy, no restriction on previous 
treatments 
 
Thirty-two trials were included in this comparison. Eight trials were excluded because 
biologics were administered merely as monotherapy. The number of trials in given 
comparisons might be different because of the distinct endpoint reporting across trials. 
 
5.3.3.3.1 Tolerability results 
 
There were significantly less or the same rate of withdrawals due to any reason for biologics 
compared to placebo (Table 4). There were significantly more withdrawals due to adverse 
event for infliximab (2.16 [1.18, 3.95]) and certolizumab (2.86 [1.11, 7.33]) compared to 
placebo. Other biologics showed no significant difference compared to placebo, RRs varied 
between 0.79 [0.56, 1.10] and 1.61 [1.07, 2.43] (Table 4). Generally, biologics were 
associated with more withdrawals due to adverse events, with a number needed to treat for 
harm of 83 [49, 264] patients. 
 
5.3.3.3.2 Safety results 
 
No significant differences in terms of any adverse event were observed between biologics and 
placebo except of abatacept and tocilizumab, where adverse events were slightly more 
frequent (Table 5). Serious adverse events were experienced significantly more frequently 
with certolizumab compared to placebo, our pooled RR was 2.86 [1.11, 7.33]. Other biologics 
showed no significant differences with respect to serious adverse events compared to placebo. 
In terms of serious infection, certolizumab and tocilizumab treatment were significantly more 
unfavourable than placebo, pooled RRs were 4.76 [1.30, 17.46] and 1.81 [1.02, 3.21], 
respectively. 
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Table 4 Tolerability of label dose of biologics in combination with conventional 
DMARD; no restriction on population 
Outcome Stu-
dies 
Partici
pants 
RR (random effect, 
95% CI) 
NNH (random 
effect, 95% CI) 
Withdrawal due to any reason 29 13754 0.58 [0.51, 0.67] nv 
abatacept 10mg/kg 6 3493 0.61 [0.44, 0.82] nv 
adalimumab 40 mg/2 weeks 3 1171 0.77 [0.60, 0.98] nv 
certolizumab 200mg 2 965 0.39 [0.30, 0.52] nv 
etanercept 2x25mg/week 3 1090 0.57 [0.41, 0.79] nv 
golimumab 50 mg 3 849 0.54 [0.44, 0.67] nv 
infliximab 3 mg/kg 4 1843 0.87 [0.52, 1.46] nv 
rituximab 2x1000mg 5 1763 0.42 [0.34, 0.51] nv 
tocilizumab 8mg 4 2580 0.66 [0.43, 1.02] nv 
Withdrawal due to adverse 
event 
30 13883 1.31 [1.04, 1.64] 83 [49, 264] 
abatacept 10mg/kg 6 3493 1.11 [0.74, 1.67] 237 [54, ∞] 
adalimumab 40 mg/2 weekst 4 1300 1.41 [0.84, 2.36] 147 [22, ∞] 
certolizumab 200mg 2 965 2.86 [1.11, 7.33] 35 [20, 129] 
etanercept 2x25mg/week 3 1090 0.79 [0.56, 1.10] nv 
golimumab 3 849 0.92 [0.30, 2.90] nv 
infliximab 3 mg/kg 4 1843 2.16 [1.18, 3.95] 27 [17, 59] 
rituximab 2x1000mg 5 1763 1.46 [0.50, 4.29] 114 [34, ∞] 
tocilizumab 8mg 4 2580 1.61 [1.07, 2.43] 49 [29, 182] 
nv: negative value, lower withdrawal rate in biologic arm 
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Table 5 Safety of label dose of biologics in combination with conventional DMARD; no 
restriction on population 
Outcome Stu-
dies 
Partici-
pants 
RR (random 
effect, 95% CI) 
NNH (random 
effect, 95% CI) 
Any adverse event 28 13371 1.06 [1.02, 1.09] 15 [9, 48] 
abatacept 10mg/kg 5 3259 1.04 [1.01, 1.07] 31 [17, 134] 
adalimumab 40 mg/2 weeks 4 1695 1.03 [0.87, 1.22] 5 [2, ∞] 
certolizumab 200 mg 2 963 1.19 [1.00, 1.43] 9 [4, ∞] 
golimumab 50mg 3 849 1.15 [0.88, 1.49] 9 [3, ∞] 
etanercept 2x25mg/week 3 1090 0.98 [0.94, 1.03] nv 
infliximab 3 mg/kg 3 1172 1.02 [0.97, 1.08] 47 [16, ∞] 
rituximab 2x1000mg 5 1763 1.02 [0.94, 1.11] 57 [11, ∞] 
tocilizumab 8mg 4 2580 1.13 [1.05, 1.22] 11 [8, 20] 
Serious adverse event 27 13258 1.01 [0.88, 1.17] 389 [68, -105] 
abatacept 10mg/kg 6 3493 0.90 [0.65, 1.23] nv 
adalimumab 40 mg/2 weeks 2 764 0.85 [0.50, 1.45] nv 
certolizumab 200 mg 2 965 2.14 [1.24, 3.69] 20 [12, 53] 
etanercept 2x25mg/week 2 1001 0.84 [0.59, 1.19] nv 
golimumab 50mg 3 849 1.13 [0.56, 2.28] 129 [18, ∞] 
infliximab 3 mg/kg 4 1843 1.06 [0.81, 1.40] 183 [29, ∞] 
rituximab 2x1000mg 5 1763 0.94 [0.69, 1.29] 437 [33, ∞] 
tocilizumab 8mg 4 2580 1.11 [0.71, 1.72] 124 [29, ∞] 
Serious infection 29 14171 1.31 [1.02, 1.70] 121 [71, 425] 
abatacept 10mg/kg 6 3493 1.38 [0.81, 2.33] 167 [69, ∞] 
adalimumab 40 mg/2 weeks 4 1679 1.92 [0.59, 6.30] 53 [21, ∞] 
certolizumab 200 mg 2 965 4.76 [1.30, 17.46] 32 [20, 70] 
etanercept 2x25mg/week 2 1001 0.82 [0.42, 1.62] nv 
golimumab 50mg 3 849 1.07 [0.42, 2.69] 593 [49, ∞] 
infliximab 3 mg/kg 4 1841 1.29 [0.53, 3.11] 164 [29, ∞] 
rituximab 2x1000mg 5 1763 0.80 [0.44, 1.47] nv 
tocilizumab 8mg 4 2580 1.81 [1.02, 3.21] 60 [36, 179] 
nv: negative value, lower adverse event rate in biologic arm 
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5.3.4 Meta-analysis: mixed treatment comparison 
 
The figures of this section present odds ratios (OR) between treatments A and B in the form 
treatment A – treatment B. Treatment A is infliximab and treatment B is a biologic agent 
other than infliximab.  
To read the figures: 
 for ACR20, ACR50, ACR70, if the point estimate is greater than 1 then the first 
treatment in the sequence A-B is more effective (although not necessarily statistically 
significantly more effective) 
 for adverse events and tolerability endpoints, if the point estimate is less than 1 then 
the first treatment in the sequence A-B is safer (although not necessarily statistically 
significantly safer) 
 
Please note that the confidence intervals provide information on whether the difference 
between treatments is statistically significant. If the CI contains 1, the difference is not 
statistically significant. 
 
 
5.3.4.1 Efficacy 
 
Regarding ACR20 and ACR50 improvements, infliximab showed similar efficacy as other 
biologics except for certolizumab (See Figure 10 and Figure 11). No significant differences in 
terms of ACR70 improvements were observed between infliximab and abatacept, 
adalimumab, etanercept, golimumab or rituximab (See Figure 12). Patients who received 
certolizumab treatment were significantly more likely to achieve any level of ACR 
improvements than infliximab. Although, certolizumab studies might be biased because of the 
extreme high rate of early withdrawal
40
, which resulted in a low ACR rate of response to 
placebo in certolizumab trials and a consequent high ORs. Significantly more patients on 
tocilizumab treatment met ACR70 endpoint than on infliximab (See Figure 12). It is worthy to 
point out that three of the seven tocilizumab trials were performed in Asia and these seemed 
to be reporting more favourable results than trials performed not in Asia as Mandema and his 
colleagues reported in their meta-analysis.
71
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Figure 10 Indirect comparisons, infliximab vs. biologics in combination with 
conventional DMARD, ACR20 at six months 
 
 
Figure 11 Indirect comparisons, infliximab vs. other biologics in combination with 
conventional DMARD, ACR50 at six months 
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Figure 12 Indirect comparisons, infliximab vs. other biologics in combination with 
conventional DMARD, ACR70 at six months 
 
 
 
5.3.4.2 Safety 
 
No significant differences in terms of serious adverse events and serious infections were 
observed between infliximab and other biologics (See Figure 13 and Figure 14).  
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Figure 13 Indirect comparisons, infliximab vs. other biologics in combination with 
conventional DMARD, serious adverse event at six months 
 
 
Figure 14 Indirect comparisons, infliximab vs. other biologics in combination with 
conventional DMARD, serious infection at six months 
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5.4 Review of previously published meta-analyses 
 
We conducted a MEDLINE search on meta-analysis with biologics in RA published in past 
five years (2008-2012). All meta-analysis including infliximab were selected for current 
descriptive review. 
 
5.4.1 Cochrane reviews on biologics 
5.4.1.1 Cochrane reviews on efficacy 
 
In the past decade several Cochrane reviews were published which were combining RCTs of 
a single biological agents
15, 16, 73, 78, 94, 101, 103
 In their meta-analysis, Singh and colleagues have 
been systematically overviewed each previously published and updated Cochrane reviews on 
biologics.
102
 Six biologics - infliximab, etanercept, adalimumab, abatacept, anakinra and 
rituximab – and 31 RCTs were included in this network meta-analysis. The ACR50 
improvement and the number of withdrawals because of adverse events were chosen as main 
efficacy and safety endpoints by authors. 
Regarding efficacy, the number needed to treat (NNT) for ACR50 was 3 for etanercept and 
infliximab and 4 for abatacept, adalimumab and infliximab. The NNT for anakinra was not 
significant. Regarding harm, the NNT for withdrawals related to adverse events was 39 for 
adalimumab, 31 for anakinra and 18 for infliximab. The NNT for abatacept, etanercept and 
rituximab were not significant. 
Authors concluded: “Given the limitations of indirect comparisons, anakinra was less 
effective than adalimumab and etanercept, and etanercept was safer than adalimumab, 
anakinra and infliximab.” 
 
5.4.1.2 Cochrane review on safety and tolerability – Singh et al. 2011 
 
Main aim of this Cochrane review
104
 was to compare the adverse effects of biologics: 
etanercept, adalimumab, infliximab, golimumab, certolizumab, anakinra, tocilizumab and 
rituximab in patients with any disease condition except human immunodeficiency disease. 
One hundred and sixty-three RCTs with 50,010 patients were included. Search was performed 
until January 2010. The serious adverse event, serious infection, tuberculosis diagnosis, 
  
35 
Clinical efficacy and safety of biological medications of rheumatoid arthritis (Baji P, 
Balogh O, Brodszky V) 
leukaemia, congestive heart failure, withdrawals due to adverse event or any adverse event 
were chosen as endpoints for this meta-analysis. 
 
Regarding infliximab, no significant difference compared with placebo in serious adverse 
events (OR=1.29; 0.98-1.70), serious infection (OR=1.45; 0.99-2.13) and any adverse event 
(OR=1.33 1.13-1.57) were found. Moreover, biologics were similar to placebo regarding to 
the occurrence of congestive heart failure and leukaemia, while biologics resulted in 
significantly more TBC-reactivation. 
 
Authors concluded that “people using biologics in the short term, will probably not 
experience more serious side effects, serious infections, cancer, or congestive heart failure 
than people who take placebo”. 
 
 
5.4.2 Comparison of biologics 
 
5.4.2.1 Aaltonen et al. 2012 
 
Five TNF-blockers - infliximab, etanercept, adalimumab, certolizumab and golimumab – and 
26 RCTs were included in this meta-analysis.
1
 Search was performed until 30.06.2010. 
Studies with one (or more) of the TNF-blockers delivered the same route and dose as the 
commercial drug and reported any level of ACR improvement and safety outcomes were 
included. The ACR 50% improvement and the discontinuation of study due to adverse events 
at six months were chosen as main efficacy and safety endpoints for this meta-analysis. 
 
Efficacy 
 
Authors reported non-significant risk ratio for infliximab-placebo comparison at six months 
(3.08; 95%CI: 0.91–10.43) combining results from two RCTs (Maini 1999 and Schiff 2008). 
The START study (Westhovens 2006) was excluded from the analysis though it is a 
randomized, double blind, placebo controlled study reporting ACR50% improvement for 3 
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mg/kg infliximab at 22 weeks. Authors gave no detailed explanation for exclusion.
i
 
Combining three studies (Maini 1999, Schiff 2008 and Westhovens 2006), infliximab 
significantly improves the ratio of patients with ACR 50% response: RR=2.92 (95% CI: 1.69-
5.05) (Figure 15). 
 
Authors concluded that “results suggest that infliximab and golimumab do not differ 
significantly from the control”. This conclusion regarding to infliximab is questionable based 
on our criticism above. 
 
Figure 15 Infliximab vs. placebo at six months, ACR 50% improvement. Recalculating 
result from Altoonen’s meta-analysis 
 
 
 
Safety 
 
While the patients on infliximab (3.22, 1.76–5.91), adalimumab (1.59, 1.13–2.23), and 
certolizumab (2.72, 1.23–6.01), had an increased risk to discontinue, the patients on 
etanercept (0.71, 0.54–0.92) had a decreased risk. On the other hand, occurrence any adverse 
events, serious adverse, all infection and any infection were similar at the patients on 
infliximab and etanercept. Injection or infusion site reactions were more frequent at 
etanercept. 
 
5.4.2.2 Alonso-Ruiz 2008 
 
Three TNF-α blockers - infliximab, etanercept and adalimumab – and 13 RCTs were included 
in this meta-analysis.
6
 Search was performed until October 2006. Studies with one (or more) 
                                                 
i
 „Patients, interventions, controls, outcomes or design of the studies did not meet the inclusion criteria of the 
systematic review in 17 publications [30–46].” 
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of the three TNF-α blockers delivered the same route and dose as recommended in label 
information were included. Trial duration had to be at least 6 months with efficacy measured 
by ACR response. ACR20, 50 and 70 improvements were used as efficacy endpoints. The 
following safety parameters were analysed: any adverse event, withdrawals due to adverse 
events, serious adverse events, infections, serious infections, infusion or injection-site 
reactions, malignancies and overall mortality. 
 
Author reported similar effect (ACR20) of TNF-α blockers, combined relative ratios were 
1.89 (1.30–2.75) for adalimumab, 1.71 (1.11–2.63) for etanercept and 1.82 (1.19–2.77) for 
infliximab. ACR50 and 70 improvement at TNF-α blocker treatments were similar, too. 
 
Authors concluded that “patients receiving infliximab showed a higher frequency of serious 
adverse events (p = 0.048) and infections (p = 0.004)”. These results included also off-label 
dose (10 mg/kg) of infliximab. Later, authors concluded that “the risk of severe infection 
when receiving high doses of infliximab was significantly increased”. According either to our 
meta-analysis (See Figure 8) or to other published meta-analysis
1, 104, 126, 127
, approved doses 
of infliximab did not cause significantly more frequently serious infection than placebo. 
 
5.4.2.3 Schmitz et al. 2012 
 
Five TNF-α blockers - infliximab, etanercept, adalimumab, golimumab and certolizumab – 
and 16 RCTs were included in this meta-analysis.
99
 Search was performed until October 2010. 
Studies including MTX naïve patients or patients with early RA were excluded from this 
analysis. Studies with at least one the TNF-α blocker arm were included, there were no 
restriction on doses (also off-label doses were included). The ACR20 and 50 and HAQ 
improvements were chosen as efficacy endpoints for this meta-analysis. A Bayesian mixed 
treatment comparison model was fitted for each of the outcome measures. 
 
ACR improvements 
 
Combining 16 trials, authors concluded: “All anti-TNF-α agents achieved a significant ACR 
response over placebo (the credible intervals are higher than, and do not include, 1). The RR 
for certolizumab achieving ACR20 and ACR50 indicated improved efficacy over 
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adalimumab, infliximab and golimumab. The outcomes also provide evidence of etanercept 
being superior to infliximab and golimumab. For ACR50, etanercept appeared approximately 
equal in efficacy to certolizumab (Cert vs. Eta, RR 1.03); adalimumab shows improvement 
over infliximab.”99  
 
HAQ improvements 
 
Combining 13 trials, authors concluded: “all anti-TNF agents show significant improvement 
over placebo, etanercept achieving the highest improvement (m = 0.31). All anti-TNF agents 
have greater efficacy than infliximab. Certolizumab and etanercept appear superior to 
adalimumab. Etanercept shows improved efficacy over golimumab. 
 
These results are in contradiction with findings from earlier meta-analysis. For example, 
Nixon and his colleagues
79
 using the same meta-analysis model, but applying different 
exclusion and inclusion criteria stated that there were no significant differences between TNF-
blockers’ efficacy. They reported odds ratios of 0.97 (0.34-2.93) and 0.92 (0.39-2.37) for 
ACR20 and of 0.98 (0.45-1.93) and 0.96 (0.48-1.9) for ACR50, respectively infliximab-
etanercept and adalimumab-infliximab comparisons. These results indicated almost the same 
efficacy of TNF-α blockers. Also Brodszky used the same model in his previous meta-
analysis.
19
 He reported no significant differences between TNF-α blockers regarding ACR70 
endpoint. 
 
 
5.4.2.4 Devine et al. 2011 
 
Nine biologic therapies - infliximab, abatacept, anakinra, etanercept, adalimumab, 
golimumab, tocilizumab, rituximab and certolizumab – and 30 RCTs were included in this 
meta-analysis.
31
 Search was performed until July 2010. Studies in which patients have failed 
DMARD therapy and had not yet received biologic therapies were included. Studies where 
patients had previously failed or had an inadequate response to biologics were excluded. ACR 
50% improvements at 6 and 12 months was used as efficacy endpoints. 
The results of the 6-month analysis showed that the efficacy of each of the nine biologic 
agents were greater than placebo significantly. According to the indirect comparison, 
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infliximab was more efficacious than abatacept (OR=1.49), adalimumab (OR=1.20), anakinra 
(OR=1.79), etanercept (OR=1.15) and golimumab (OR=1.23), differences were not 
significant. On the other hand, infliximab was less efficacious than certolizumab (OR=0.35), 
tocilizumab (OR=0.90) and rituximab (OR=0.95), differences were not significant. 
 
5.4.2.5 Wiens et al. 2009 
 
Seven RCTS with infliximab were included in this meta-analysis.
126
 Search was performed 
until March 2009. Studies with infliximab plus methotrexate vs. placebo plus methotrexate 
comparison were included. The ACR20, 50 and 70 improvement and the discontinuation of 
study due to adverse events at six months and one year were chosen as main efficacy and 
safety endpoints for this meta-analysis. 
At six months of treatment with infliximab the relative ratios compared to control for ACR20, 
ACR50 and ACR70 responses were 1.87, 2.68 and 2.68, respectively. Similarly at one year, 
relative ratios were 2.33, 1.61 and 1.69, respectively. For withdrawals due to adverse events, 
the relative ratio was 2.05 comparing infliximab and control group.  
Author final conclusion was: “This meta-analysis shows a higher efficacy of infliximab 
relative to placebo without significant safety differences between the infliximab-treated and 
control groups.” 
 
5.4.2.6 Brodszky 2011 
 
Eight biologics - abatacept, adalimumab, certolizumab, golimumab, etanercept, infliximab, 
rituximab and tocilizumab – and 32 RCTs involving 18,500 patients were included in this 
meta-analysis. A Bayesian mixed treatment meta-analysis was conducted. Meta-regression 
was used to explore the relationship between disease characteristic variables and observed 
efficacy. The ACR 70% was used by authors as main efficacy endpoints. 
According to his results, the relative odds ratios of biological treatments compared to placebo 
varied between 3.6 to 20.0 and 6.4 to 35.5 in case of biologics monotherapy and combination 
with conventional DMARD therapy, respectively. Certolizumab was the most efficacious 
(OR=35.5) followed by infliximab (OR=13.4) (Figure 16). There were no statistically 
significant differences between biologics except certolizumab-golimumab comparison. 
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Disease duration and added non-biological therapy were in positive relationship with relative 
efficacy. More severe disease resulted smaller relative effect.  
The author’s main conclusion was the following: “The results show that efficacy of biological 
treatments are similar. The relative efficacy worsens with more severe disease and improves 
with disease duration.”  
 
Figure 16 Relative efficacy of biologics combined with conventional DMARD; ACR70 
response. Effect of different disease duration and baseline HAQ score across studies 
were eliminated. 
 
Source: Brodszky 2011 
 
5.4.2.7 Launois et al. 2011 
 
Seven biologics - infliximab, etanercept, adalimumab, golimumab, certolizumab, anakinra 
and tocilizumab – and 19 RCTs were included in this meta-analysis.63 Main objective was to 
compare certolizumab with other biologics. Search was performed until 30
th
 of June 2009. 
RCTs including patients with RA who had an inadequate response to DMARD were enrolled 
by authors. In addition, the studies evaluated labelled doses of biologics versus placebo in 
combination with continuation of inadequate conventional DMARD. The ACR 20%, 50% and 
70% improvement at 24±8 weeks were chosen as efficacy endpoints for this meta-analysis. 
Indirect comparison was carried out using a multiple-treatment Bayesian mixed treatment 
comparison model.  
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Each biologics were significantly more efficacious than placebo regarding of any ACR 
endpoints. For ACR20, 50 and 70 responses, ORs for infliximab were 3.31 (2.05–5.03), 3.59 
(1.97–6.13) and 3.55 (1.77–7.15), respectively. Certolizumab and etanercept had the highest 
ORs. While, number of patients in etanercept studies was the lowest in this meta-analysis, for 
example etanercept studies included 240 patients and infliximab studies included 1,345 
patients. Regarding to certolizumab, authors did mention in limitations but certolizumab 
studies might be biased because of the extreme high rate of early withdrawal.
40
 Author 
mentioned the low ACR20 rate of response to placebo in certolizumab trials as a limitation. 
Low placebo response rate was the consequence of early withdrawal and resulted in high 
ORs. 
Authors’ main conclusion was following: “Results of this original multiple-treatment 
Bayesian meta-analysis indicate that certolizumab pegol is at least as efficacious as the 
preexisting antirheumatic anticytokine biotherapies.” 
 
5.4.3 Switching  
 
5.4.3.1 Remy et al. 2011 
 
Treatment effect of switching from one TNF-α blocker to another TNF-α blocker was 
analysed in this study.
90
 It was not a “regular” meta-analysis combining RCTs, but a meta-
analysis combining mainly uncontrolled and open label prospective cohort studies. Direct 
results from RCTs on switching are rare therefore we found useful to mention this analysis. 
Thirty-two studies with three TNF-α blocker – adalimumab, etanercept and infliximab – 
involving 4,441 patients were included by Remy and his colleagues. The ACR 20%, 50% and 
70% and EULAR improvement were chosen as efficacy endpoints. 
The amount of available information on switching was unevenly distributed between potential 
switches. Much more data were available on switching from infliximab to adalimumab or 
etanercept (22 studies with 2,152 patients) than on reverse directions (7 studies with 82 
patients). The pooled percentage of responders according to ACR 20%, 50% and 70% and 
EULAR response were 55.1%, 31.5%, 13.8% and 74.9%, respectively. Author concluded: 
“This meta-analysis suggests that switching to a second TNF-α inhibitor is clinically relevant 
in RA. Response to a second TNF-α inhibitor appears to be slightly better if the first TNF-
alpha inhibitor was discontinued because of adverse events.”90 
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5.4.3.2 Alivernini et al. 2009 
 
Efficacy of switching from any biologics to any other biologics was examined in this meta-
analysis.
5
 Search was performed until December 2008. Clinical trials in RA were included in 
the analysis if a second biologic was used in the trial after failure of a first biologic. The ACR 
20%, 50% and 70% improvement and DAS remission were chosen as efficacy endpoints for 
this meta-analysis. 
Results on switching to infliximab showed that after inadequate response to etanercept, 62% 
and 31% of patients receiving infliximab achieved ACR20 or ACR50 response. On the other 
hand, 29% and 14% of patients remaining on etanercept treatment achieved ACR response. 
Authors concluded regarding of major outcome (ACR70 and DAS remission): “The efficacy 
of a second biological agent, irrespective of the mode of action, in reaching an ACR70 or 
DAS remission after a first biologic is observed from 5% to 15% and from 9% to 15.4%, 
respectively.” Authors emphasized that few studies had strong evidence, most of the studies 
were open-label and included small number of patients.  
 
5.4.3.3 Malotti et al. 2011 
 
Five biologics - infliximab, etanercept, adalimumab, abatacept and rituximab – and 35 clinical 
studies (RCTs, open label or uncontrolled studies) were included in this meta-analysis.
70
 
Search was performed until July 2010. Both randomized and non-randomized studies were 
included. Efficacy of switching to TNF-α blockers from other biologics was assessed based 
on nine non-randomized studies. TNF-α blocker switches were efficacious. The quality of 
evidences was poor. 
 
 
5.4.4 Dose escalation 
 
5.4.4.1 Mandema et al. 2011 
 
Main aim of this review
71
 was to analyse the dose-dependent efficacy of biologics. Nine 
biologics - abatacept, adalimumab, anakinra, certolizumab, golimumab, etanercept, 
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infliximab, rituximab and tocilizumab – and 50 RCTs involving more than 21,500 patients 
were included in this meta-analysis. A regression method based on dose–response 
relationships to account for differences in efficacy as a function of dose was used by authors.  
 
Efficacy of each biologics was in a positive relationship with doses. Higher doses resulted in 
higher rate of ACR response. Authors concluded: “The analysis showed that all anti-TNFs 
share the same dose–response relationship for ACR 20, 50, and 70, differing only in their 
potency.”  
 
 
5.4.5 Age and treatment effect 
 
5.4.5.1 Köller et al. 2009 
 
Treatment effect with TNF-blockers in different age was analysed in this study
61
 by Köller 
and his colleagues. Patient-level data from two large RCTs of adalimumab and infliximab 
(ASPIRE and PREMIER trials) were analysed. Age quartiles of pooled study populations 
were compared the following age groups were compared: 18–41, 42–50, 51–60 and 61–82 
years. Calculated composite indexes, HAQ score and radiological scores were compared 
between age groups at baseline and one year. 
Authors did not find a correlation between age and treatment response. They concluded that 
the efficacy of biologics in elderly RA patients is comparable with that in younger patients. 
They suggest that physicians should not use patients’ age to limit their therapeutic options. 
 
5.5 Conclusions 
 
5.5.1 Efficacy and safety 
 
Our review delivers results from both direct and indirect comparisons of the clinical efficacy 
and safety of 7 biologics for rheumatoid arthritis based on published double-blind, placebo-
controlled trials. Firstly, a number of classical direct meta-analysis were undertaken to obtain 
summary estimates of clinical effectiveness and safety parameters. Following the recent NICE 
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guidelines, mixed treatment comparisons were conducted allowing for indirect comparisons in 
the absence of head-to-head trials. 
 
The systematic search identified forty RCTs. Most studies were of good internal validity and 
compared one biologic to placebo (with or without methotrexate).  
 
Generally, biologics showed similar clinical efficacy and safety profile. The meta-analysis 
showed that all biologics demonstrated statistically significant improvements compared to 
placebo with respect to ACR20, ACR50 and ACR70 improvements. No statistically 
significant differences could be seen between most of the biologics including infliximab and 
placebo with respect to any adverse events, serious adverse events and serious infections. All 
three safety endpoints were experienced significantly more frequently with certolizumab 
compared to placebo and any adverse events were experienced significantly more frequently 
with tocilizumab. 
 
Our mixed treatment analysis indicated that infliximab was associated with a lover ACR70 
response rate compared to certolizumab and tocilizumab and with a lover ACR20 and ACR50 
response rate compared to certolizumab. At the same time, certolizumab was associated the 
highest rate of serious infection and adverse events. Although, certolizumab studies might be 
biased because of the extreme high rate of early withdrawal
40
, which resulted in a low ACR 
response rate and adverse events rate to placebo in certolizumab trials and a consequent high 
ORs. 
 
5.5.2 Limitations 
 
A potential weakness of this meta-analysis arises from the fact that the trials from which data 
are combined are likely to differ in their design and patient population characteristics. 
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6 Biological therapies for the treatment of RA – systematic review of 
the health economic literature (V. Hevér N) 
 
Summary 
Our systematic review revealed thirty-six cost-utility analyses of biological therapies for RA. 
The majority of the studies (n=19) evaluated biological treatment for RA patients who have 
already failed at least one traditional DMARD therapy, eight considered those who have 
failed at least one biological drug. However the number of studies involving DMARD naive 
RA patients was rather substantial as well (n=9). There was extensive methodological 
heterogeneity across the selected health economics evaluations. The key issue is the 
transferability of the results from these health economics studies to very different jurisdictions 
of Central and Eastern Europe. 
 
6.1 Literature search 
 
We performed a literature search for health economic evaluations of abatacept, adalimumab, 
certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab for the 
treatment of RA. The search included the time period between 2008 and April 2012 and ran in 
the following databases: Ovid MEDLINE(R) 1946 to Present with Daily Update, Ovid 
MEDLINE(R) In-Process & Other Non-Indexed Citations, Web of Knowledge and Centre for 
Reviews and Dissemination (CRD). The search strategies applied are presented in Appendix 
8.7. 
Original articles of full economic evaluations presenting cost-utility data (cost/QALY) of 
biological therapies (abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, 
infliximab, rituximab, tocilizumab) for RA were retrieved by two independent reviewers. 
Articles with full text in English or German were analysed. Data were extracted using a 
standard collection form and are presented in a table format but also short descriptive 
summary of each is provided. Quality of the economic evaluations was assessed using the 
checklist developed by Drummond et al.
34
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Articles written in other language than English or German (but fulfilling our inclusion criteria 
based on their title and English abstract) are listed as potentially relevant publications.  
 
Cost-utility analyses form before 2008 were captured by a review article.
119
 Van der Velde et 
al. performed a systematic literature search for cost-effectiveness studies of biological drugs 
(etanercept, infliximab, adalimumab, anakinra, abatacept, rituximab, natalizumab, 
golimumab, and efalizumab) compared to any DMARD for RA.
119
 The electronic literature 
search was closed in the 3rd quarter of 2008. Altogether 18 health economic evaluations were 
selected, 16 of them were cost-utility analyses which were included in our current report. 
 
6.2 Results 
 
Our search resulted 450 hits, 23 articles fulfilled our inclusion criteria. 
The number of hits and included articles were as follows (articles overlapping between 
databases are listed only where first appeared): 
- Ovid MEDLINE(R) 1946 to Present with Daily Update – 85 hits / 17 articles 
included
12, 14, 23, 30, 42, 52, 57, 64, 66, 76, 89, 95, 100, 116, 121, 122
 
 
- Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations – 15 hits / 2 articles 
included
32, 106
 
 
- Web of Knowledge – 250 hits / 3 articles included13, 58, 70 
 
- Centre for Reviews and Dissemination (CRD) -100 / 1 included article98. 
 
The list of hits and reasons of exclusion are presented in Appendix 8.8. 
Among the 23 articles 1 was in Czech and 1 in Russian and the full text was not available for 
1, thus we performed detailed analysis of 20 publications and provide only abstract for the 
other three. 
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The systematic review by Velde et al. included 16 articles analysing the cost-utility of 
adalimumab, etanercept or infliximab, no studies on rituximab or abatacept were identified. 
119
 
 
In the next sections first we give a summary of the 16 cost-utility studies (time period: - 2008) 
discussed by Velde et al.
119
 Then a short description of the 20 articles from our additional 
search (2008-2012) is provided. Main data (characteristics and results) of the analysis are 
presented also in tables using a standardized extraction format. (Table 6, Table 7, Table 8) 
Quality assessment of the economic evaluations according to the Drummond checklist is 
presented separately. (Table 9, Table 10, Table 11) 
 
6.2.1 Systematic review by Velde el al. (2011) 
 
In this systematic review
119
 incremental cost-effectiveness ratios (ICERs) were stratified by 
biologic agent and indications for the use of biologics in RA patients. 
 
Sixteen cost-utility studies were involved
9-11, 18, 27, 28, 47, 55, 56, 59, 72, 109, 115, 123, 128
: 
- DMARD naive patients: five studies evaluated a DMARD sequence containing a 
biologic agent compared to a DMARD sequence without biologics in patients with no 
previous DMARD experience (one study focused on early RA patients) 
- Patients with MTX failure: three studies evaluated biologic combination therapy in 
methotrexate-resistant patients 
- Patients with min. 2 DMARD failures: eight evaluations analysed the cost-utility of 
inserting a biologic monotherapy or combination therapy into a DMARD sequence 
compared to a DMARD sequence in patients who failed at least 2 DMARDs. 
 
Biologic agents evaluated included adalimumab, etanercept, and infliximab, either as 
monotherapies or combination therapies and one study evaluated biologics as a class (tumour 
necrosis factor-alpha antagonists). Authors did not identify evaluations of the interleukin-1 
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receptor antagonist anakinra, second-generation biologics (e.g., abatacept, rituximab) or the 
lately registered agents (golimumab or certolizumab pegol). 
Biologics were compared to DMARD monotherapies, combination therapies, DMARD 
sequences and mixed drug treatments that included DMARDs and other drugs. There was 
extensive heterogeneity across the selected evaluations in terms of characteristics of the 
patient population and methods applied. Most evaluations were conducted in the US (n=5), 
UK (n=4), Sweden (n=3), Canada (n=2), The Netherlands (n=1) and Japan (n=1). Economic 
perspectives included societal (n=8) and payer (n=11). Most evaluations considered a lifetime 
time horizon (n=10). All of the studies considered direct costs, 9 incorporated indirect costs as 
well. All cost-utility studies used model-based analytic approaches. Efficacy data from the 
Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy 
(ATTRACT) were used in all of the studies that evaluated infliximab, except 3 studies that 
used registry or other data. Similarly RCT data for etanercept and adalimumab were the most 
frequently applied. 
The quality of life weight most often used to calculate QALYs was a score derived from the 
EQ-5D Index (and one missed to identify the utility used), weights were mainly (n=10) 
derived by transforming HAQ scores using linear regression. 
 
ICERs were converted and presented in 2009 Canadian dollars by the authors. 
 
 In patients with no previous DMARD experience (biologic DMARD sequence vs. traditional 
DMARD sequence) no studies were conducted from the societal perspective. The median 
ICER from the payer’s perspective varied between $270,000 and $77,000 per QALY 
depending on the position of the biologic drug within the sequence (the later the more 
beneficial), and the overall median ICER was $130,000/QALY. (The median ICER of 
infliximab + MTX was $142,000/QALY [range $100,000 –$169,000/QALY].) 
 
In patients who failed methotrexate monotherapy (biologic combination therapy versus 
methotrexate monotherapy) 3 studies evaluated biologic combination therapy 
(infliximab+MTX), all the three took the societal perspective and 2 studies also took a payer 
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perspective.
56, 72, 128
 Efficacy data were retrieved from the ATTRACT trial. ICER values 
ranged from $6,000–$92,000/QALY. 
 
In patients who failed at least 2 DMARDs eight evaluations estimated the cost-utility of 
inserting a biologic monotherapy or combination therapy into a DMARD sequence compared 
to a DMARD sequence. All of them took the societal perspective (one performed the analysis 
from the payer perspective as well). ICER values varied highly within a range of $45,000–
$612,000/QALY. Median ICERs by biologic drug were $81,000/QALY for adalimumab, 
$79,000/ QALY for adalimumab+MTX, $127,000/QALY for etanercept, $75,000/QALY for 
etanercept+MTX, and $133,000/QALY for infliximab+MTX. There were no consistent trends 
across the results. 
 
Authors conclude that at a willingness to pay threshold of $50,000 per QALY gain (Canada 
2009), biologics were not cost effective in patients with no previous DMARD exposure and 
patients who failed MTX combination therapy or sequential DMARD administration. 
Evidences suggest cost-effectiveness in patients who failed MTX monotherapy, nevertheless, 
this might be partly due to the choice of comparator, where methotrexate-resistant patients 
continued to receive methotrexate. 
 
6.2.2 Analysis of the articles revealed by the additional search 
 
The 20 articles were stratified by patient groups: 
- DMARD naive patients: 4 articles30, 57, 98, 116 
- RA patients with synthetic DMARD failure: 8 articles32, 58, 64, 95, 100, 106, 121, 122 
- RA patients with biologic DMARD failure: 8 articles14, 23, 42, 52, 66, 70, 76, 121 
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6.2.2.1 Methotrexate naive RA patients 
 
Davies et al., United States (2009) – TNF-α antagonists30 
The objective of this study was to estimate the comparative lifetime cost-effectiveness of 
sequenced therapy with TNF-α antagonists as the initial therapeutic intervention for patients 
with early RA.
30
 The model following a structure described by Bansback et al.
9
 examined 
costs and clinical outcomes over a course of five competing sequential regimens, rather than 
by comparing single agents against another: 
- a reference sequence without biologic therapy 
- 3 sequences with a single biologic followed by traditional DMARD  
- a dual biologic sequence in which treatment was initiated with adalimumab+MTX 
followed by etanercept monotherapy (within a supplementary analysis)  
 
In the base case analysis the adalimumab-plus-MTX-initiated sequence resulted in the greatest 
number of QALY (3.24). When the adalimumab-plus-MTX-initiated sequence was followed 
by etanercept before switching to other DMARD, the number of QALY was increased by 
one-third over the course of therapy (4.22 QALY vs 3.24 QALY). Regarding the ICERs, the 
sequences of etanercept and infliximab+MTX were extendedly dominated by the 
adalimumab-plus-MTX-initiated sequence. Comparing DMARD and single TNF-sequences, 
the adalimumab-plus-MTX-sequence provided the greatest ICER of US $47,157 per QALY. 
When productivity costs included, the infliximab-plus-MTX-sequence was dominated by the 
etanercept sequence, although both remain extendedly dominated by the adalimumab-plus-
MTX-sequence for which ICER was US $23,377 per QALY compared with the etanercept 
sequence.  
According to the supplementary analysis, the strategy of treating with etanercept as a second-
line TNF-antagonist subsequent to first-line adalimumab could yield an additional QALY 
compared with adalimumab and extendedly dominated all single TNF-strategies, at a cost of 
US $42,727 per QALY and US $19,663 per QALY if productivity was included. At US 
$50,000 considered a minimum cost-effectiveness threshold in the US adalimumab-plus-
MTX therapy was found to have a 70% probability of being cost-effective.  
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The results of sensitivity analyses demonstrated how the cost-effectiveness of adalimumab 
versus DMARD changed with varying assumptions: 
- applying a EQ-5D utility regression by Kobelt, et al increased the cost per QALY of 
adalimumab to US $65,000 
- when the HAQ progression was assumed to be twice or when the withdrawal rate from 
DMARD therapy was half both that applied in the base case, cost per QALY was also 
between US $60,000 and US $70,000 
- radiographic progression evidence suggests that TNF-antagonists may arrest disease 
progression to the extent that the HAQ score remains stable during periods of 
continued response. This scenario produced the lower ICER for adalimumab of US 
$36,000.  
- other sensitivity analyses produced cost per QALY for adalimumab versus etanercept 
of between US $42,000 and US $54,000.  
 
The analysis outlined above had 3 primary limitations: 
- ERA trial data were used to model responses to etanercept monotherapy as 
combination therapy with MTX was not studied in the ERA 
- the model did not consider the influence of delays in treatment initiation for early 
ERA 
- the study suffered from a paucity of evidence on the effectiveness  of traditional 
DMARD 
 
This model based analysis showed that of the 3 TNF-antagonists, adalimumab had the most 
favourable cost-effectiveness, whether used as initial therapy followed by DMARD or 
followed sequentially by another TNF-antagonist. 
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Van den Hout et al., The Netherlands (2009) - infliximab
116
 
The objective of this study was to evaluate societal costs and QALYs of four treatment 
strategies for patients recent-onset active RA (sequential monotherapy, step-up combination 
therapy, initial combination therapy with prednisone, or initial combination therapy with 
infliximab – BeST trial).116 The study differs from previous ones at certain points: 
- the article based on the observational data of BeSt study while previous ones were all 
modelling studies, combining different types of data from different sources 
- previous studies all compared fixed medication therapies, whereas the study of Van 
den Hout et al. compared dynamic strategies, intensifying or tapering medication 
based on the patient’s status 
- the study contained exclusively cost-utility analysis 
As for the results, in the primary analysis based on the British EQ-5D, with societal costs, 
according to the friction cost method, the QALYs and costs for strategy 1 were less 
favourable than for strategies 2 and 3. Strategy 4 resulted in the highest number of QALYs, 
but at considerably higher costs: the cost-utility ratio of strategy 4 compared with the best 
alternative, strategy 3, was €130,000 per QALY, which is generally considered too high.   
In the secondary analysis based on the Dutch EQ-5D, SF-6D and time trade-off (TTO), the 
QALY differences between strategies were smaller than for the British EQ-5D, therefore the 
cost-utility ratios of strategy 4 compared with strategy 3 were higher: €140,000; €250,000 and 
€320,000 per QALY, respectively.  
Restricting costs to only health care (with QALYs based on the British EQ-5D), the cost-
utility ratio of strategy 4 compared with strategy 3 was €190,000 per QALY. 
The most crucial factor in the secondary analyses was the method used to value productivity 
costs. If productivity was valued according to the human capital method, then the costs and 
QALYs for strategies 1 and 2 were less favourable than for strategies 3 and 4. The cost-utility 
ratio of strategy 4 compared with strategy 3 was €22,000 per QALY, which was generally 
considered highly acceptable. It is an important establishment of the article that using the 
human capital method, the more favourable productivity costs almost completely 
compensated for the higher costs of the initial combination therapy with infliximab. 
The study showed that initial combination therapy with infliximab resulted in significantly 
better quality of life than the other treatment strategies. Considering only health care costs, 
this improvement is obtained at costs that are generally considered too high, and initial 
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combination therapy with prednisone would be preferred. Depending to the extent to which 
productivity was valued, the costs of infliximab could be largely compensated by saving on 
productivity costs. 
 
Kobelt et al., Sweden (2011) – etanercept57 
In this article the cost-effectiveness of early biologic treatment, followed by dose-reduction in 
the case of remission is compared with standard treatment.
57
 The economic model adapted 
was based on the combined effect of function and disease activity to estimate costs and utility 
of different treatment options and radiographic progression was incorporated as an effect on 
function. Regarding the results, the ICER for etanercept/MTX was €13,500 compared with 
MTX alone. As for sensitivity analyses, it was performed for the time horizon, the 
perspective, the discontinuation rate, the proportion of patients switching or returning to full 
dose and the utility adjustment in the biologics group. As for the results of sensitivity 
analyses, costs for the etanercept/MTX strategy were slightly higher, but associated with a 
QALY gain of 1 to 2.3. Results were most sensitive to the drop-out rate, the duration of 
treatment with reduced etanercept dose, time horizon and the perspective of the analysis. The 
utility adjustment did not change the results significantly. ICERs changed with varying certain 
assumptions: 
- when 75 percent instead of 50 percent of drop-outs are switching to a biologic, the 
cost per QALY gained with etanercept/MTX decreases to €10,400 as costs in the 
MTX strategy increased proportionally more due to the higher underlying drop-out 
rate 
- if the drop-out rate increased in both groups, the cost per QALY for 
etanercept/MTX decreased, again due to a larger cost increase in the MTX 
strategy: with a double drop-out rate, the ICER decreased to €2,200. 
- if failure to maintain remission was double, or if dose reduction was only 
possible during the clinical trial period, the ICER for etanercept/MTX 
increased to €19,400.  
- including only medical costs, the ICER increased to €34,000 
- a longer time perspective (20 years) reduced the ICER to €8,200 
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The core point of the study was that the dose-reduction in the early RA may influence 
positively the cost-effectiveness of biologic treatment. The results indicated that a 
situation where a considerable proportion of patients achieved remission, dose-
adjustments will increase the cost-effectiveness of treatment.   
 
Schipper et al., The Netherlands (2011) – TNF-α inhibitors98 
A Markov model was used to evaluate the cost-effectiveness of the following three strategies 
on 5-year horizon: starting MTX monotherapy, followed by the addition of leflunomide 
(LEF), followed by MTX with addition of anti-TNF; Strategy 2: start with MTX and LEF 
combination followed by MTX with anti-TNF; and Strategy 3: immediate start with MTX and 
anti-TNF. The analysis was performed following both a health care and societal perspective. 
Starting with a combination (MTX plus LEF or anti-TNF) was more costly than starting with 
MTX alone, the ICER for starting on anti-TNF vs. initially MTX was from the health-care 
perspective €138,028/QALY and from a societal perspective of €136,150/QALY over 5 
years.  
 
6.2.2.2 RA patients who failed synthetic DMARD therapy 
 
Vera-Llonch et al., US (2008) – abatacept121 
The cost-utility of abatacept treatment in women aged 55–64 years with moderately to 
severely active RA and inadequate response to MTX was analysed on a 10-year and lifetime 
horizon.
121
 Abatacept plus methotrexate therapy was compared to methotrexate treatment, no 
other biological drugs were considered as alternative strategies. Efficacy data were retrieved 
from the abatacept phase III clinical trial (AIM). Abatacept therapy was assumed to result an 
improvement in the HAQ-DI in comparison with MTX alone. Patients with HAQ-DI 
improvements of 0.5 or greater at 6 months were assumed to continue to receive abatacept; 
those failing to achieve this level were assumed to discontinue treatment with a HAQ 
returning to a value equal to what it would have been in the absence of such treatment. All 
patients discontinuing abatacept (irrespective of reason) were assumed to continue to receive 
MTX. For patients receiving MTX only the HAQ-DI was assumed to increase by 0.065 
annually to reflect disease progression. For patients receiving abatacept plus MTX the 
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estimated mean (SD) percentage HAQ-DI change at 3 months following therapy initiation 
was -30.2% (±36.1%); at 6 months, it was -35.2% (±37.6%). This clinical benefit was 
assumed to remain constant in those who continued abatacept, nevertheless an annual disease 
progression of 0.015 was applied. Only medical treatment costs were considered and both 
costs end utilities were estimated on predicted values of the HAQ. A discount rate of 3% was 
applied. Mortality risk was estimated based on age and the expected value of the HAQ-DI. 
Over 10 yrs, the non-discounted QALY gain with abatacept was 1.2 per patient (4.6 vs. 3.4 
for MTX) at an incremental (discounted) cost of $51,426 ($103,601 vs. $52,175, 
respectively); over a lifetime, corresponding figures were 2.0 QALYS (6.8 vs. 4.8) and 
$67,757 ($147,853 vs. $80,096). Cost-effectiveness was [mean (95% CI)] $47,910 ($44,641; 
$52,136) per QALY gained over 10 years and $43,041 ($39,070; $46,725) per QALY gained 
over a lifetime. The probability that abatacept would be cost-effective at a threshold of 
$50,000 per QALY was 0.80 over a 10 year time horizon, and 0.99 when a lifetime 
perspective was employed. 
Sensitivity analysis was performed for different scenarios (e. g. no therapy discontinuation for 
lack of efficacy or other reasons; therapy discontinuation for lack of efficacy occurs at 3 
months; variation of mortality related to HAQ; no mortality benefit with abatacept therapy; 
variation of annual HAQ increase; variation of the threshold for clinically meaningful 
improvement) confirming the robustness of the results (10-year: $40,190 to $70,209, lifetime: 
$37,551 to $60,106 per QALY). 
 
Virkki et al., Finland (2008) – infliximab122 
Cost-utiliy of infliximab was estimated in Finnish RA patients in a real-life clinical setting 
(n=297).
122
 The median ICER of infliximab versus synthetic DMARD treatment was 51,884 
€/QALY. The strength of this analysis is that real-life data were extensively used nevertheless 
methodological weaknesses hampers the results (e.g. no alternative biologicals were 
considered for the analysis). 
 
Kobelt et al., Sweden (2009) - TNF-α inhibitors58 
Kobelt used patient level data from a registry to feed a discrete event simulation model. They 
analysed the cost-utility of TNF inhibitor treatments in Sweden. The 10-year costs in the base 
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case amounted to USD336,000 (S.D.=USD 64,000) or €223,000, with a total of 4.4 QALYs. 
Over 5 years, the costs amounted to USD 208,000 or EUR 138,000 and QALYs to 2.5. The 
results were most sensitive to HAQ level at treatment start, but also to underlying disease 
progression, age, and disease duration. Starting treatment at a lower HAQ level (0.85) reduces 
costs by 10% and increases QALYs by 20%. 
 
Sany et al., France (2009) – infliximab95 
A cost–utility analysis of the annual costs was done with a comparison between the previous 
and the following year under infliximab treatment based on registry data, involving a cohort 
of 635 RA patients.
95
 The analysis was performed from the health insurance coverage point of 
view however indirect costs were also considered. Before the use of infliximab, after 1 and 2 
years, the mean annual cost per patient for the care of RA was €9,832, €27,723 and €46,704, 
respectively. In this analysis the incremental net benefit (INB) was used instead of ICER. INB 
is an indicator equivalent to the cost–effectiveness ratio. It is defined for a willingness to pay 
lambda by the formula INB(lambda)=lambda delta Effectiveness–delta Costs. 
INB(lambda)>0 means that, for the willingness to pay lambda, the cost–effectiveness ratio is 
perhaps acceptable by the society and will be so if the 95% CI is positive and lower than the 
acceptable threshold lambda (€45,000 in France). According to the analysis when it was 
expressed in QALYs, also for severe HAQ, lambda>€100,000. 
 
Lekander et al., Sweden (2010) – infliximab64 
The main feature of this study is that the assessment of cost-effectiveness of infliximab 
compared to nonbiological treatment based on real-world patient-level data.
64
 These patient-
level data were derived from the SRQ (Swedish Rheumatology Quality) Register. Such 
patient registries have several advantages: 
- enable important complementary analyses of cost-effectiveness of TNF-use in RA 
- represent real-world use compared with the more selective and controlled nature of the 
trial-based data 
- using large patient cohorts from clinical practice ensures high external validity of the 
assessments 
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- disease-progression while on treatment can also be tracked over longer time compared 
with data from clinical trials which generally have shorter follow-up 
- using registry data enable incorporation of real-world data on drug discontinuation 
patterns in the economic evaluation 
On the other hand, where it was necessary, the data have been complemented with published 
data, including rate of natural disease progression, costs and utilities. For example, the 
comparator arm (natural progression without biological treatment) was based on published 
results from the ERAS study and not on STURE registry data which reflects the most 
important limitation to cost-effectiveness assessments based on real-world data. 
Another particular characteristic of the model applied is that data on adverse events were 
included. 
 
According to the STURE registry data, there was a change in treatment patterns over time, 
identifying a change to infliximab use earlier in the course of the disease in more recent years 
which was reflected both in shorter disease duration and lower baseline HAQ values. Based 
on disease duration at start of infliximab therapy, subgroups of patients in the data set with 
earlier stage RA and later stage RA were, therefore, analysed separately and compared with 
the base case, enabling a reflection of how the cost-effectiveness have been affected by this 
shift in treatment strategy. 
Regarding the results, the base case analyses showed that the gain in QALYs associated with 
infliximab treatment was 1.019. Infliximab was also associated with an incremental cost of 
€23,264, resulting in an ICER of €22,830. According to the analyses of earlier- and later-stage 
RA, the ICER was lower for patients with earlier-stage RA and higher for patients with later-
stage RA compared with the base case. 
The sensitivity analyses conducted estimated the effects of a range of variables: adverse 
events, age at start of treatment, costs, discount rate, disease progression, drug costs, and 
mortality. In addition, both best- and worst-case scenario were performed. As for results, age 
at start of treatment initiation and the rate of natural disease progression had the largest effect 
on the ICER.  The results ranged from €18,000 to €47,000. The best-case scenario resulted in 
an ICERs of €8,360 and the worst-case scenario €67,237. 
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The main surplus value of this analysis was the assessment based on real-world data. The 
ICERs of infliximab compared with natural progression and ICERs in all sensitivity analyses 
fell well below €65,000 per QALY which is a commonly referred threshold for cost-
effectiveness in Sweden. A further important interpretation of the results is that treating 
patients with earlier- than later- stage RA was potentially most cost-effective. 
 
Schulze et al., Germany (2009) – etanercept100 
This article based on the TEMPO study which had shown that the combination of etanercept 
and MTX in the treatment of RA is superior to monotherapy.
100
 It further suggested that 
remission of RA is a realistic treatment goal. Taking into consideration these establishments, 
the objective of the study was to demonstrate the sustainability of the combination for daily 
clinical practice taking economic aspects into account. 
The main characteristics of the study in which it differs from the most ones: 
- containing both cost-effectiveness (CEA) and cost utility (CUA) analyses 
- besides HAQ applying a German instrument, namely Funktionsfragebogen Hannover 
(FFbH) to measure the functionality of patients 
 
As for the results, the incremental cost-effectiveness ratio of the combination was €21,300 per 
life year in remission as compared with MTX alone. The incremental cost-utility ratio of the 
combination was €38,700 per QALY. 
These results indicate that both health-economic parameters suggest adopting the combination 
therapy into daily clinical practice of RA patients. 
 
Soini et al., Finland (2012)– adalimumab, etanercept, tocilizumab106 
Different treatment sequences were compared in a hypothetical Finnish moderate to severe 
RA patients using a probabilistic microsimulation model in a lifetime scenario. Adalimumab 
+ MTX, etanercept + MTX, or tocilizumab + MTX were used as first biologics followed by 
rituximab + MTX and infliximab + MTX and MTX alone was added as a further comparator. 
(The first-line biologic DMARD comparators included were the two established and 
reimbursed TNF inhibitors – the most used (adalimumab, ADA) and most affordable 
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(etanercept, ETA) – and a new option (tocilizumab, TOC). Important note: infliximab + MTX 
and rituximab + MTX were considered as second line biological therapies.).The resources 
were valued with Finnish unit costs (year 2010) from the healthcare payer perspective but 
additional analyses were carried out, including productivity losses. Biologic DMARDs 
significantly increase the QALYs gained when compared to MTX alone. Tocilizumab + MTX 
was more cost-effective than adalimumab + MTX or etanercept + MTX in comparison with 
MTX alone, and adalimumab + MTX was dominated by etanercept + MTX. The ICER with 
tocilizumab + MTX methotrexate was €18,957 (€17,057) compared to MTX alone. According 
to the cost-effectiveness efficiency frontier and cost-effectiveness acceptability frontier in 
Finland, tocilizumab + MTX should be considered before rituximab + MTX, infliximab + 
MTX, and basic supportive care.  
 
Diamantopoulous et al., Italy (2012) – tocilizumab32 
An individual patient simulation model was used assess the cost-utility of treatment sequences 
starting with tocilizumab or the most commonly prescribed biologics (etanercept, 
adalimumab, or infliximab) in Italy.
32
 In the analysis strategy ETA – ADA – RTX -ABA – 
palliative was compared to TOC – ADA – RTX – ABA – palliative care strategy. Alternative 
analysis replaced etanercept with adalimumab or infliximab: ADA – ETA – RTX – ABA – 
palliative; INF – ETA – RTX ABA – palliative. Authors also analysed the cost-utility of 
adding TOC to standard-of-care: TOC – ETA – ADA – RTX – ABA – palliative. Other TNF-
α blockers such as golimumab or certolizumab pegol were not considered in the analysis. The 
model applied lifetime horizon. Patient characteristics, treatment efficacy, and quality-of-life 
data were based on three phase 3 tocilizumab clinical trials (OPTION, TOWARD, LITHE). 
Only direct costs were considered. In the base-case analysis tocilizumab dominated standard 
of care. In the basecae analysis replacement of etanercept with tocilizumab reduces costs and 
realized more QALYs. Similar results were found if adalimumab was replaced, the ICER in 
case of infliximab replacement was €2,655/QALY. Adding tocilizumab to standard-of-care 
sequence resulted an ICER of €17,119/QALY. Tocilizumab was dominant in sensitivity 
analyses. 
 
 
  
60 
Biological therapies for the treatment of RA – systematic review of the health economic 
literature (V. Hevér N) 
6.2.2.3 RA patients who failed at least one biologic DMARD therapy 
 
Kielhorn et al., UK (2008) – rituximab52 
Incremental cost-effectiveness of rituximab treatment was modelled on the lifetime horizon 
using a Markov model of 6-months cycles.
52
 The analysis compared cost and outcomes of two 
treatment sequences, representing the current UK standard both with and without rituximab. 
The population characteristics matched those of the Randomised Evaluation of Long-term 
Efficacy of rituximab in RA (REFLEX) phase III randomised control trial. Five HAQ 
categories were established in the model and average cost for each category was estimated 
from the UK registry. Only direct medical costs were considered for the analysis. Utility data 
(health gain) were mapped from HAQ. 
The model assumed that patients receive etanercept prior to entering the simulated treatment 
sequence, thus no further data on etanercept were presented. 
In the primary analysis patients either follow the current standard treatment sequence of 
synthetic DMARDs reflecting real life clinical practice in the UK or an alternative sequence, 
which is identical, except for the introduction of rituximab: 
- leflunomide, gold, cyclosporin, palliative care/methotrexate vs. 
- rituximab+methotrexate, leflunomide, gold, cyclosporin, palliative care-methotrexate. 
In the secondary analysis, switch between TNFα blocking agents is included: 
- adalimumab+methotrexate, infliximab+methotrexate, leflunomide, gold, cyclosporin, 
palliative care/methotrexate vs. 
- rituximab+methotrexate, adalimumab+methotrexate, infliximab+methotrexate, leflunomide, 
gold, cyclosporin, palliative care/methotrexate 
Repeated courses of 2x1000 mg rituximab at every 9 months was considered, for all other 
drugs licences dose as per the EU label was used. (Infliximab: 3 mg/kg, average patient 
weight: 75 kg, no drug wastage or increase in dose was included in the calculation; 
adalimumab 40 mg every second week). 
Patients enter the model and are allocated to either of the two treatment sequences. They are 
then exposed to the first treatment in the sequence and are allocated to one of the three 
responder groups (ACR 20–49, 50–69, 70+) or to the non-responder group. The mean drop in 
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HAQ for each of these groups was calculated from the rituximab phase III trial (REFLEX). 
The HAQ score is assumed to drop by 0.1 for non-responders, 0.45 for ACR20–49, 0.85 for 
ACR50–69 and 1.11 for ACR70+ responders. While on treatment, patient HAQ scores are 
assumed to progress by 0.017 during each model cycle. For patients on palliative care a HAQ 
progression of 0.065 was assumed. Once treatment stops, the entire initial gain in HAQ is 
assumed to be lost instantly (100% rebound effect). Time on treatment was applied from a 
study by Barton et al.
11
 assuming 4.25 years for all bDMARDs (including rituximab) apart 
from infliximab where a higher drop-out was assumed (2.46 years). Regarding the non-
biological DMARDs treatments, duration was 1.7 years for cyclosporin, 3.85 years for gold 
and 4.1 years for leflunomide. Mortalities derived from the life-table were adjusted to the 
individual’s HAQ score (1.33 / unit HAQ). A discount rate of 3.5% was applied. Total 
discounted QALYs were 3.051 and 2.324 for the rituximab arm and the standard of care arm, 
respectively, resulting in an incremental QALY gain of 0.727 in the primary analysis. In the 
secondary analysis a lower QALY gain was observed (0.526). The incremental cost-
effectiveness ratio (ICER) was £11 749 and £6103 per QALY in the primary and secondary 
analysis, respectively. In the sensitivity analysis significant variability was observed in 
changes to rituximab dosing re-treatment (from 9 months to 6 months) and when changing the 
HAQ long-term progression. Variability was also observed when baseline age is increased. 
However when measuring the cost-effectiveness acceptability, the model estimates that there 
is an 89% probability of rituximab being cost-effective at a threshold of £30,000. 
 
Vera-Llonch et al., US (2008) – abatacept121 
Cost-utility of abatacept compared to synthetic DMARD treatment was assessed using a 
simulation model to depict progression of disability (HAQ) in women with moderately to 
severely active RA and inadequate response to anti-TNF.
121
 Outcomes and costs were 
simulated alternatively over 10 years and a lifetime for a hypothetical cohort of 1,000 women 
between the ages of 55 and 64 years. At model entry, patients were assumed to receive either 
oral disease modifying antirheumatic drugs (DMARD) only or oral DMARD plus abatacept. 
(At the time the study was conducted, efficacy data in this patient population were available 
for abatacept only.) Efficacy data were retrieved from the ATTAIN clinical trial. For patients 
receiving oral DMARD only, the HAQ-DI was assumed to increase by 0.065 annually to 
reflect disease progression. Patients with HAQ improvements of –0.50 or greater at 6 months 
were assumed to continue to receive abatacept; those failing to achieve this level of clinical 
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benefit were assumed to discontinue treatment. Patients also were assumed to possibly 
discontinue abatacept for other reasons (adverse events). All patients discontinuing abatacept 
were assumed to continue to receive stable doses of oral synthetic DMARD. Authors did not 
consider switching from abatacept to another biologic DMARD as there are no data on the 
efficacy of the latter agents given prior failure with abatacept. For patients discontinuing 
abatacept, the HAQ-DI was assumed to return to a value equal to what it would have been in 
the absence of such treatment. The QALY gain with abatacept compared to synthetic 
DMARD was 1.0 QALY (undiscounted) per patient over 10 years and 1.6 QALY over a 
lifetime. Incremental cost-effectiveness of abatacept (2006 US$) over a 10-year time horizon 
was estimated to be [mean (95% CI)] $50,576 ($47,056, $54,944) per QALY gained (3% 
discount rate used for both costs and effectiveness). On a lifetime basis, cost-effectiveness 
was $45,979 ($42,678, $49,932) per QALY gained. Findings were robust in sensitivity 
analyses. 
 
Lindgren et al., Sweden (2009) – rituximab66 
Lindgren et al. estimated the cost-effectiveness of rituximab in RA patients not responding 
adequately to the first TNF-α inhibitor using a model constructed to predict resource 
consumption and health outcomes in a population-based registry of biological treatments in 
Southern Sweden.
66
 Resource consumption was based on a regular population-based survey 
of patients in Southern Sweden. Rituximab was incorporated as second line treatment, using 
effectiveness from a clinical trial (REFLEX and it was thus compared to the mix of second 
line biologics used in SSATG. Total costs in the rituximab strategy are estimated at €401,100 
compared with €403,000 in the TNF-inhibitor arm. Total QALYs are 5.98 and 5.78, 
respectively. In terms if ICER rituximab therapy was dominant strategy and findings were 
found to be robust in extensive sensitivity analysis.  
 
Brodszky et al., Hungary (2010) - rituximab 
Cost-utility of rituximab (RTX) versus palliative care (synthetic DMARD) was modelled on a 
lifetime horizon in Hungary.
23
 Two scenarios were applied: 1 course of RTX treatment (2 
infusions) and 3-year RTX therapy. Baseline patient characteristics were equivalent to the 
patient population of the REFLEX rituximab trial (moderate and severe RA, who have failed 
DMARDs and at least one TNF-α inhibitor) and efficacy data were retrieved from this same 
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trial. Linear regression between HAQ and EQ-5D from a previous Hungarian survey was used 
to generate utility inputs. Official price lists were used for cost calculation and costs not 
directly connected with RTX treatment were estimated according to HAQ level, based on a 
Hungarian survey. Additionally a cost-minimization analysis was also performed to compare 
RTX treatment with switching from one TNF-α inhibitor to another. One course of rituximab 
treatment resulted an ICER of -31,140 €/QALY from societal perspective and 38,763 
€/QALY from health care payer perspective. Results for repeated courses of rituximab were 
11,234 €/QALY and 13,400 €/QALY, respectively. 
 
Hallinen et al., Finland (2010)
42
 
The aim of this study was to evaluate the cost-utility of different treatment strategies after 
treatment failure with one TNF-inhibitor in a Finnish setting.
42
 Initially, the patients received 
either best supportive care (BSC) or one of the following treatments before BSC: adalimumab 
(ADA), abatacept (ABA), etanercept (ETA), infliximab (INF) or rituximab (RTX). Further 
treatments were added to the most cost-effective strategy in a stepwise manner. Rituximab 
and abatacept was considered as an option for those RA patients who did not tolerate or who 
did not get an adequate response to other treatments, including at least one TNF-inhibitor 
therapy. Regarding the results, the most efficient strategy is to use RTX+MTXBSC or, if 
the WTP of €37,013 per QALY gained is not too much, RTX+MTXINFL+MTXBSC 
treatment strategies after TNF-inhibitor failure. In detail: 
- adding a second biologic treatment after TNF-inhibitor failure increased the average 
treatment failure costs by €16,843-41,866 and gave 0.46-0.70 additional QALYs 
compared with BSC alone, depending on which biologic treatment was chosen. The 
most cost-effective choice was RTX+MTX with an ICER of €30 248 per QALY 
gained, which was lower than those of either INF+MTX (€36,121), ETA+MTX 
(€50,372), ADA+MTX (€50,941) or ABA+MTX (€67,003). Treatment with 
RTX+MTX dominated ETA+MTX, ADA+MTX and ABA+MTX, as it was less 
costly and more effective. Compared with INF+MTX, the cost of an additional QALY 
with RTX+MTX was €18,585. 
- when a third biologic treatment was added after RTX+MTX, the average treatment 
costs increased further by €14,024-35,414 and resulted in 0.38-0.52 additional 
QALYs, depending on which biologic treatment came next. Compared with treatment 
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with RTX+MTX (BSC), the ICERs of adding biologic treatment ranged from 
€37,013 (INF+MTX) to €68,100 (ABA+MTX) per QALY gained. Compared with 
giving INF,+MTX as the third biologic treatment, an additional QALY with 
ADA+MTX, ETA+MTX and ABA+MTX cost €260,197, €145,658 and €151,562, 
respectively.  
- in case of a fourth biologic treatment was added after INF+MTX, the average 
treatment costs increased further by €20,595-34,547 and 0.38-0.49 additional QALYs 
were gained. Compared with treatment with RTX+MTXINF+MTXBSC, the 
additional QALY with ETA+MTX costed €54,836, with ADA+MTX €54,701 and 
with ABA+MTX €70,616. Compared with ETA+MTX and ADA+MTX, an additional 
QALY with ABA+MTX costs €158,411 and €123,755, respectively.  
The study showed that treatment with rituximab was a cost-effective treatment strategy in 
Finland.  
 
Merkesdal et al., Germany (2010) – TNF-α inhibitors, rituximab76 
This study investigated the cost-effectiveness ratios of either (1) rituximab or (2) a TNF-α 
inhibiting agent as second line biological treatment in patients with active RA and an 
inadequate response to etanercept therapy.
76
 The study differs from most of the cost-
effectiveness analyses related to RA in several points. 
- objective: while most economic evaluations focus on the cost effectiveness of TNF-
inhibitors as (1) first line biological therapy after failure of DMARDS, or (2) first line 
therapy in early RA in comparison with MTX therapy, this cost-effectiveness analysis 
focused on second-line biological therapy comparing biological options after failure of 
TNF-inhibitors 
- sensitivity analysis: uncertainties addressed by extensive sensitivity analysis, included 
not only the important input parameters for the model but also the methods used to 
derive these key parameters  
- effectiveness evidence: the treatment sequence applied for the German treatment line 
was based on expert opinion. The employment of expert opinions in fields where 
superior evidence is missing is a common and accepted tool for the development of 
economic models 
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Regarding the results, the ICER of rituximab compared to the standard sequence amounted to 
€24,517 per QALY focussing on direct medical costs.  
The inclusion of indirect costs in both treatment sequences showed higher cost estimates of 
€266,063 and €274,901. The incremental QALY gain was 0.57. This gave an ICER of 
€15,565 per QALY.  
The inclusion of indirect costs reflects the cost-saving potential of highly effective drugs on 
long-term outcomes such as work-productivity or work-disability rates. This is an important 
issue for the demonstration of the real value for money of an expensive but effective treatment 
option. The economic impact of these positive long-term effects in rituximab treatment 
became obvious when comparing the ICERs when productivity costs are either included or 
not (€13,922 vs €8,836), indicating a drop of incremental costs of about 40% due to effects on 
indirect costs.   
 
Malottki et al., UK (2011) - adalimumab, etanercept, infliximab, rituximab and 
abatacept
70
 
Malottki et al. conducted a systematic literature search in 2009 for RCTs, cost-effectiveness 
and cost-utility studies of adalimumab, etanercept, infliximab, rituximab and abatacept 
treatment in RA patients who failed at least one biological therapy. They identified three cost-
utility studies which were identical to literature search was closed at those captured by our 
search.
52, 66, 121
 They performed an independent economic assessment as well. 
One course of RTX results in 0.144 QALY gain compared with palliative treatment (non-
biological DMARD) in lifetime horizon, incremental direct and total costs are 5,582 € and 
4,494 €, respectively, resulting an ICER of  – 31,140 €/QALY from societal perspective and 
38,763 € from health care payer perspective. Three-year treatment with RTX provided a gain 
of 0.511 QALY at an incremental direct and total costs of 13,400 € and 11,234 €, 
respectively, the ICER was 26,223 €/QALY from societal and 21,980 €/QALY from health 
care payer perspective. Cost-minimization proved that that RTX dominates TNF-α inhibitor 
for patients who have failed 1 previous TNF-α inhibitor therapy. 
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Benucci et al., Italy (2011)
14
 
This study focused on the cost-effectiveness of rituximab treatment based on follow-up data 
of 32 RA patients in Italy.
14
 Only direct costs were considered in the analysis. After 1 year of 
treatment the observed ICER on 28 patients was €23,696/QALY. The ICER was more 
favourable if rituximab was applied as second line compared to third line treatment. 
 
6.2.3 Summary of the main findings of the new literature search 
 
6.2.3.1 DMARD naive RA patients 
 
Evidences are summed in Table 6. The four articles involving DMARD naive RA patients 
assessed the cost-utility of etanercept, infliximab and adalimumab as first line therapies. Two 
of them were performed in The Netherlands, one in the US and one in Sweden. Among the 
studies 1 applied payers’, 2 societal perspective and 1 both. All of them applied discount rates 
(3% n=3; 4% n=1) both for the effects and costs. Efficacy data were derived from different 
sources including registry and RCT data (e.g. BeSt trial, COMET trial) but also assumptions 
were made i.e. efficacy of TNF-α inhibitors was considered from patients with DMARD 
experience in one of the Dutch analysis. All the four were modelling studies (2 individual 
sampling, 2 Markov models), the time horizon was 2 years (n=1), 5 years (n=1) and lifetime 
(n=2). Utilities were obtained by the EQ-5D (n=3) and HUI (n=1) and one study performed 
sensitivity analysis for other utility measurements as well. In the US, the ICER of 
adalimumab sequence dominated the etanercept and infliximab sequences. In The Netherlands 
the ICER of strategy 4 (initial combination with infliximab) compared with strategy 3 (initial 
combination with prednison) was €130,000/QALY, and in the other Dutch study the ICER of 
anti-TNF strategy compared with the MTX strategy was €136,207/QALY from the societal 
perspective. In Sweden early etanercept therapy was compared to MTX alone, no other 
biologicals were considered in the analysis. The ICER for the biologic strategy was 
€13,518/QALY if dose adjustment was allowed for patients in remission.  
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6.2.3.2 RA patients who failed at least one traditional DMARD therapy 
 
The summary of the evidences is given in Table 7. Eight analyses estimated the cost-utility of 
biologicals in RA patients who failed at least one traditional DMARD therapy. The studies 
were performed in Sweden (n=2), Finland (n=2) US, (n=1), France (n=1), Italy (n=1) and 
Germany (n=1). The health care payer’s perspective was used in the majority of the studies 
(n=5). Besides the TNF-α inhibitors abatacept and tocilizumab were also analysed. Six 
models and two observational studies were applied and data sources of efficacy were not 
restricted only to RCTs but real life data were also incorporated in many analyses. Seven 
studies derived EQ-5D utilities from HAQ (regression) and only one in Sweden used survey 
results of a registry. Most studies used lifetime horizon but alternative assessments were often 
performed in sensitivity analyses. In general, the ICER for TNF- α inhibitors was within the 
acceptable range. Studies suggest that tocilizumab might be beneficial as well, abatacept 
resulted an ICER $47,910 on 10-year horizon when compared to MTX therapy (no other 
alternatives were considered). 
 
6.2.3.3 RA patients who failed at least one biological DMARD 
 
The summary of evidences are presented in Table 8.Eight studies analysed the cost-utility of 
biologicals for RA patients whom has already failed at least one biological DMARD therapy. 
The studies were performed in the UK (n=2), US (n=1), Sweden (n=1), Finland (n=1), 
Germany (n=1), Italy (n=1), Hungary (n=1). Rituximab and abatacept treatments were 
compared to traditional DMARD and TNF-α inhibitor sequences. With the exception of a 1-
year observational study in Italy, all evaluations applied modelling approach on a lifetime 
horizon, data for effectiveness were retrieved from RCTs. Societal perspective was used only 
in three studies. Rituximab seems to be dominant strategy compared to TNF-α inhibitor 
sequences. The ICER of abatacept compared to MTX therapy was $50,576/QALY on a 10-
year horizon and $45,979/QALY on lifetime horizon in the US. 
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6.2.4 Potentially useful articles with English abstract 
 
Prokes M.,Czeh Republic (2009) [Article in Czech]– adalimumab, infliximab, 
etanercept
89
 
A comparison of effectiveness of adalimumab, infliximab and etanercept in the treatment of 
RA was made and cost-effectiveness of each TNF antagonist for Czech Republic was 
performed.
89
 The prices of therapy of all three TNF antagonists are similar in the first year of 
treatment of patients with average weight, in the second year the price of infliximab is lower, 
but only in the case of patients where the doses do not reach 4 amp. of infliximab. Clinical 
effectiveness was evaluated in DAS28 and HAQ units. Cost-effectiveness of all TNF 
antagonists was similar, when 2 amp. of infliximab per dose physician considered sufficient, 
but when patients were given higher doses of infliximab the trend to lower cost-effectiveness 
of infliximab compared to adalimumab and etanercept was observed. 
 
Belevitin AB et al, Russia (2010) [Article in Russian]
12
 
According to Medline parameters of the article authors discuss the costs and benefits of 
adalimumab in RA and the methods of economic assessment of advisability of modern 
biological medication usage in military medicine.
12
 
 
Benucci et al., Italy (2009) [full text not available]
13
 
The objective of this study is to perform a cost-effective analysis of 86 patients with RA in 
therapy with adalimumab 40 mg every other week and etanercept 50 mg/week for two years 
in a population of patients observed in clinical practice. Incremental costs and QALYs gains 
are calculated compared with baseline, assuming that without biologic treatment patients 
would remain at the baseline level through the year. The results after two years showed an 
ICER for the adalimumab group €42,521.13/QALY and for the etanercept group 
€39,171.76/QALY. 
  
69 
Biological therapies for the treatment of RA – systematic review of the health economic 
literature (V. Hevér N) 
6.3 Discussion, conclusions 
 
There is an increasing demand for cost-effectiveness data in the decision making process 
across Europe. Cost–effectiveness analyses are always comparative and incremental, that is, 
they permit an insight to the benefits, costs and the potential savings of a product compared 
with other pharmaceuticals and/or treatment, optimally in a reliable, reproducible, and 
verifiable way. However, to make the cost-effectiveness analysis useful for decisions on 
resource allocation, the health benefit must be expressed with a measure that is comparable 
across diseases. Cost-utility analysis expresses the incremental benefits of a treatment 
compared to others in ”quality adjusted life year” (QALY) where the ”Q” include information 
on the utility of a health status from a societal point of view. The incremental cost-utility ratio 
(ICUR, but often called simply as incremental cost-effectiveness ratio - ICER) presents then 
the incremental expenditures needed to achieve 1 QALY gain. The lower the ratio of a cost 
per QALY, the most cost-effective the intervention is said to be. 
Even though there is no theoretical or empirical basis for it, ICER values ranging from 
$50,000 to $100,000 / QALY are sometimes used as a threshold in the United States, where as 
in the UK, NICE has adopted a cost–effectiveness threshold range of £20,000 to £30,000 / 
QALY gained.
80
 Although in several European countries (including Hungary and many others 
from the Eastern and Central region) there is not a well-defined threshold for reimbursement 
decisions, the ICER ratio is often used as basis for the evaluation of new technologies. 
Therefore, in our current report we focussed on cost-utility analyses of biological therapies in 
RA. Our systematic literature review revealed 36 cost-utility studies. The majority (n=19) 
evaluated biological treatment for RA patients who have already failed at least one traditional 
DMARD therapy, eight considered those who have failed at least one biological drug. 
However the number of studies involving DMARD naive RA patients was rather substantial 
as well (n=9).  
There are several key steps when performing and interpreting health economic reports. These 
include (1) defining perspective and time horizon, (2) collecting data on healthcare utilization, 
(3) costing healthcare resources,(4) analysing data on utilization and cost, (5) defining and 
measuring health effects, (6) adjusting costs and effects for inflation and discounting, (7) and 
evaluating uncertainty.
80
 There was extensive methodological heterogeneity across the 36 
selected health economic evaluations. Economic perspectives included societal and payer, 
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some studies presented results for both. The majority applied model-based analytic approach 
but some relied on short (1 or 2 years) observational data. All of the studies considered direct 
costs but indirect costs were ignored by many evaluations. Data from randomized controlled 
trials were used the most frequently to assess effectiveness but in some cases (especially in 
the latest analysis) findings from registries were also incorporated. Real-world data might 
refine the results of RCT based economic evaluations and be more generalizable to the field. 
However at the same time their outputs are more difficult to interpret and the internal validity 
of the findings is more limited. 
The quality of reporting is crucial in health economic publications since usually neither the 
model itself nor the inputs (e.g. patient level data from RCTs or cohorts) are available. Hence 
the analysis is not reproducible for outsiders and critical appraisals have to rely on the 
reported data. The checklist developed by Drummond et al. is widely used for the quality 
assessment of health economic papers.
34
 Applying these criteria on the 36 selected 
publications we found that reporting practices often failed to present key data appropriately. 
Authors commonly missed to describe methods for identifying, selecting, and synthesizing 
data for key model parameters and also study design was not clearly described in many 
publications. Important details which might have significant impact on the results (e.g. dose 
escalation) were frequently missing from the description.  
 
Considering the above mentioned variability and weaknesses of the methods definitive 
conclusions are difficult to make regarding the cost-utility of biologicals in RA. There is 
mixed evidence of cost-effectiveness in selected populations. For instance, the ICER of 
infliximab+methotrexate therapy for RA patients who failed methotrexate monotherapy 
varied between 6,451-91,484 CAN$/QALY in a Canadian review.
119
 Not only the time 
horizon and discounting were deterministic but also different utility measures (EQ-5D, HUI-
2, HUI-3, SF-6D) resulted quite diverse ICERs (37,209 – 80,620 CAN$/QALY) even if the 
same perspective was applied.
72
 
 
However for the current health technology assessment the basic questions are whether the 
available literature results are relevant to Central and Eastern European countries (namely 
Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic), and how to 
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transfer them to support local policy making, financing and reimbursement decisions and 
professional guidelines.  
Most of the cost-utility analyses were performed in the US (n=8) and Northern Europe 
(Sweden n=7, Finland n=3), but countries from Western Europe also contributed with 
numerous evaluations (UK n=6, The Netherlands n=3, Germany n=2, Italy n=2, France n=1). 
Canada and Japan had 2 and 1, respectively. Only one publication from Hungary was 
available in English. 
These countries differ considerably from Central and Eastern European countries in GDP per 
capita, health and social care systems, demography, morbidity, health status of the given 
population in question (RA), comparator medications, standard practice, prescription 
behaviours of the doctors, reimbursement mechanisms of medications and financing of health 
care institutions, price level, unit costs, direct and indirect costs. Thus the transferability
i
 of 
these health economic results to jurisdictions of Central and Eastern Europe is rather limited. 
Furthermore, there are noticeable limitations in terms of HTA capacity (number of 
professionals and budget to generate new country specific HTA results) in the Central and 
Eastern European region. Hence it is essential to find out how can these published results be 
made more transferable and more useful. Managed transferability is crucial for sustainable 
financing of biological medications. 
For that purpose a wide spectrum of deterministic factors has to be analysed, such as country-
specific RA guidelines (both professional and financing), financing mechanisms, patient data, 
financing incentives, access to health care facilities where biologicals provided to RA 
patients. Some important questions will be answered by this HTA report. However, we will 
presumably face the problem of lack or at least shortage of information. To bridge this gap 
and to achieve reliable data we have to collect as many reliable local data as possible and 
develop a model which is able to represent the environment where it is used (country-specific 
characteristics) and which also allows investigating the effect of different hypotheses and 
scenarios on a number of outcomes. Conference abstracts reflect an increasing activity in 
                                                 
i
The ISPOR Task Force’s working definitions were that economic evaluations were generalizable if 
they applied, without adjustment, to other settings. On the other hand, data were transferable if they 
could be adapted to apply to other settings. Also, the generic term ‘jurisdiction’ was used to mean any 
setting where there is a need for local estimates of cost-effectiveness. Often this would be a country, 
but could also be a region within a country, or a particular payer, such as a health plan. However, 
when referring to a particular study, more specific terms like ‘country’ or ‘clinical center’ are used if 
they help in the explanation of the study’s methods (Drummond 2009, Gulácsi 2005) 
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many countries and it is highly probable that further studies can be captured by reviewing 
local papers and submission dossiers. For instance in Hungary, several cost-of-illness studies, 
partial and full HTA reports are available in Hungarian often with short English abstract.
20-22, 
24, 25, 41, 69, 86, 87
 These sources might offer important inputs for country-specific health 
economic modelling and provide relevant information about the reimbursement practice in a 
specific country. 
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Table 6 Methotrexate naive early RA patients - summary of cost-utility evidence identified 
Data Davies et al., USA (2009)
30
 Ven den Hout et al., The 
Netherlands (2009)
116
 
Kobelt et al., Sweden (2011)
57
 Schipper et al., The 
Netherlands (2011)
98
 
Perspective payer societal societal health care; societal 
Comparators adalimumab+MTX, etanercept, 
infliximab+MTX, 
adalimumab+MTX/etanercept 
and palliative care (DMARD) 
sequental monotherapy, step-up 
combination therapy, initial 
combination therapy with 
prednisone and initial 
combination therapy with 
infliximab (BeSt trial) 
etanercept+MTX vs. MTX MTX – MTX+LEF – 
MTX+anti-TNF; MTX+LEF – 
MTX+anti-TNF; immediate 
start with MTX+anti-TNF 
Model structure Individual patient simulation 
model based on the model by 
Bansback et al.
9
, five alternative 
sequences of therapies, lifetime 
horizon, 6 months cycles, 
responses according to ACR 
and associated HAQ score..   
Individual sampling model  Markov model, 6 month cycles, 
lifetime horizon; adapted to 
early RA and transformation of 
the model to accommodate dose 
reductions and treatment 
switches.  
Markov model, 3-month cycles, 
5-year horizon, health states by 
disease activity 
Patient inputs patient characteristics from the 
PREMIER trial 
 baseline characteristics: 508 
patients with recent onset active 
RA from 20 Dutch medical 
centers were enrolled 
Patients with the characteristics 
of the total population enrolled 
in COMET 
registry 
Sources of 
effectiveness 
evidence 
Short-term trial data 
(PREMIER, ASPIRE and ERA) 
were used  to determine the 
response rates and HAQ  
Effectiveness from BeSt study COMET trial. Discontinuation 
rates: South Swedish Biologics 
Registry (SSATG) to determine 
HAQ and DAS28 
registry, efficacy data of anti-
TNF were derived from patients 
with prior DMARD use 
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Data Davies et al., USA (2009)
30
 Ven den Hout et al., The 
Netherlands (2009)
116
 
Kobelt et al., Sweden (2011)
57
 Schipper et al., The 
Netherlands (2011)
98
 
Sources of cost 
data 
HAQ profiles were used to 
calculate direct and indirect 
costs.  
Monitoring and administration 
costs were calculated based on 
clinicians’ assessments. To 
measure other direct medical 
costs (e.g ., physician visits, 
hospitalizations) a regression 
equation based in HAQ scores 
was used. Productivity costs 
were based on the proportion of 
annual average earnings lost 
associated with worsening 
HAQ scores  
Costs reported by the patients 
were used. Besides, published 
costs or market costs were 
applied. In the primary analysis 
the friction cost method, in the 
secondary analysis the human 
capital method was used.   
Population-based survey 
including direct costs and 
indirect costs (productivity 
losses  in the Malmö area, 
combined with early retirement 
data for a more urban 
population  in Stockholm area)  
related to disease activity states  
(from a 48-week multicentre 
trial) 
Utilities 4 adalimumab trials were used 
to estimate utilities.  
HAQ scores were used to 
calculate utility values on a 
scale of 0 to 1 using a 
regression equation derived 
from HUI-3 utility scores. 
Patients’ utility scores were 
modelled to decline by 0,28 for 
each one-unit increase in HAQ 
score  
The British and Dutch EQ-5D 
utilities and the Short-Form 6D 
utility were calculated from 
EQ-5D and SF-36 
questionnaires, respectively. 
Time-trade-Off method was 
used 
Utilities (EQ-5D) were taken 
from the same observational 
study in Malmö 
related to disease activity states 
(EQ-5D data from a survey) 
Discount rate 3.0% 3.0% 3.0% 4.0% 
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Data Davies et al., USA (2009)
30
 Ven den Hout et al., The 
Netherlands (2009)
116
 
Kobelt et al., Sweden (2011)
57
 Schipper et al., The 
Netherlands (2011)
98
 
Base case results adalimumab+MTX/etanercept 
of 19,663 US$/QALY 
compared with adalimumab as 
sole TNF-antagonist and of 
23,377 US$/QALY for 
adalimumab+MTX  compared 
with the etanercept sequence. 
The sequences of etanercept 
and infliximab+MTX were 
extendedly dominated.   
Primary analysis: based on the 
British EQ-5D, QALY was 1,41 
for strategy 4 (initial 
combination with infliximab) at 
a cost of €32,403. The ICER of 
strategy 4 compared with 
strategy 3 was €130,000.  
Secondary analysis: based on 
the Dutch EQ-5D, SF-6D and 
TTO cost-utility ratios of 
strategy 4 compared with 
strategy 3 were €140,000; 
€250,000 and €320,000 per 
QALY, respectively.  
With human capital method the 
cost-utility ratio of strategy 4 
compared with strategy 3 was 
€22,000 per QALY    
Incremental QALY was 1,25 
and incremental cost was 
€15,546 for etanercept+MTX. 
This gives an ICER for this 
biologic strategy of €13,518. 
anti-TNF strategy compared 
with the MTX 
strategy from the health-care 
perspective €138,056/QALY, 
€136,207/QALY from the 
societal perspective 
Key sensitivity 
analysis 
ICER was sensitive to many of 
the changes in parameters: 
DMARD withdrawal rate, HAQ 
progression on anti-TNF, HAQ 
progression response, age, 
direct costs, mortality and 
utility 
- Results were sensitive to the 
drop-out rate, the duration of 
treatment with reduced ETA-
dose, time horizon and the 
perspective of the analysis 
If estimate of 30% of the 
DMARD-naive patients 
achieving remission with anti-
TNF was applied: healthcare 
perspective €116,598/QALY, 
societal perspective 
€114,982/QALY 
LEF= leflunomide, CYC= cyclosporine, MTX=methotrexate, RTX= rituximab;nbDMARD=non-biological Disease Modifying Antirheumatic 
Drug 
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Table 7 RA patients who failed at least one synthetic DMARD therapy - summary of cost-utility evidence identified 
Data Vera-Llonch et 
al., US (2008)
121
 
Virkki et al., 
Finland 
(2008)
122
 
Kobelt et al., 
Sweden (2009)
58
 
Sany et al., 
France (2009)
95
 
Lekander et al., 
Sweden (2010)
64
 
Schulze-Koops 
et al., Germany 
(2009)
100
 
Soini et al., 
Finland 
(2012)
106
 
Diamantopoulo
s et al., Italy 
(2012)
32
 
Perspective third party payer healthcare payer societal health insurance 
coverage 
societal societal healthcare payer  National Health 
Service 
Comparator
s 
MTX versus 
MTX+abatacept 
(<60 kg:500 
mg/vial; 60-100 
kg: 750 mg/vial; 
>100 kg: 1 g) 
infliximab vs. 
traditional 
DMARD 
TNF blockers  before infliximab 
treatment 
compared to 
results after 1st 
and 2nd year of 
infliximab 
treatment 
infliximab vs. no 
biological 
treatment 
(natural 
progression) 
etanercept+MTX 
vs. MTX 
adalimumab+M
TX, 
etanercept+MTX
, or 
tocilizumab+MT
X were used as 
first biologics 
followed by 
rituximab+MTX 
and 
infliximab+MTX
; 
supportive care 
(MTX) 
tocilizumab 
Basecase: ETA – 
ADA – RTX -
ABA – palliative 
vs. TOC – ADA 
– RTX – ABA – 
palliative care; 
Alternatives:  
ADA – ETA – 
RTX – ABA – 
palliative; INF – 
ETA – RTX 
ABA – 
palliative; adding 
TOC to 
standard-of-care: 
TOC – ETA – 
ADA – RTX – 
ABA – palliative 
Model 
structure 
simulation 
model, horizon: 
10 yrs and 
lifetime; 3-
months cycles, 
simulation of 
1000 patients 
real life data, 
assumption for 
patients without 
inflximab 
therapy 
discrete event 
simulation, 5-
year and 10-year 
horizon 
analysis of real 
world data 
Markov model  
with  five health 
state (HAQ) 
categories each 
with two DAS28 
states 
Monte-Carlo-
Markov-Chain 
stimulation, 5 
HAQ states. 
individual 
sampling model, 
6 months cycles, 
lifetime horizon 
individual 
patient 
simulation 
model, 6-month 
cycles, lifetime 
horizon 
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Data Vera-Llonch et 
al., US (2008)
121
 
Virkki et al., 
Finland 
(2008)
122
 
Kobelt et al., 
Sweden (2009)
58
 
Sany et al., 
France (2009)
95
 
Lekander et al., 
Sweden (2010)
64
 
Schulze-Koops 
et al., Germany 
(2009)
100
 
Soini et al., 
Finland 
(2012)
106
 
Diamantopoulo
s et al., Italy 
(2012)
32
 
Patient 
inputs 
women aged 55-
64 years with 
moderate to 
severe RA, 
inadequate 
response to 
MTX 
297 patients, 
mean age 51 yrs, 
69% female, 
mean disease 
duration 12 
years, HAQ 1,33 
from a registry mean age at 
entry 
53.4 SD11.8 
years, 
 median DAS28 
5.82 (5.15–6.56), 
NSAID 
treatment 90%, 
MTX 98.7%. 
Individual 
sampling model 
using real-world 
patient -level 
data from the 
Stockholm TNF-
alfa follow-up 
registry 
(STURE) 
 n= 637, 1999 
and 2008. 
2 subgroups:  
were: patients 
with earlier- and 
late-stage RA  
Individual 
sampling model 
using real-world 
patient -level 
data from the 
TEMPO study. 
686 patients with 
active RA, mean 
disease duration 
>6 years. 
moderate-sever 
RA, mean 52.5 
years old, HAQ 
1.51 at the 
baseline, weight 
73 kg; 18% men 
equivalent to 
baseline 
characteristics of 
tocilizumab 
trials’ samples 
Sources of 
effectivenes
s evidence 
AIM trial follow-up 
results; patients 
without 
infliximab were 
assumed to 
progress a.a31 
HAQ/year  
registry registry; 
dose escalation 
of infliximab 
was considered 
 STURE registry, 
the comparator 
arm 
(nonbiological 
treatment): 
ERAS study  
TEMPO trial mixed treatment 
comparison of 
bDMARD trials 
tocilizumab: 
three phase III 
trials, mixed 
treatment 
comparison for 
the therapy 
sequences 
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Data Vera-Llonch et 
al., US (2008)
121
 
Virkki et al., 
Finland 
(2008)
122
 
Kobelt et al., 
Sweden (2009)
58
 
Sany et al., 
France (2009)
95
 
Lekander et al., 
Sweden (2010)
64
 
Schulze-Koops 
et al., Germany 
(2009)
100
 
Soini et al., 
Finland 
(2012)
106
 
Diamantopoulo
s et al., Italy 
(2012)
32
 
Sources of 
cost data 
medical 
treatment costs 
direct costs, 
official price 
lists; dose 
escaslation of 
infliximab was 
considered 
official price 
lists; cost of 
biological 
treatment was 
estimated based 
on three 
parameters: 
actual usage, 
dose of each of 
the agents, and 
adverse events; 
other costs were 
obtained from a 
survey and 
related to HAQ 
official price 
lists, data 
obtained from 
patient self-
questionnaire 
The direct and 
indirect costs 
were based on an 
empirical study 
by Kobelt et al., 
where costs were 
stratified by 
functional status 
based on 
Swedish registry 
data. 
The cost for 
added life-years 
were also 
estimated 
derived from 
Ekman et al.    
Costs: German 
database. 
Indirect costs 
were calculated 
using the human 
capital approach  
(sensitivity 
analysis included 
productivity loss 
as well) 
drugs: official 
prices, other 
direct costs: 
Italian survey 
Utilities derived from 
HAQ (range: 
0.86±0.16 – 
0.03±0.33) 
derived from 
HAQ (HAQ was 
measured int he 
follow up) 
directly from a 
registry 
derived from 
HAQ: 
 EQ-5D=0.862–
0.327*HAQ 
Utilities were 
derived from an 
empirical study 
by Kobelt et al. 
and based on the 
current HAQ 
state and by 
disease activity 
The instruments 
of HAQ and 
FFbH were used 
to generate 
utilities 
derived from 
HAQ: 
EQ5D=0.82-
0.11*HAQ-
0.07*(HAQ*HA
Q) 
derived from 
HAQ: EQ-5D = 
0.82 – 0.11 x 
HAQ - 0.07 x 
HAQ
2
 
Discount 
rate 
3.0% not applied 3.0% not applied 3.0% applied but not 
specified 
3.0% 3.0% 
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Data Vera-Llonch et 
al., US (2008)
121
 
Virkki et al., 
Finland 
(2008)
122
 
Kobelt et al., 
Sweden (2009)
58
 
Sany et al., 
France (2009)
95
 
Lekander et al., 
Sweden (2010)
64
 
Schulze-Koops 
et al., Germany 
(2009)
100
 
Soini et al., 
Finland 
(2012)
106
 
Diamantopoulo
s et al., Italy 
(2012)
32
 
Base case 
results 
10-year horizon: 
$47 910 ($44 
641, $52 136) / 
QALY; lifetime 
horizon: $43 041 
($39 070, $46 
725) / QALY 
median ICER  
51,884 
Euro/QALY 
5-year horizon: 
cost EUR 
138,000 and 2.5 
QALY gain. 10-
year horizon: 
cost EUR 
223,000 and 4.4 
QALY gain. 
QALY gain total 
sample: 0.15 
Incremental net 
benefit (INB): 
The INB was, 
in the total 
sample  
significantly 
positive >249 
663. 
Infliximab: 
QALYs 1,019, 
costs €190,089. 
Non-biological: 
costs €166,824. 
ICER of 
infliximab vs. 
non-biological 
therapy: 
€22,830/QALY.  
MTX: QALYs 
1017,1, costs 
€162,520,668. 
Etanercept+MT
X: QALYs 
2119,6, costs 
€206,163,041. 
ICER 
etanercept+MTX 
vs. MTX: € 
39,585.  
 
Tocilizumab was 
more cost-
effective than 
etanercept and 
adalimumab in 
comparison with 
MTX alone (and 
both etanercept 
and tocilizumab 
dominated 
adalimumab 
(tocilizumab+M
TX vs. MTX 
€17,057) 
Tocilizumab 
dominates 
standard-of-care, 
also if ETA was 
replaced with 
adalimumab, but 
for INF 
replacement the 
ICER was 
€2,655. Adding 
TOC to 
standard-of-care: 
ICER 
17,119/QALY. 
Key 
sensitivity 
analysis 
10-year: $40 190 
to $70 209 / 
QALY; $37 551 
to $60 106  
QALY 
(n=79 (35%)of 
the patients with 
QALY gain had 
an ICER of 
≤40,000 
Euro/QALY) 
initiating 
biological 
therapy at 
shorter disease 
duration is more 
beneficial 
(higher gain at a 
lower cost). 
Subgroups with 
higher HAQ 
result more 
beneficial 
results. 
ICER was 
sensitive to 
many of the 
changes in 
parameters, in 
particular age at 
start of treatment 
initiation and the 
rate of natural 
disease 
progression  
Results were 
sensitive to cost 
of etanercept, 
cost of acquired 
disability, the 
probability of 
withdrawals, the 
discount rate of 
costs and 
discount rate of 
effects 
The modelling 
assumptions only 
had a small 
impact on the 
relative results. 
Tocilizumab 
dominant. 
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Table 8 RA patients who failed at least one biologic DMARD therapy - summary of cost-utility evidence identified 
Data Kielhorn et al., 
UK (2008)
52
 
Vera-Llonch 
et al., US 
(2008)
121
 
Lindgren et 
al., Sweden 
(2009)
66
 
Brodszky et 
al., Hungary 
(2010)
23
 
Hallinen et al., 
Finland 
(2010)
42
 
Merkesdal et 
al., Germany 
(2010)
76
 
Malottki et al., 
UK (2011)
70
 
Benucci  et al., 
Italy (2011)
14
 
Perspective National Health 
Service (NHS) 
third party 
payer 
societal society 
(alternative 
analysis: health 
care payer) 
societal 
perspective 
health care 
payer 
National 
Health Service 
(NHS) 
not stated (drug 
costs 
considered) 
Comparato
rs 
rituximab vs. 
therapy 
sequences: 
Scenario A: 
LEF, gold, 
CYC, palliative 
care; Scenario 
B: ADA+MTX, 
INF+MTX, 
LEF, gold, 
CYC, palliative 
care; compared 
to: RTX+MTX 
(every 9 
months) 
included in the 
sequence 
abatacept+MT
X vs. MTX 
rituximab 
(mean 2.4 
years,  5.2 
treatments) vs. 
second line 
TNF-α blocker 
treatment 
rituximab (1 
course; 3 yrs 
treatment) vs. 
palliative 
treatment 
RTX+MTX; 
ABA+MTX; 
ETA+MTX; 
ADA+MTX; 
INF+MTX 
rituximab vs. 
an alternative 
TNF-alfa 
inhibiting 
treatment as 
second-line 
biological 
treatment after 
etanercept 
therapy  
Sequences 
starting with 
one of the 
following 
biologicals: 
adalimumab, 
etanercept, 
infliximab, 
rituximab, 
abatacept; 
 and synthetic 
DMARDs 
rituximab+MT
X compared to 
baseline 
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Data Kielhorn et al., 
UK (2008)
52
 
Vera-Llonch 
et al., US 
(2008)
121
 
Lindgren et 
al., Sweden 
(2009)
66
 
Brodszky et 
al., Hungary 
(2010)
23
 
Hallinen et al., 
Finland 
(2010)
42
 
Merkesdal et 
al., Germany 
(2010)
76
 
Malottki et al., 
UK (2011)
70
 
Benucci  et al., 
Italy (2011)
14
 
Model 
structure 
Markov model, 
lifetime horizon, 
6-months 
cycles, 10 000 
simulations 
patient-level 
simulation 
model, 10 
years and 
lifetime 
horizon 
patient-level 
discrete event 
simulation 
model, lifetime 
horizon 
Markov model, 
lifetime 
horizon 
Markov model, 
lifetime 
horizon, 
response 
according to 
ACR20, 
ACR50 and 
ACR70 
determined. 
Markov model, 
lifetime 
microstimulatio
n.  
Response 
according to 
ACR 
determined and 
associated 
HAQ score 
individual 
sampling 
(Birmingham 
RA Model –
BRAM) 
NA (real life 
experiment), 1-
year horizon 
Patient 
inputs 
81% female, 
baseline age 
52.2 yrs, body 
weight 78 kg, 
HAQ 1.88; 
inadequate 
response to two 
nbDMARDs 
and one TNFα 
inhibitor 
women, aged 
55–64 years, 
(HAQ 1,8, 
EQ-5D 0,39) 
with 
moderately to 
severely 
active RA 
with at least 1 
TNF-α 
blocker failure 
base case: 52-
year-old female 
patient with a 
HAQ of 1.9 at 
the start of the 
second biologic 
and a disease 
duration of 12 
years 
predominantly 
women (81%), 
mean age 52.5 
years, moderate 
to severe RA, 
failure of 
nbDMARDS 
and at least 1 
TNFα inhibitor 
(REFLEX trial) 
Identical, 
hypothetical 
RA patients 
cohort with 
3000 patients  
Individual 
sampling 
model using 
baseline patient 
characteristics 
from the 
REFLEX trial. 
Patients having 
failed at least 
one prior 
DMARD 
therapy and 
one subsequent 
TNF-inhibiting 
therapy   
from registry  moderate or 
severe RA 
(DAS28 5.84 
±0.8; DAS28-
CRP 5.05 ±0.9; 
HAQ 2.04 
±0.44) with 
min. 1 TNF-α 
blocker failure 
Sources of 
effectivene
ss evidence 
REFLEX trial ATTAIN trial rituximab: 
REFLEX trial; 
second line 
TNF-α data 
from a registry 
REFLEX trial Effectiveness 
from published 
clinical trials 
adjusted RCT 
data, expert 
opinion 
randomized 
controlled trials 
real life data 
(n=32) 
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Data Kielhorn et al., 
UK (2008)
52
 
Vera-Llonch 
et al., US 
(2008)
121
 
Lindgren et 
al., Sweden 
(2009)
66
 
Brodszky et 
al., Hungary 
(2010)
23
 
Hallinen et al., 
Finland 
(2010)
42
 
Merkesdal et 
al., Germany 
(2010)
76
 
Malottki et al., 
UK (2011)
70
 
Benucci  et al., 
Italy (2011)
14
 
Sources of 
cost data 
drug, 
administration 
and monitoring 
costs, direct 
medical costs 
(official prices) 
only direct 
medical costs 
were 
considered, 
varying by 
HAQ 
drug costs: 
official price 
lists; data of a 
survey were 
used to 
calculate other 
costs as a 
function of 
HAQ and 
DAS28 
official price 
lists 
(infliximab 
dose escalation 
was 
considered) 
Resource use 
and costs were 
obtained from 
the Finnish 
treatment 
practice, one 
published 
study, the 
Finnish Unit 
Cost list and 
Finnish 
Medicine 
Tariffs  
drug costs: 
German drug 
retail prices for 
pharmacists. 
The HAQ score 
groups and 
related 
inpatient costs: 
German 
registry. 
Indirect costs 
were estimated 
by impaired 
work capacity 
due to RA 
only direct 
costs; official 
price lists 
direct medical 
costs 
Utilities derived from 
HAQ:  
QoL =0.76–
0.28xHAQ+0.05
xfemale 
EQ-5D 
derived from 
HAQ 
(national RA 
registry) 
registry data 
were used to 
link utilities to 
HAQ and 
DAS28 
EQ-5D derived 
from HAQ 
(linera 
regression) 
QoL were 
estimated on 
the basis of the 
formula 
provided by 
Bansback et al. 
on the basis of 
HUI-3 and 
HAQ. 
ACR response 
ACR response 
categories were 
converted into 
HAQ score 
improvement 
according to 
the data of the 
REFLEX trial 
EQ-5D derived 
from HAQ 
derived from 
HAQ 
Discount 
rate 
3.5% 3.0% 3.0% 5.0% 3% 3,5% 3.5% not applied 
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Data Kielhorn et al., 
UK (2008)
52
 
Vera-Llonch 
et al., US 
(2008)
121
 
Lindgren et 
al., Sweden 
(2009)
66
 
Brodszky et 
al., Hungary 
(2010)
23
 
Hallinen et al., 
Finland 
(2010)
42
 
Merkesdal et 
al., Germany 
(2010)
76
 
Malottki et al., 
UK (2011)
70
 
Benucci  et al., 
Italy (2011)
14
 
Base case 
results 
Scenario A, 
ICER: 
£14 690/QALY 
Scenario B, 
ICER: 
£11 601/QALY 
ICER 10 
years: 
$50,576/QAL
Y, lifetime 
$45,979. 
rituximab is 
dominant 
(incremental 
cost: - €2500, 
incremental 
QALY: 0.2) 
1 course RTX, 
ICER: – 
€31,140/QALY
, 3-year RTX: 
€26,223/QALY 
from societal 
perspective.  
The ICERs of 
RTX compared 
to BSC was 
€30248/QALY; 
ADA vs. 
€50 941/QALY
, ETA vs BSC 
€50 372/QALY
, INF vs. BSC 
€36121/QALY, 
ABA vs. BSC 
€67 003/QALY
. 
ICER RTC vs 
stand seq. 
€24,517/QALY
. 
When indirect 
costs were also 
included, the 
ICER was 
€15,565. 
Compared to 
conventional 
DMARD alone 
RTX 
dominates TNF 
inhibitors (e.g. 
RTX-
sDMARD: 
£21,100/QALY
; ADA-RTX 
dominant, 
ETA-RTX 
dominant, INF-
RTX 
dominant) 
€23,696/QALY 
Key 
sensitivity 
analysis 
RTX dosing 
frequency: 12 
months: 
9759/QALY; 6 
months: 
23 774/QALY 
ICER 10 
years: $46,675 
- 
$80,673/QALY
; lifetime: 
40,836 - 
59,875/QALY. 
Only if 
rituximab were 
administered 
every 4 months 
or less are costs 
for this strategy 
higher 
ICERs -
€31,140€/QAL
Y and 
€21,980/QALY
, respectively 
from the health 
care payer 
perspective 
(RTX vs. 
switch to a 2nd 
biological: 
RTX 
dominant) 
Results were 
sensitive to the 
length of the 
treatment, 
negative 
QALYs, the 
discount rate 
and the impact 
of the Finnish 
system 
Results were 
sensitive to the 
RTX dosing 
scheme, on 
changes to 
HAQ 
deterioration, 
discounting, 
rebound effect 
value, the 
model entry 
age or entry 
HAQ score, the 
risk multiplier 
and the effect 
of work 
capacity 
the assumed 
time between 
RTX treatment 
had significant 
effect 
subgroup 
analysis by the 
number of 
TNF- α blocker 
failures: ICER 
is more 
beneficial in 
patients with 
only 1 TNF-α 
blocker failure: 
€14,447/QALY 
  
84 
Biological therapies for the treatment of RA – systematic review of the health economic 
literature (V. Hevér N) 
 
Table 9 DMARD naive RA patients - Quality assessment of the health economic evaluations by the Drummond checklist  
✔ or X or NA (not applicable) 
Checklist Davies et al., US (2009)
30
 Kobelt et al., Sweden 
(2009)
57
 
Van den Hout et al., The 
Netherlands (2009)
116
 
Schipper et al., The 
Netherlands (2011)
98
 
Research question     
 ✔ ✔ ✔ ✔ 
2. Alternatives compared × ✔ ✔ ✔ ✔ 
3. The viewpoint(s)/perspective of the 
analysis is clearly stated(e.g. NHS, 
society) 
✔ ✔ ✔ ✔ 
Selection of alternatives     
4. All relevant alternatives are 
compared (including ‘do nothing’ 
if applicable) 
✔ ✔ ✔ ✔ 
5. The alternatives being compared 
are clearly described (who 
did what, to whom, where and how 
often) 
✔ ✔ ✔ ✔ 
6. The rationale for choosing the 
alternative programmes or 
interventions compared is stated 
✔ ✔ ✔ ✔ 
Form of evaluation     
7. The choice of form of economic 
evaluation is justified in relation to 
the questions addressed  
✔ ✔ ✔ ✔ 
8. If a cost-minimisation design is 
chosen, have equivalentoutcomes 
been adequately demonstrated? 
NA NA NA NA 
Effectiveness data     
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Checklist Davies et al., US (2009)
30
 Kobelt et al., Sweden 
(2009)
57
 
Van den Hout et al., The 
Netherlands (2009)
116
 
Schipper et al., The 
Netherlands (2011)
98
 
9. The source(s) of effectiveness 
estimates used are stated 
(e.g. single study, selection of studies, 
systematic review, expert opinion) 
✔ ✔ ✔ ✔ 
10. Effectiveness data from RCT or 
review of RCTs 
✔ ✔ ✔ X (cohort, registry) 
11. Potential biases identified 
(especially if data not from RCTs)  
X X ✔ ✔ 
12. Details of the method of synthesis 
or meta-analysis of estimates are 
given (if based on an overview of a 
number of effectiveness studies) 
✔ ✔ ✔ NA 
Costs     
13. All of the important and relevant 
resource use included  
✔ ✔ X ✔ 
14. All of the important and relevant 
resource use measured accurately 
(with methodology) 
✔ ✔ X ✔ 
15. Appropriate unit costs estimated 
(with methodology) 
✔ X ✔ ✔ 
16. Unit costs reported separately 
from resource use data 
X NA X ✔ 
17. Productivity costs treated 
separately from other costs  
✔ X ✔ ✔ 
18. The year and country to which 
unit costs apply is stated with 
appropriate adjustments for inflation 
and/or currency conversion 
X ✔ ✔ ✔ 
Benefit measurement and valuation     
19. The primary outcome measure(s) 
for the economic evaluation 
✔ ✔ ✔ ✔ 
20. Methods to value health states 
and other benefits are stated  
✔ ✔ ✔ ✔ 
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Checklist Davies et al., US (2009)
30
 Kobelt et al., Sweden 
(2009)
57
 
Van den Hout et al., The 
Netherlands (2009)
116
 
Schipper et al., The 
Netherlands (2011)
98
 
21. Details of the individuals from 
whom valuations were obtained are 
given 
✔ ✔ ✔ ✔ 
Decision modelling     
22. Details of any decision model 
used are given (e.g. decision tree, 
Markov model) 
✔ ✔ ✔ ✔ 
23. The choice of model used and the 
key input parameters on which it is 
based are adequately detailed and 
justified 
✔ ✔ X ✔ 
24. All model outputs described 
adequately 
✔ ✔ ✔ ✔ 
Discounting     
25. Discount rate used for both costs 
and benefits 
✔ ✔ ✔ ✔ 
26. Do discount rates accord with 
NHS guidance? 
X X X ✔(The Netherlands) 
Allowance for uncertainty     
Stochastic analysis of patient-level 
data 
    
27. Details of statistical tests and CIs 
are given for stochastic data 
✔ X ✔ ✔ 
28. Uncertainty around cost-
effectiveness expressed (e.g. CI 
around ICER, CEACs) 
✔ ✔ ✔ ✔ 
29. Sensitivity analysis used to assess 
uncertainty in nonstochastic 
variables (e.g. unit costs, discount 
rates) and analytic decisions (e.g. 
methods to handle missing data)  
✔ ✔ X ✔ 
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Table 10 RA patients who failed at least one synthetic DMARD - Quality assessment of the health economic evaluations by the 
Drummond checklist  
✔ or X or NA (not applicable) 
Checklist Vera-
Llonch et 
al., US 
(2008)
121
 
Virkki et 
al., 
Finland 
(2008)
122
 
Kobelt et 
al., 
Sweden 
(2009)
58
 
Sany et 
al., 
France 
(2009)
95
 
Lekander 
et al., 
Sweden 
(2010)
64
 
Scultze-
Koops et 
al., 
Germany 
(2009)
100
 
Soini et 
al., 
Finland 
(2012)
106
 
Diamanto
poulos et 
al, Italy 
(2012)
32
 
Research question         
 ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
2. Alternatives compared × ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
3. The viewpoint(s)/perspective of the 
analysis is clearly stated(e.g. NHS, 
society) 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Selection of alternatives         
4. All relevant alternatives are 
compared (including ‘do nothing’ 
if applicable) 
X (no 
other 
biologic 
therapies 
were 
considere
d) 
X (no 
other 
biological 
drugs 
were 
considere
d) 
✔ X (health 
status and 
costs 
before 
and after 
infliximab 
treatment
; no other 
alternative
s) 
✔ ✔ X 
(infliximab 
was 
considere
d only as 
second 
line 
biologic 
therapy) 
X 
(certolizu
mab pegol 
and 
golimuma
b not 
included) 
5. The alternatives being compared 
are clearly described (who 
did what, to whom, where and how 
often) 
✔ ✔ ✔ ✔ X ✔ ✔ ✔ 
6. The rationale for choosing the 
alternative programmes or 
interventions compared is stated 
✔ X ✔ ✔ ✔ ✔ ✔ ✔ 
Form of evaluation         
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Checklist Vera-
Llonch et 
al., US 
(2008)
121
 
Virkki et 
al., 
Finland 
(2008)
122
 
Kobelt et 
al., 
Sweden 
(2009)
58
 
Sany et 
al., 
France 
(2009)
95
 
Lekander 
et al., 
Sweden 
(2010)
64
 
Scultze-
Koops et 
al., 
Germany 
(2009)
100
 
Soini et 
al., 
Finland 
(2012)
106
 
Diamanto
poulos et 
al, Italy 
(2012)
32
 
7. The choice of form of economic 
evaluation is justified in relation to 
the questions addressed  
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
8. If a cost-minimisation design is 
chosen, have equivalentoutcomes 
been adequately demonstrated? 
NA NA NA NA NA NA NA NA 
Effectiveness data         
9. The source(s) of effectiveness 
estimates used are stated 
(e.g. single study, selection of studies, 
systematic review, expert opinion) 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
10. Effectiveness data from RCT or 
review of RCTs 
✔ X X 
(registry) 
X 
(registry) 
X X ✔ ✔ 
11. Potential biases identified 
(especially if data not from RCTs)  
✔ X X X X X ✔ ✔ 
12. Details of the method of synthesis 
or meta-analysis of estimates are 
given (if based on an overview of a 
number of effectiveness studies) 
✔ X X X X X ✔ ✔ 
Costs         
13. All of the important and relevant 
resource use included  
X (only 
medical 
treatment 
costs) 
X (only 
direct 
costs) 
✔ ✔ ✔ ✔ ✔(indirect 
costs in 
the sens. 
analysis) 
X (only 
direct 
costs) 
14. All of the important and relevant 
resource use measured accurately 
(with methodology) 
✔ ✔ ✔ ✔ ✔ X ✔ ✔ 
15. Appropriate unit costs estimated 
(with methodology) 
✔ ✔ ✔ ✔ X X ✔ ✔ 
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Checklist Vera-
Llonch et 
al., US 
(2008)
121
 
Virkki et 
al., 
Finland 
(2008)
122
 
Kobelt et 
al., 
Sweden 
(2009)
58
 
Sany et 
al., 
France 
(2009)
95
 
Lekander 
et al., 
Sweden 
(2010)
64
 
Scultze-
Koops et 
al., 
Germany 
(2009)
100
 
Soini et 
al., 
Finland 
(2012)
106
 
Diamanto
poulos et 
al, Italy 
(2012)
32
 
16. Unit costs reported separately 
from resource use data 
✔ ✔ ✔ ✔ NA NA ✔ ✔ 
17. Productivity costs treated 
separately from other costs  
NA (no 
indirect 
costs) 
NA (no 
indirect 
costs) 
✔ ✔ X ✔ ✔ NA (no 
indirect 
costs) 
18. The year and country to which 
unit costs apply is stated with 
appropriate adjustments for inflation 
and/or currency conversion 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Benefit measurement and valuation         
19. The primary outcome measure(s) 
for the economic evaluation 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
20. Methods to value health states 
and other benefits are stated  
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
21. Details of the individuals from 
whom valuations were obtained are 
given 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Decision modelling         
22. Details of any decision model 
used are given (e.g. decision tree, 
Markov model) 
✔ NA (follow 
up data) 
✔ NA 
(registry 
data) 
✔ ✔ ✔ ✔ 
23. The choice of model used and the 
key input parameters on which it is 
based are adequately detailed and 
justified 
✔ NA ✔ NA X ✔ ✔ ✔ 
24. All model outputs described 
adequately 
✔ NA ✔ NA ✔ ✔ ✔ ✔ 
Discounting         
25. Discount rate used for both costs 
and benefits 
✔ X ✔ X ✔ ✔ ✔ ✔ 
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Checklist Vera-
Llonch et 
al., US 
(2008)
121
 
Virkki et 
al., 
Finland 
(2008)
122
 
Kobelt et 
al., 
Sweden 
(2009)
58
 
Sany et 
al., 
France 
(2009)
95
 
Lekander 
et al., 
Sweden 
(2010)
64
 
Scultze-
Koops et 
al., 
Germany 
(2009)
100
 
Soini et 
al., 
Finland 
(2012)
106
 
Diamanto
poulos et 
al, Italy 
(2012)
32
 
26. Do discount rates accord with 
NHS guidance? 
✔ (US) NA ✔ NA X X ✔(Finland
) 
✔ (Italy) 
Allowance for uncertainty         
Stochastic analysis of patient-level 
data 
        
27. Details of statistical tests and CIs 
are given for stochastic data 
✔ X ✔ X X X ✔ ✔ 
28. Uncertainty around cost-
effectiveness expressed (e.g. CI 
around ICER, CEACs) 
✔ X ✔ X X ✔ ✔ ✔ 
29. Sensitivity analysis used to assess 
uncertainty in nonstochastic 
variables (e.g. unit costs, discount 
rates) and analytic decisions (e.g. 
methods to handle missing data)  
✔ X ✔ X ✔ ✔ ✔ ✔ 
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Table 11 RA patients who failed at least one biologic DMARD - Quality assessment of the health economic evaluations by the 
Drummond checklist 
✔ or X or NA (not applicable) 
Checklist Kielhorn 
et al., UK 
(2008)
52
 
Vera-
Llonch et 
al., US 
(2008)
121
 
Lindgren 
et al., 
Sweden 
(2009)
66
 
Brodszky 
et al., 
Hungary 
(2010)
23
 
Hallinen 
et al., 
Finland 
(2010)
42
 
Merkesda
l et al., 
Germany 
(2010)
76
 
Malottki 
et al., UK 
(2011)
70
 
Benucci et 
al., Italy 
(2011)
14
 
Research question         
 ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
2. Alternatives compared × ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
3. The viewpoint(s)/perspective of the 
analysis is clearly stated(e.g. NHS, 
society) 
✔ ✔ ✔ ✔ ✔ ✔ ✔ X 
Selection of alternatives         
4. All relevant alternatives are 
compared (including ‘do nothing’ 
if applicable) 
✔ X (switch 
between 
TNF 
inhibitors 
ignored) 
✔ ✔ ✔ ✔ ✔ X 
(compared 
to baseline 
data) 
5. The alternatives being compared 
are clearly described (who 
did what, to whom, where and how 
often) 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
6. The rationale for choosing the 
alternative programmes or 
interventions compared is stated 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Form of evaluation         
7. The choice of form of economic 
evaluation is justified in relation to 
the questions addressed  
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
8. If a cost-minimisation design is 
chosen, have equivalentoutcomes 
NA NA NA ✔(sensitiv
ity 
NA NA NA NA 
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Checklist Kielhorn 
et al., UK 
(2008)
52
 
Vera-
Llonch et 
al., US 
(2008)
121
 
Lindgren 
et al., 
Sweden 
(2009)
66
 
Brodszky 
et al., 
Hungary 
(2010)
23
 
Hallinen 
et al., 
Finland 
(2010)
42
 
Merkesda
l et al., 
Germany 
(2010)
76
 
Malottki 
et al., UK 
(2011)
70
 
Benucci et 
al., Italy 
(2011)
14
 
been adequately demonstrated? analysis) 
Effectiveness data         
9. The source(s) of effectiveness 
estimates used are stated 
(e.g. single study, selection of studies, 
systematic review, expert opinion) 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
10. Effectiveness data from RCT or 
review of RCTs 
✔ ✔ ✔ ✔ ✔ ✔ ✔ X (real life 
data) 
11. Potential biases identified 
(especially if data not from RCTs)  
✔ ✔ ✔ ✔ X X ✔ X 
12. Details of the method of synthesis 
or meta-analysis of estimates are 
given (if based on an overview of a 
number of effectiveness studies) 
✔ NA NA ✔ ✔ ✔ ✔ NA 
Costs         
13. All of the important and relevant 
resource use included  
X (only 
direct 
medical 
costs) 
X (only 
direct 
medical 
costs) 
✔ ✔ ✔ ✔ X (only 
direct 
costs) 
X (only 
direct 
medical 
costs) 
14. All of the important and relevant 
resource use measured accurately 
(with methodology) 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
15. Appropriate unit costs estimated 
(with methodology) 
✔ ✔ ✔ ✔ ✔ X ✔ ✔ 
16. Unit costs reported separately 
from resource use data 
✔ ✔ ✔ ✔ ✔ NA ✔ X 
17. Productivity costs treated 
separately from other costs  
NA (no 
indirect 
costs) 
NA (no 
indirect 
costs) 
✔ ✔ X ✔ NA (only 
direct 
costs) 
NA (no 
indirect 
costs) 
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Checklist Kielhorn 
et al., UK 
(2008)
52
 
Vera-
Llonch et 
al., US 
(2008)
121
 
Lindgren 
et al., 
Sweden 
(2009)
66
 
Brodszky 
et al., 
Hungary 
(2010)
23
 
Hallinen 
et al., 
Finland 
(2010)
42
 
Merkesda
l et al., 
Germany 
(2010)
76
 
Malottki 
et al., UK 
(2011)
70
 
Benucci et 
al., Italy 
(2011)
14
 
18. The year and country to which 
unit costs apply is stated with 
appropriate adjustments for inflation 
and/or currency conversion 
✔ ✔ ✔ ✔ ✔ ✔ ✔ X 
Benefit measurement and valuation         
19. The primary outcome measure(s) 
for the economic evaluation 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
20. Methods to value health states 
and other benefits are stated  
✔ ✔  ✔ ✔ ✔ ✔ ✔ 
21. Details of the individuals from 
whom valuations were obtained are 
given 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Decision modelling         
22. Details of any decision model 
used are given (e.g. decision tree, 
Markov model) 
✔ ✔ ✔ ✔ ✔ ✔ ✔ NA 
23. The choice of model used and the 
key input parameters on which it is 
based are adequately detailed and 
justified 
✔ ✔ ✔ X (partly) ✔ ✔ ✔ NA 
24. All model outputs described 
adequately 
✔ ✔ ✔ ✔ ✔ ✔ ✔ NA 
Discounting         
25. Discount rate used for both costs 
and benefits 
✔ ✔ ✔ ✔ ✔ ✔ ✔ X 
26. Do discount rates accord with 
NHS guidance? 
✔ ✔ (US ) ✔ 
(Sweden) 
✔(HUN) X X ✔ X 
Allowance for uncertainty         
Stochastic analysis of patient-level 
data 
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Checklist Kielhorn 
et al., UK 
(2008)
52
 
Vera-
Llonch et 
al., US 
(2008)
121
 
Lindgren 
et al., 
Sweden 
(2009)
66
 
Brodszky 
et al., 
Hungary 
(2010)
23
 
Hallinen 
et al., 
Finland 
(2010)
42
 
Merkesda
l et al., 
Germany 
(2010)
76
 
Malottki 
et al., UK 
(2011)
70
 
Benucci et 
al., Italy 
(2011)
14
 
27. Details of statistical tests and CIs 
are given for stochastic data 
X ✔ ✔ X X ✔ ✔ X 
28. Uncertainty around cost-
effectiveness expressed (e.g. CI 
around ICER, CEACs) 
X ✔ ✔ X ✔ ✔ ✔ X 
29. Sensitivity analysis used to assess 
uncertainty in nonstochastic 
variables (e.g. unit costs, discount 
rates) and analytic decisions (e.g. 
methods to handle missing data)  
✔ ✔ ✔ X (partly) ✔ ✔ ✔ X 
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8 Appendices 
 
8.1 Search terms for RCTs and meta-analyses 
 
"arthritis, rheumatoid"[MeSH Terms] AND (abatacept OR adalimumab OR certolizumab OR 
golimumab OR etanercept OR infliximab OR rituximab OR tocilizumab) AND ((randomized 
controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR 
"clinical trials as topic"[MeSH Terms:noexp] OR randomly[tiab] OR trial[ti]) NOT ("animals"[MeSH 
Terms] NOT "humans"[MeSH Terms])) AND ("2009/11/01"[PDAT] : "2012/03/31"[PDAT]) 
 
8.2 Search results and study selection 
 
See file:  infliximab.ra.hta.appendix.5.2.literaturesearch.docx 
 
 
8.3 Quality assessment of included studies; detailed description of Jadad 
score 
 
Calculating Jadad score is based on a three-point questionnaire published by Jadad et al.
46
. 
Each question can be answered with either a yes or a no. Each yes scores one point, each no 
zero points. The questions were: 
1. Was the study described as randomized? 
2. Was the study described as double blind? 
3. Was there a description of withdrawals and dropouts? 
To receive the corresponding point, an article should describe the number of withdrawals and 
dropouts, in each of the study groups, and the underlying reasons.  
Additional points were given if: 
The method of randomisation was described in the paper, and that method was appropriate. 
The method of blinding was described, and it was appropriate. 
Points would however be deducted if: 
The method of randomisation was described, but was inappropriate. 
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The method of blinding was described, but was inappropriate. 
A paper reporting a clinical trial could therefore receive a Jadad score of between zero and 
five. 
 
8.4 Description of mixed treatment models and WinBUGS codes 
All MTC models used the odds ratio as the measure of relative treatment effect and assumed 
that treatment effects on the odds-ratio scale were multiplicative and exchangeable between 
trials. Each model was run with 3 chains and 10,000 burn-in iterations in order to limit the 
influence of the initial values on the simulated posterior distribution. A further 20,000 MCMC 
iterations were run, and the sampled values were used to estimate posterior means and 95% 
credibility intervals (CrIs). Credibility intervals are the Bayesian equivalent of classical 
confidence intervals.  
Convergence was assessed based on Brooks-Gelman-Rubin (BGR) plot. The accuracy of the 
posterior estimates was done by calculating the Monte Carlo error for each parameter. As a 
rule of thumb, the Monte Carlo error for each parameter of interest is less than about 5% of 
the sample standard deviation. The overall residual deviance was compared to the number of 
independent data points to check if the model fit the data satisfactory. For a Binomial 
likelihood, each trial arm contributes 1 independent data point.  
Differences between treatments were considered significantly significant at the 0.05 level if 
the 95% CrIs around the odds ratio did not cross 1. 
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WinBUGS code for mixed treatment comparison 
# Binomial likelihood, logit link 
# Random effects model for multi-arm trials 
model{                               # *** PROGRAM STARTS 
for(i in 1:ns){                      # LOOP THROUGH STUDIES 
    w[i,1] <- 0    # adjustment for multi-arm trials is zero for control 
arm 
    delta[i,1] <- 0             # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)           # vague priors for all trial 
baselines 
    for (k in 1:na[i]) {             # LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood 
        logit(p[i,k]) <- mu[i] + delta[i,k]  # model for linear predictor 
        rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators  
#Deviance contribution 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))   
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-
rhat[i,k])))         } 
#  summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]])        
    for (k in 2:na[i]) {             # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
# mean of LOR distributions (with multi-arm trial correction) 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] 
# precision of LOR distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k 
# adjustment for multi-arm RCTs 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
# cumulative adjustment for multi-arm trials 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
      } 
  }    
totresdev <- sum(resdev[])           # Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
# vague priors for treatment effects 
for (k in 2:nt)[  d[k] ~ dnorm(0,.0001) } 
sd ~ dunif(0,5)     # vague prior for between-trial SD 
tau <- pow(sd,-2)   # between-trial precision = (1/between-trial variance) 
 
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2 
for (c in 1:(nt-1)) { 
for (k in (c+1):nt) { 
or[c,k]  <-  exp(d[k] - d[c]) 
lor[c,k] <- (d[k]-d[c]) 
} 
} 
# ranking on relative scale 
for (k in 1:nt) { 
rk[k] <- nt+1-rank(d[],k) # assumes events are “good” 
#rk[k] <- rank(d[],k) # assumes events are “bad” 
best[k] <- equals(rk[k],1) #calculate probability that treat k is best 
} 
 
}                           # *** PROGRAM ENDS                           
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8.5 Detailed description of RCTs included 
 
Table 12 Bathon 2000, etanercept 
Examination multicenter, randomized, placebo controlled study 
 
Number of patients 632 
Inclusion criteria - at least 18 years of age 
- had rheumatoid arthritis for no more than three years 
- had no other important concurrent illnesses, and had not been 
treated with methotrexate 
Stable doses of nonsteroidal antiinflammatory drugs and prednisone 
(«10 mg daily) were allowed. 
Exclusion criteria - got disease-modifying antirheumatic drugs (including 
hydroxychloroquine and sulfasalazine) less than four weeks before 
the study began 
Therapy - 10 mg etanercept twice-weekly + 3 placebo tablets weekly 
- 25 mg etanercept twice-weekly + 3 placebo tablets weekly 
- three (2.5-mg) tablets of methotrexate weekly and twice weekly 
subcutaneous injections 
Rescue therapy (number of 
patients) 
0  
Follow-up time 12 months 
Primary endpoint ACR-N (20, 50, 70) and change in total Sharp core 
Secondary endpoints  
JADAD score 1  
Comment  
 
Table 13 Breedveld 2006, adalimumab 
Examination multicenter, double-blind, phase III, active comparator-controlled 
study 
Number of patients 799 
Inclusion criteria - active disease of <3 years’ duration  
- had never been treated with MTX 
- patients have to be 18 years of age or older and have to have disease 
that fulfilled the 
American College of Rheumatology 1987 revised criteria for the 
classification of RA with a disease duration of 3 years.  
- patients had to have had 8 swollen joints, 10 tender joints, and an 
erythrocyte sedimentation rate of 28mm/hour or C-reactive protein 
(CRP) concentration of 1.5 mg/dl, and had to either be rheumatoid 
factor positive or have had at least 1 joint erosion 
Exclusion criteria - patients who had received treatment with MTX, cyclophosphamide, 
cyclosporine, azathioprine, or 2 other DMARDs, were excluded 
Therapy - adalimumab 40 mg subcutaneously every other week plus oral MTX 
- adalimumab 40 mg subcutaneously 
every other week,  
- weekly oral MTX 
Rescue therapy (number of 
paients) 
0 
Follow-up time 52 weeks 
Primary endpoint ACR50 and change in total Sharp score 
Secondary endpoints DAS28, HAQ-DI, change from baseline the modified total Sharp 
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score at year 2, ACR20, ACR50, ACR70, ACR90 at year 2 
JADAD score 5 
Comment  
 
Table 14 Clair 2004, infliximab 
Examination randomized, placebo controlled study  
Number of patients 1049 
Inclusion criteria - at least 18 years old but no older than 75 years 
- met the 1987 revised criteria of the ACR (formerly, the American 
Rheumatism Association) for the classification of RA  
- had persistent synovitis for 3 months and 3 years, 10 swollen joints, 
12 tender joints 
 - patients had to have had one or more of the following: a positive 
test result for serum rheumatoid factor, radiographic erosions of the 
hands or feet, or a serum C-reactive protein (CRP) level 2.0 mg/dl 
Exclusion criteria - had any prior treatment with MTX, had received other DMARDs 
within 4 weeks of entry (or leflunomide within the past 6 months), or 
had been treated with infliximab, etanercept, adalimumab, or other 
anti-TNFagent 
- infection with human immunodeficiency virus, hepatitis B virus, or 
hepatitis C virus as well as a history of active or past tuberculosis, 
congestive heart failure, or lymphoma or other malignancy within the 
past 5 years (excluding excised skin cancers) 
Therapy - Infliximab 3mg/kg + methotrexate 
- Infliximab 6mg/kg + methotrexate 
- placebo + methotrexate 
Rescue therapy (number of 
patients) 
0 
Follow-up time 54 weeks 
Primary endpoint ACR-N, and change in total Sharp score, HAQ* 
Secondary endpoint  
JADAD score 3 
Comment * The primary end point for improvement 
in physical function was the change from baseline in HAQ scores 
averaged over weeks 30–54 
 
  
109 Appendices 
Table 15 Cohen 2006, rituximab 
Examination multicenter, randomized, double-blind, placebo-controlled, phase III 
trial 
Number of patients 520 
Inclusion criteria - patients had RA for at least 6 months, according to the ACR 1987 
revised criteria and had active disease, which was defined as 8 
swollen joints and 8 tender joints, a C-reactive protein (CRP) level 
1.5 mg/dl or an erythrocyte sedimentation rate (ESR) 28 mm/hour, 
and radiographic evidence of at least 1 joint with a definite erosion 
attributable to RA, as determined by a central reading site 
- patients had to be taking MTX (10–25 mg/week) for at least 12 
weeks prior to screening, with the last 4 weeks at a stable dosage 
Exclusion criteria - a history of a rheumatic autoimmune disease other than RA (except 
secondary Sjögren’s syndrome), significant systemic involvement 
secondary to RA (vasculitis, pulmonary fibrosis, or Felty’s 
syndrome), or ACR functional class IV disease  
Therapy - rituximab 2x500mg + MTX 
- placebo + MTX 
Rescue therapy (number of 
patients) 
81  
Follow-up time 24 weeks 
Primary endpoint ACR20 
Secondary endpoints ACR50, ACR70, DAS28, EULAR criteria and the individual 
parameters of the ACR improvement criteria: swollen joint count, 
tender joint count, patient’s and physician’s global assessments of 
disease activity, patient’s assessment of pain, patient’s assessment 
of disability the CRP level, and the ESR 
JADAD score 5 
Comment  
 
 
Table 16 Edwards 2004, rituximab 
Examination multicenter, randomized, double-blind, controlled study 
Number of patients 161 
Inclusion criteria - at least 21 years of age, fulfilled the revised 1987 American 
Rheumatism Association criteria, and had active disease despite 
treatment with at least 10 mg of methotrexate per week 
- active disease was defined by the presence of at least eight swollen 
and eight tender joints and at least two of the following: a serum C-
reactive protein level of at least 15 mg per liter, an erythrocyte 
sedimentation rate of at least 28 mm per hour, or morning stiffness 
lasting longer than 45 minutes 
- patients were seropositive for rheumatoid factor, as defined by a 
plasma rheumatoid factor level of at least 20 IU per milliliter 
Exclusion criteria - had an autoimmune disease other than rheumatoid arthritis (except 
concurrent Sjogren’s syndrome), American Rheumatism Association 
functional class IV disease, 
active rheumatoid vasculitis, a history of systemic diseases associated 
with arthritis, chronic fatigue syndrome, serious and uncontrolled 
coexisting diseases, active infection, a history of recurrent clinically 
significant infection or of recurrent bacterial 
infections with encapsulated organisms, primary or secondary 
immunodeficiency, or a history of cancer 
Therapy - Rituximab 2x500mg 
  
110 Appendices 
- Rituximab 2x500mg +cyclophosphamide 
- Rituximab 2x500mg + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
0 
Follow-up time 24 weeks 
Primary endpoint ACR50 
Secondary endpoints ACR20, ACR70, a change in the disease-activity score, EULAR 
response 
JADAD score 3 
Comment  
 
Table 17 Emery 2008, etanercept 
Examination double-blind, randomised, parallel-group, multicentre, outpatient 
study with two periods 
Number of patients 542 
Inclusion criteria - age 18 years or older with diagnosis of adult-onset rheumatoid 
arthritis 
- disease duration of at least 3 months but not more than 2 years 
- DAS28 of 32 or more, and either Westergren ESR of 28 mm/h or 
more or C-reactive protein of 20 mg/L or more 
Exclusion criteria - had received previous treatment with methotrexate, etanercept, or 
another TNF antagonist at any time or had received treatment with 
other DMARDs or corticosteroid injections in the 4 weeks before 
baseline visits 
- important concurrent medical disease  
Therapy - Etanercept 50 mg weekly + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
0 
Follow-up time 52 weeks 
Primary endpoint DAS28, and change in total Sharp score 
Secondary endpoints health assessment questionnaire disability 
index and stopping work were analysed as change from baseline by 
use of ANCOVA 
JADAD score 5 
Comment comparison with other randomised clinical trials of early rheumatoid 
arthritis 
 
Table 18 Emery 2008, tocilizumab 
Examination phase III, randomised, double-blind, placebo controlled, parallel 
group study 
Number of patients 499 
Inclusion criteria - 18 years of age and older with moderate to severe active RA and 
failure to respond or intolerance to one or more TNF antagonists 
within the past year  
- had active RA for 6 months or more, swollen joint count (SJC) of 6 
or more, tender joint count (TJC) of 8 or more, and C-reactive protein 
(CRP) greater than 1.0 mg/dl or erythrocyte sedimentation rate (ESR) 
greater than 28 mm/h at baseline 
- discontinued etanercept (>2 weeks), infliximab or adalimumab (>8 
weeks), leflunomide (>12 weeks) and all DMARD other than 
methotrexate before receiving study medication 
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- had to be treated with methotrexate for 12 weeks or more before 
baseline (stable dose >8 weeks) 
Exclusion criteria - treatment with celldepleting agents, uncontrolled medical conditions 
history of other inflammatory diseases or functional class 4 RA, 
history of malignancies or recurrent infections, primary or secondary 
immunodeficiency, haemoglobin less than 8.5 g/dl, leucopenia, 
neutropenia, thrombocytopenia, abnormal liver function, triglycerides 
greater than 10 mmol/l, or recognised active tuberculosis, hepatitis B, 
or hepatitis C 
Therapy - Tocilizumab 8mg/kg + MTX 
- Tocilizumab 4mg/kg + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
117 patients 
Follow-up time 24 weeks 
Primary endpoint ACR20 
Secondary endpoints efficacy measures: adverse events, infections, infusion reactions 
JADAD score 3 
Comment  
 
Table 19 Emery 2009, golimumab 
Examination phase III, Multicenter, Randomized, Double-Blind, Placebo-
Controlled Study followed by an open-label 5-year extension 
Number of patients 637 
Inclusion criteria - adults who had RA, according to the American College of 
Rheumatology (ACR; formerly, the American Rheumatism 
Association) criteria, for at least 3 months before administration of 
the initial study agent and had not received more than 3 weekly doses 
of oral MTX as treatment of RA 
- had active RA, with at least 4 swollen joints and at least 4 tender 
joints at both screening and baseline, and met at least 2 of the 
following criteria at screening and/or baseline: 1) C-reactive protein 
(CRP) level of _1.5 mg/dl or erythrocyte sedimentation rate (ESR) of 
28 mm/hour according to the Westergren method, 2) morning 
stiffness lasting 30 minutes or longer, 3) bone erosion by radiography 
and/or magnetic resonance imaging prior to initiation of treatment 
with the study agent, or 4) anti–cyclic citrullinated peptide antibody 
positivity or rheumatoid factor positivity 
Exclusion criteria - had previously received infliximab, etanercept, adalimumab, 
rituximab, natalizumab, or cytotoxic agents, including chlorambucil, 
cyclophosphamide, nitrogen mustard, and other alkylating agents 
Therapy - Golimumab 100 mg + MTX 
- Golimumab 50 mg + MTX 
- Golimumab 100 mg + placebo 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
0 
Follow-up time 52 weeks 
Primary endpoint ACR-50 at week 24, and change in total Sharp score at week 52 
Secondary endpoint  
JADAD score 5 
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Comment The primary end point was the difference in the ACR50 response at 
week 24 between groups 3 and 4 combined (combined group) versus 
group 1 and a pairwise comparison (group 3 or group 4 versus group 
1). 
ACR20, ACR70, and ACR90 responses were also measured. 
 
Table 20 Emery 2010, rituximab 
Examination multicentre, randomized, double-blind, 
placebo-controlled, phase III study  
Number of patients 512 
Inclusion criteria - aged 18–80 years with RA according to American College of 
Rheumatology (ACR) criteria for ≥6 months, which was active 
despite MTX (10−25 mg/week for at least 12 weeks) 
- active disease was defined as swollen joint count (SJC) and tender 
joint count (TJC) both ≥8, and either C reactive protein (CRP) ≥0.6 
mg/dl or erythrocyte sedimentation rate (ESR) ≥28 mm/h 
- had to have an absolute neutrophil count ≥1500 cells/μl, a 
haemoglobin level ≥8 g/dl and IgM and IgG levels of ≥40 and ≥500 
mg/dl, respectively 
Exclusion criteria - had not previously received biological treatment for RA 
Therapy - Rituximab 2x1000 mg + MTX 
- Rituximab 2x500 mg + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
26 
Follow-up time 48 weeks 
Primary endpoint ACR20 
Secondary endpoints ACR50, ACR70, EULAR, DAS28-ESR and remission, HAQ-DI, 
MCIDs, FACIT-F 
JADAD score 3 
Comment  
 
Table 21 Emery 2006, rituximab 
Examination phase IIb, randomized, doubleblind, double-dummy, placebo-
controlled, international multifactorial trial  
Number of patients 465  
Inclusion criteria - between 18 and 80 years of age and had presented at least 6 months 
prior to randomization with moderate or severe RA (diagnosed 
according to the American College of Rheumatology despite ongoing 
treatment with MTX at a dosage of 10–25 mg/week (orally or 
parenterally) for at least 12 weeks before randomization, with a stable 
dosage during the last 4 weeks  
- active disease was defined as a swollen and tender joint count 8 and 
either an erythrocyte sedimentation rate 28 mm/hour or a C-reactive 
protein (CRP) serum level 1.5 mg/dl 
- must have failed prior treatment, manifesting as a lack or loss of 
response to treatment with at least 1 but not more than 5 DMARDs 
(other than MTX) and/or biologic response modifiers 
- discontinued DMARDs (except MTX) and biologic therapy at least 
4 weeks before randomization and discontinued infliximab, 
adalimumab, or leflunomide at least 8 weeks before randomization 
Exclusion criteria - concomitant treatment with any DMARD (other than MTX), anti–
tumor necrosis factor, or other biologic therapy 
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- had significant systemic involvement secondary to RA, evidence of 
significant other illnesses or laboratory abnormalities, a history of 
severe allergic or anaphylactic reactions to humanized or murine 
monoclonal antibodies, or previous treatment with rituximab or any 
lymphocyte-depleting therapies 
- had a history of recurrent significant infection 
Therapy - Rituximab 2x1000 mg + (10-25mg) MTX weekly 
- Rituximab 2x500 mg + (10-25mg) MTX weekly 
- Placebo + (10-25mg) MTX weekly 
Rescue therapy (number of 
patients) 
 
Follow-up time 24 weeks 
Primary endpoint ACR20 
Secondary endpoints ACR50, ACR70 and the effect on individual 
parameters of the ACR improvement criteria, DAS28, EULAR, 
FACIT-F subscore, HAQ-DI  
JADAD score 5 
Comment Rituximab was administered by intravenous (IV) infusion in RF-
positive patients: placebo, 500 mg or 1,000 mg on days 1 and 15 
(total dose 0 mg, 1,000 mg, and 2,000 mg). Glucocorticoids were 
administered as placebo methylprednisolone, given IV 30–60 minutes 
before the infusion of rituximab (or rituximab placebo) on days 1 and 
15, premedication methylprednisolone 100 mg, given IV on days 1 
and 15 (250 mg prednisone equivalent), or premedication 
methylprednisolone 100 mg, given IV on days 1 and 15 plus 60 mg of 
oral prednisone on days 2–7 and 30 mg on days 8–14 (total 
glucocorticoid dose 820 mg prednisone equivalent). RF-negative 
patients received either placebo or rituximab (2 1,000-mg infusions), 
with or without glucocorticoids. All patients received a weekly 
regimen of MTX (10–25 mg orally or parenterally) with folate (_5 
mg/week). 
 
Table 22 Fleischmann 2009, certolizumab 
Examination multicentre, randomised, double-blind, placebo-controlled study  
Number of patients 220 
Inclusion criteria - aged 18–75 years, had adult onset RA, defined by the 1987 
American College of Rheumatology (ACR) criteria of duration >6 
months, and had failed >1 prior DMARD due to lack of efficacy or 
intolerance 
- had to have active disease at screening and baseline, defined by >9 
(out of 68) tender joints and >9 (out of 66) swollen joints and >1 of 
the following: >45 min of morning stiffness, erythrocyte 
sedimentation rate (ESR; Westergren method) >28 mm/h,or C-
reactive protein (CRP)10 mg/litre 
Exclusion criteria - had any inflammatory arthritis other than RA or a history of chronic, 
serious or life-threatening infection, any current infection, a history of 
or a chest x ray suggesting tuberculosis or a positive (defined by local 
practice) purified protein derivative (PPD) skin test 
- had received biological therapies for RA within 6 months, or prior 
treatment with TNFa inhibitors 
Therapy - Certolizumab pegol 400mg every 4 weeks 
- Placebo every 4 weeks 
Rescue therapy (number of 
patients) 
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Follow-up time 24 weeks 
Primary endpoint ACR20 
Secondary endpoint ACR50, ACR70, ACR component scores, DAS28 (ESR3), patient-
reported outcomes, safety, HAQ-DI, HrQOL, VAS, mBPI, FAS 
JADAD score 5 
Comment  
 
Table 23 Furst 2003, adalimumab 
Examination double-blind, randomized, controlled trial  
Number of patients 636 
Inclusion criteria - 18 years of age or older 
 - had active RA at both screening and baseline visits defined by at 
least 6 swollen joints and at least 9 tender joints (excluding distal 
interphalangeal joints), and met the 1987 revised American College 
of Rheumatology (ACR) criteria9 for diagnosis of RA for at least 3 
months 
Exclusion criteria - used other biologic DMARD in RA  
- treated with anti-CD4 therapy or biologic DMARD (e.g., TNF 
antagonists, interleukin-1 receptor antagonists) and/or with a history 
of an active inflammatory arthritide other than RA, a history of active 
listeriosis or mycobacterial infection, a major episode of infection 
(i.e., infections requiring hospitalization, treatment with intravenous 
antibiotics within 30 days prior to screening, or oral antibiotics within 
14 days prior to screening), and any uncontrolled medical condition 
- a variety of comorbid diseases 
Therapy - Adalimumab 40 mg every other week + DMARD 
- Placebo + DMARD 
Rescue therapy (number of 
patients) 
 
Follow-up time 24 weeks 
Primary endpoint safety: adverse events, physical examination findings, and standard 
laboratory test results 
Secondary endpoints Efficacy was the secondary endpoint of this study and was assessed as 
ACR20, ACR50, and ACR70 responses 
JADAD score 3 
Comment  
 
Table 24 Genovese 2005, abatacept 
Examination randomized, double-blind, phase 3 trial 
Number of patients 393 
Inclusion criteria - met the American College of Rheumatology (ACR) criteria for 
rheumatoid arthritis, were at least 18 years of age, had had 
rheumatoid arthritis for at least one year, and had an inadequate 
response to anti TNFa therapy with etanercept, infliximab, or both at 
the approved dose after at least three months of treatment 
- at randomization, patients had to have at least 10 swollen joints, at 
least 12 tender joints, and C-reactive protein levels of at least 1 mg 
per deciliter (upper limit of the normal range, 0.5)  
- patients had to have been taking an oral DMARD or anakinra for at 
least 3 months, and the dose had to have been stable for at least 28 
days 
- all users were required to stop taking etanercept or infliximab for at 
least 28 or 60 days, respectively, before undergoing 
randomization 
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Exclusion criteria  
Therapy - Abatacept 10 mg + DMARD 
- Placebo + DMARD 
Rescue therapy (number of 
patients) 
 
Follow-up time 6 months 
Primary endpoint ACR20, HAQ-DI 
Secondary endpoint ACR50, ACR70 
JADAD score 5 
Comment  
 
Table 25 Genovese 2008, tocilizumab 
Examination phase III, randomized, double-blind, placebo-controlled 
Number of patients 1220 
Inclusion criteria - at least 18 years of age with moderate-tosevere RA of 6 months’ 
duration, diagnosed according to the American College of 
Rheumatology (ACR; formerly, the American Rheumatism 
Association) 1987 revised criteria for the classification of RA (21), 
with a swollen joint count (SJC) of 6, a tender joint count (TJC) of 8, 
and a C-reactive protein (CRP) level 1 mg/dl or an erythrocyte 
sedimentation rate (ESR) 28 mm/hour were enrolled 
- had received stable doses of permitted DMARDs (methotrexate, 
chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, 
azathioprine, and leflunomide) for 8 weeks prior to study entry 
Exclusion criteria - unsuccessfully treated with an anti-TNF agent or were previously 
treated with any cell-depleting therapy  
Therapy - Tocilizumab 8mg/kg + DMARD every 4 weeks 
- Placebo + DMARD every 4 weeks 
Rescue therapy (number of 
patients) 
64 
Follow-up time 24 weeks 
Primary endpoint ACR20 
Secondary endpoint ACR50, ACR70, DAS28, EULAR, ESR, HAQ, FACIT-F, systematic 
markers 
JADAD score 5 
Comment  
 
Table 26 Jones 2010, tocilizumab 
Examination double-blind, randomised, double-dummy, parallel-group study 
Number of patients 673 
Inclusion criteria - > 18 years, with moderate to severe RA for >3 months. Active RA 
was defined by the presence of >6 swollen joints (SJC) from a total of 
66, >8 tender joints (TJC) from a total of 68, and a C-reactive protein 
(CRP) level >1 mg/dl or erythrocyte sedimentation rate (ESR) >28 
mm/h 
- wanted to become pregnant  
Exclusion criteria - had clinically unstable concurrent illnesses (and screened according 
to local standards and also excluded if they had active or untreated 
latent tuberculosis), had been unsuccessfully treated with an anti-
TNFa agent, had received methotrexate in the 6 months preceding 
randomisation or discontinued previous methotrexate treatment 
because of clinically important adverse effects or lack of efficacy 
Therapy - Tocilizumab 8mg/kg every 4 weeks 
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- Methotrexate (7,5-20mg/week) 
Rescue therapy (number of 
patients) 
32 
Follow-up time 24 weeks 
Primary endpoint ACR20 
Secondary endpoints ACR50, ACR70, DAS28 (ESR), EULAR, HAQ-DI 
JADAD score 5 
Comment  
 
Table 27 Keystone 2009, golimumab 
Examination phase III, multicentre, randomised, double-blind, placebo controlled 
trial 
Number of patients 444 
Inclusion criteria - 18 years of age or older, had a diagnosis of RA according to the 
revised 1987 criteria of the American College of Rheumatology 
(ACR), for at least 3 months before screening, and were to have been 
on a stable methotrexate dose of 15 mg/week or greater but 25 
mg/week or less during the 4-week period immediately preceding 
screening 
- patients were to have tolerated 15 mg/ week or greater of 
methotrexate for at least 3 months before screening 
- required to have active RA, defined as four of more swollen joints 
(out of 66 total) and four or more tender joints (out of 68 total) and at 
least two of the following: (1) C-reactive protein (CRP) of 1.5 mg/dl 
or greater (normal range 0–0.6 mg/dl) or erythrocyte sedimentation 
rate (ESR) by the Westergren method of 28 mm/h or greater; (2) at 
least 30 minutes of morning stiffness; (3) bone erosion determined by 
x ray and/or magnetic resonance imaging; or (4) anticyclic 
citrullinated peptide antibody or rheumatoid factor positiv test results 
Exclusion criteria - had a known hypersensitivity to human immunoglobulin proteins or 
other components of golimumab 
- any previous use of any anti- TNF agent, rituximab, natalizumab or 
cytotoxic agents 
- should not have received anakinra; disease-modifying antirheumatic 
drugs other than methotrexate; or intravenous, intramuscular, or intra-
articular corticosteroids within 4 weeks before the first dose of study 
agent or alefacept or efalizumab within 3 months before the first dose 
of the study agent 
Therapy - Golimumab 100mg + MTX 
- Golimumab 50mg + MTX 
- Golimumab 100mg + Placebo 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
92 
Follow-up time 24 weeks 
Primary endpoint ACR20 at week 14, HAQ-DI at week 24 
Secondary endpoints ACR50, ACR70, ACR90, ACR-N, DAS28, EULAR 
JADAD score 5 
Comment  
 
Table 28 Keystone 2008, certolizumab 
Examination phase III, multicenter, randomized, double-blind, placebo-controlled, 
parallelgroup trial 
Number of patients 982 
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Inclusion criteria - at least 18 years of age and had a diagnosis of RA, as defined by the 
American College of Rheumatology (ACR; formerly, the American 
Rheumatism Association) 1987 criteria (11) for 6 months prior to 
screening but for 15 years 
Active disease was defined as 9 tender and 9 swollen joints at 
screening and at baseline, with either an erythrocyte sedimentation 
rate (ESR; Westergren) 30 mm/ hour or a C-reactive protein (CRP) 
level 15 mg/liter.  
- required to have received MTX for 6 months, with a stable dosage 
of 10 mg/week for 2 months prior to baseline 
Exclusion criteria - diagnoses of any other inflammatory arthritis or a secondary 
noninflammatory arthritis that could have interfered with our 
evaluation of the effects of certolizumab pegol on RA 
- patients with a history of tuberculosis or a chest radiograph showing 
active or latent tuberculosis 
- patients with positive findings on a purified protein derivative (PPD) 
skin test were excluded, unless the PPD positivity was associated with 
previous vaccination with BCG (PPD positive by local standard) 
- had a history of malignancy, demyelinating disease, blood 
dyscrasias, or severe, progressive, and/or uncontrolled renal, hepatic, 
hematologic, gastrointestinal, endocrine, pulmonary, cardiac, 
neurologic, or cerebral disease 
- had received any biologic therapy within 6 months (or had received 
etanercept and/or anakinra within 3 months) of baseline and/or any 
previous biologic therapy that resulted in a severe hypersensitivity or 
anaphylactic reaction were excluded, as were patients who had 
previously failed to respond to treatment 
with an anti-TNF agent 
Therapy - Certolizumab 400 mg + MTX 
- Certolizumab 200 mg + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patinets) 
 
Follow-up time 52 weeks 
Primary endpoint ACR20 at week 24, total Sharp score at week 52 
Secondary endpoints total Sharp score at week 24, HAQ-DI at weeks 24 and 52, ACR20 at 
week 52, ACR50 and ACR70 at weeks 24 and 52, mean 
changes from baseline in erosion and joint space narrowing scores, 
swollen (n 66 joints) and tender (n 68 joints) joint counts, physician’s 
and patient’s global assessments of disease activity, patient’s 
assessment of arthritis pain, physical function (according to the HAQ 
DI), the Disease Activity Score 28-joint assessment (DAS28), the 
ESR, and the CRP level 
JADAD score 5 
Comment  
 
 
Table 29 Keystone 2004, adalimumab 
Examination double-blind, parallel-group, placebo-controlled study  
Number of patients 619 
Inclusion criteria - 18 years of age or older, had active RA diagnosed according to the 
1987 revised American College of Rheumatology (ACR; formerly, 
American Rheumatism Association) criteria, and had 9 tender joints 
(of 68 evaluated), 6 swollen joints (of 66 evaluated), a C-reactive 
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protein concentration 1 mg/dl, and either rheumatoid factor positivity 
or at least 1 joint erosion on radiographs of the hands and feet 
- required to have been on MTX therapy for 3 months at a stable dose 
of 12.5–25 mg/week (or 10 mg/week in patients intolerant to MTX) 
for 4 weeks 
Exclusion criteria - prior use of anti-CD4 antibody therapy or TNF antagonists, a history 
of an active inflammatory arthritide other than RA, a history of active 
listeriosis or mycobacterial infection, a history of lymphoma or 
leukemia or other malignancy besides nonmelanoma skin cancer 
within 5 years, a major episode of infection (i.e., infections requiring 
hospitalization, treatment with intravenous antibiotics within 30 days 
prior to screening, or oral antibiotics within 14 days prior to 
screening), any uncontrolled medical condition, and pregnancy or 
breastfeeding 
Therapy - Adalimumab 40mg every other week + MTX 
- Adalimumab 20mg weekly + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
(nem vagyok benne biztos, h az az ág a rescue, amit ide írok) 48 
Follow-up time 52 weeks 
Primary endpoint ACR20 at week 24, total Sharp score at week 52, HAQ at week 52 
Secondary endpoint  
JADAD score 3 
Comment  
 
Table 30 Klareskog 2004, etanercept 
Examination double-blind, randomised study  
Number of patients 682 treated 
Inclusion criteria - aged 18 years or older with disease duration of 6 months to 20 years 
who had active, adult-onset rheumatoid arthritis (American College of 
Rheumatology [ACR] functional class I–III), defined as ten or more 
swollen and 12 or more painful joints and at least one of the 
following: erythrocyte sedimentation rate 28 mm/h or greater; plasma 
C-reactive protein 20 mg/L or greater; or morning stiffness for 45 min 
ormore 
- should also have had a less than satisfactory response at the 
discretion of the investigator to at least one disease-modifying 
antirheumatic drug other than methotrexate 
Exclusion criteria - had previously received etanercept or other TNF antagonists 
-previous treatment with immunosuppressive drugs within 6 months 
of screening; use of any investigational drug or biological agent 
within 3 months of screening; any other disease-modifying 
antirheumatic drug or corticosteroid injection within 4 weeks of 
baseline visit; and presence of relevant comorbidity, including active 
infections 
Therapy - Etanercept (25mg twice a week and oral placebo once a week) 
- Etanercept + MTX (combination of 25 mg subcutaneous etanercept 
injections twice a week and oral methotrexate capsules once a week) 
- Methotrexate only (7·5 mg escalated to 20 mg oral capsules once a 
week within 8 weeks if patients had any painful or swollen joints,12 
and placebo subcutaneous injections twice a week) 
Rescue therapy (number of 
patients) 
 
Follow-up time 52 weeks 
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Primary endpoint The primary efficacy endpoint was the numeric index of the ACR 
response (ACR-N) area under the curve (AUC) over the first 24 
weeks 
Secondary endpoint ACR20, ACR50, ACR70, DAS28 
JADAD score 5 
Comment  
 
Table 31 Kremer 2003, abatacept 
Examination randomized, double-blind, placebo-controlled study 
Number of patients 339 
Inclusion criteria - 18 to 65 years of age who met the ACR criteria for rheumatoid 
arthritis and were in functional class I, II, or III 
- active disease, characterized by 10 or more swollen joints, 12 or 
more tender joints, and C-reactive protein levels of at least 1 mg per 
deciliter (upper limit of the normal range, 0.4) 
- had to have been treated with methotrexate (10 to 30 mg weekly) for 
at least 6 months and to have received a stable dose for 28 days 
before enrollment  
- all other disease-modifying antirheumatic drugs discontinued 
Exclusion criteria - women who were nursing or pregnant 
Therapy - abatacept 10mg/kg + MTX 
- abatacept 2mg/kg + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
 
Follow-up time 26 week 
Primary endpoint ACR20 at week 26  
Secondary endpoints ACR50, ACR70 
JADAD score 5 
Comment  
 
Table 32 Kremer 2006, abatacept 
Examination multicenter, randomized, double-blind, placebocontrolled trial 
Number of patients 652 
Inclusion criteria - at least 18 years of age, had had rheumatoid arthritis for at least 1 
year, and met the American Rheumatism Association criteria for 
rheumatoid arthritis 
- must have been treated with methotrexate (15 mg/wk) for 3 months 
or longer, with a stable dose for 28 days before enrollment  
- required patients to undergo a washout of all other disease-
modifying antirheumatic drugs at least 28 days before randomization.  
- required to have 10 or more swollen joints, 12 or more tender joints, 
and C-reactive protein levels of 10.0 mg/L or greater (normal range, 
1.0 mg/L to 4.0 mg/L) while receiving methotrexate 
- required tuberculin skin testing before randomization 
Exclusion criteria - a positive tuberculin skin test result unless they had completed 
treatment for latent tuberculosis before enrollment 
Therapy - Abatacept 10mg/kg + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
 
Follow-up time 1 year 
Primary endpoint ACR20 at 6 months, clinically meaningful improvements in physical 
function, and change from baseline in joint erosion score at 1 year 
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Secondary endpoint ACR50, ACR70 at 6 months and all ACR responses at 1 year, DAS28 
JADAD score 5 
Comment  
 
Table 33 Kremer 2010, golimumab 
Examination Phase III Randomized, Double-Blind, Placebo-Controlled Study 
Number of patients 643 
Inclusion criteria - adults with a diagnosis of RA, as defined by the American College 
of Rheumatology (ACR; formerly, the American Rheumatism 
Association) criteria, in whom disease remained active despite 
receiving treatment with MTX for 3 months prior to screening and 
being treated with stable dosages of MTX (15–25 mg/week) for 4 
weeks prior to screening. Persistent active disease was defined as 4 
swollen joints and 4 tender joints and 2 of the following criteria at 
baseline and/or the time of screening: C-reactive protein (CRP) level 
of 1.5 mg/dl or an erythrocyte sedimentation rate (ESR) of 28 
mm/hour according to the Westergren method, morning stiffness 
lasting 30 minutes, bone erosion by radiography and/or magnetic 
resonance imaging, or positivity for anti–cyclic citrullinated peptide 
or rheumatoid factor 
Exclusion criteria - receipt of infliximab, alefacept or efalizumab within 3 months, 
treatment with etanercept or adalimumab within 2 months, or 
treatment with anakinra within 4 weeks prior to the first receipt of the 
study agent excluded patients, as did any prior receipt of rituximab, 
abatacept, or natalizumab 
Therapy - Golimumab 4mg/kg + MTX 
- Golimumab 2mg/kg + MTX 
- Golimumab 4mg/kg 
- Golimumab 2mg/kg 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
108  
Follow-up time 24 week 
Primary endpoint ACR50 at week 14 
Secondary endpoints ACR50 at week 24, ACR20 at week 14, DAS-CRP at week 14, PCS 
at week 14 
JADAD score 5 
Comment  
 
Table 34 Maini 1999, infliximab 
Examination an international double-blind placebo-controlled phase III clinical 
trial 
Number of patients 428 
Inclusion criteria - had been diagnosed with rheumatoid arthritis according to the 1987 
American College of Rheumatology criteria and had evidence of 
active disease despite treatment with methotrexate (six or more 
swollen and tender joints plus two of: morning stiffness greater than 
or equal to 45 min, erythrocyte sedimentation rate greater than 28 
mm/h, C-reactive protein greater than 2 mg/dL 
- must also have been receiving oral or parenteral methotrexate for at 
least 3 months with no break in treatment of more than 2 weeks 
during this period. The methotrexate dose must have been stable at 
12·5 mg/week or more, for at least 4 weeks before screening and the 
patient must have been on a stable dose of folic acid for the same 
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period. Patients using oral corticosteroids (10 mg/kg or less 
prednisone equivalent) or non-steroidal anti-inflammatory drugs 
(NSAIDs) must have been on a stable dose for at least 4 weeks before 
screening: if a patient was not using such drugs, the patient must not 
have received either drug for at least 4 weeks before screening. The 
screening laboratory tests must have met the following criteria: 
haemoglobin 5·3 mmol/L or more, white blood cells 3·5_109/L or 
more, neutrophils 1·5_109/L, platelets 100_109/L or more, serum 
aminotransferase and alkaline phosphatase concentration 2 times or 
less the upper limit of normal, and serum creatinine 150 _mol/L or 
less 
Exclusion criteria - had little or no ability for self-care; any current inflammatory 
condition with signs and symptoms that might confound the diagnosis 
(eg, connective tissue disease or Lyme disease); used a DMARD 
other than methotrexate or received intraarticular, intramuscular, or 
intravenous corticosteroids in the 4 weeks before screening; received 
any other agent to reduce tumour necrosis factor or had any previous 
use of cyclophosphamide, nitrogen mustard, chlorambucil, or other 
alkylating agents; or a history of known allergies to murine proteins 
- had had infected joint prosthesis during the previous 5 years; serious 
infections, such as hepatitis, pneumonia, pyelonephritis in the 
previous 3 months; any chronic infectious disease such as renal 
infection, chest infection with bronchiectasis or sinusitis; active 
tuberculosis requiring treatment within the previous 3 years; 
opportunistic infections such as herpes zoster within the previous 2 
months; any evidence of active cytomegalovirus; active Pneumocystis 
carinii; or drug-resistant atypical mycobacterial infection 
- current signs or symptoms of severe, progressive, or uncontrolled 
renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, 
cardiac, neurological, or cerebral disease; a history of 
lymphoproliferative disease including lymphoma or signs suggestive 
of disease, such as lymphadenopathy of unusual size or location (ie, 
lymph nodes in the posterior triangle of the neck, infraclavicular 
epitrochlear, or periaortic areas); splenomegaly; any known malignant 
disease except basal cell carcinoma currently or in the past 5 years 
Therapy - Infliximab 10mg/kg every 8 week + MTX 
- Infliximab 10mg/kg every 4 week + MTX 
- Infliximab 3mg/kg every 8 week + MTX 
- Infliximab 3mg/kg every 4 week + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
0 
Follow-up time 30 week 
Primary endpoint ACR20 at week 30 
Secondary endpoints ACR50, ACR70, reduction in individual measurements of disease 
activity, and a general health assessment 
JADAD score 5 
Comment  
 
Table 35 Miyasaka 2008, adalimumab 
Examination Phase II/III, multicenter, double-blind, placebo controlled trial 
Number of patients 352 
Inclusion criteria - male and female patients aged 20 years or older  
- met the American College of Rheumatology (ACR) criteria for 
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active RA, had failed treatment with at least one prior disease-
modifying antirheumatic drug (DMARD), and had C10 swollen joints 
and C12 tender joints (excluding distal interphalangeal joints) at both 
the screening visit and baseline visit. Patients also had a C-reactive 
protein (CRP) concentration C2 mg/dl 
- must have discontinued DMARDs at least 28 days prior to study 
- negative pregnancy test and use of reliable contraception were 
mandatory for women of childbearing potential 
Exclusion criteria - acute inflammatory joint diseases other than RA, active Listeria or 
tuberculosis, lymphoma, or leukemia, or any malignancy except for 
successfully treated nonmetastatic basal-cell carcinoma of the skin. - 
positive serology for anti-human immunodeficiency virus antibody, 
hepatitis B virus surface antigen, or anti-hepatitis C virus antibody, 
ongoing or active infection, advanced or poorly controlled diabetes, 
or central nervous system demyelinating disorders 
Therapy - Adalimumab 20mg every other week 
- Adalimumab 40mg every other week 
- Adalimumab 80mg every other week 
- Placebo every other week 
Rescue therapy (number of 
patients) 
104 a szövegben 107-et írnak 
Follow-up time 24 week 
Primary endpoint ACR20 at week 24 
Secondary endpoints The comparison between ACR20 response rates at week 24 for the 
adalimumab 20 mg group and the placebo group. 
Additional secondary efficacy endpoints included ACR20 response 
rate at Week 12; ACR50 and ACR70 response rates at Weeks 12 and 
24; individual components of the ACR response at Weeks 0 12, and 
24; and the Health Assessment Questionnaire Disability Index at 
Weeks 0 12, and 24. 
JADAD score 5 
Comment  
 
Table 36 Moreland 1999, etanercept 
Examination Randomized, double-blind, placebo-controlled trial with blinded joint 
assessors  
Number of patients 234 
Inclusion criteria - adults who were at least 18 years of age, met the American 
Rheumatism Association's diagnostic criteria for rheumatoid arthritis, 
and were in functional class I, II, or III 
- required to have had an inadequate response to one to four 
DMARDs (such as azathioprine, methotrexate, sulfasalazine, 
penicillamine, hydroxychloroquine, or oral or injectable gold); an 
inadequate response was defined as discontinuation of therapy 
because of lack of effect 
- if patients were receiving DMARDs, they were required to complete 
a DMARD washout period that lasted at least 1 month before starting 
study drug treatment; no DMARDs were permitted during the study  
- had to have active disease at enrollment (before the DMARD 
washout period), defined as 12 or more tender joints, 10 or more 
swollen joints, and at least one of the following: erythrocyte 
sedimentation rate of at least 28 mm/h, C-reactive protein level 
greater than 20 mg/L, or morning stiffness for at least 45 minutes 
- all patients were required to have aminotransferase levels no greater 
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than twice the upper limit of normal, a hemoglobin level of 85 g/dL 
or greater, a platelet count of at least 125 000 cells/mm", a leukocyte 
count of 3500 cells/mm'' or higher, and a serum ereatinine level of 
176.8 jamol/L (2mg/dL) or less 
Exclusion criteria - intra-articular corticosteroids were not permitted during the study or 
beginning 4 weeks before enrollment 
Therapy - Etanercept 25mg twice a week 
- Etanercept 10mg twice a week 
- Placebo 
Rescue therapy (number of 
patients) 
 
Follow-up time 26 weeks 
Primary endpoint ACR20, ACR50 at 3 and 6 months 
Secondary endpoint ACR70 response at 3 and 6 months and percentage change from 
baseline at 3 and 6 months in the following: tender joint count, 
swollen joint count, duration of morning stiffness, patient's global 
assessment, physician's global assessment, patient's assessment of 
pain, quality of life, erythrocyte sedimentation rate, and C-reactive 
protein level 
JADAD score 5 
Comment  
 
Table 37 Nishimoto 2007, tocilizumab 
Examination a multi-centre, x ray reader-blinded, randomised, controlled trial 
Number of patients 306 
Inclusion criteria - age 20 years and fulfilled the American College of Rheumatology 
(ACR; formerly, the American Rheumatism Association) 1987 
revised criteria for the classification of RA,23 with a disease duration 
of  >6 months and ,5 years. In addition, they had >6 tender joints (of 
49 evaluated), >6 swollen joints (of 46 evaluated), an erythrocyte 
sedimentation rate (ESR) of >30 mm/h and C-reactive protein (CRP) 
of >20 mg/l.  
All candidates had an inadequate response to at least one disease 
modifying antirheumatic drug (DMARD) or immunosuppressant. 
- had white blood cell counts of at least 3.56109/l, lymphocyte counts 
of at least 0.56109/l and platelet counts of at least 1006109/l at 
enrolment 
- sexually active premenopausal women were required to have a 
negative urine pregnancy test at the entry and to use effective 
contraception during the study period 
Exclusion criteria - had a medical history of a serious allergic reaction, significant 
concomitant diseases, or an active intercurrent infection requiring 
medication within 4 weeks before the first dose 
Therapy - Tocilizumab 8mg/kg every 4 weeks 
- DMARD 
Rescue therapy (number of 
patients) 
 
Follow-up time 52 weeks 
Primary endpoint radiological scores* 
Secondary endpoint  
JADAD score 5 
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Comment *radiographic endpoints, such as TSS, erosion score and joint space 
narrowing score, were assessed with a rank transformed analysis of 
covariance (ANCOVA) on the change scores that included factors for 
baseline score and baseline disease duration 
 
 
 
Table 38 Nishimoto 2009, tocilizumab 
Examination multi-center, randomized, blinded, double-dummy trial 
Number of patients 125 
Inclusion criteria - patients were between 20 and 75 years old, fulfilled the American 
college of Rheumatology (ACR; formerly, the American Rheumatism 
Association) 1987 revised criteria for the classification of RA, with 
disease duration of more than 6 months 
- candidates were treated with MTX 8 mg/week for at least 8 weeks 
until enrolment. They all had C6 tender joints (of 49 evaluated), C6 
swollen joints (of 46 evaluated), ESR of C30 mm/h or CRP of C10 
mg/l at enrolment 
- patients had white blood cell counts C3.5 9 109/l, lymphocyte 
counts C0.5 9 109/l and platelet count of at least the lower limit of 
normal as defined by the respective local laboratory used 
- sexually active premenopausal women were required to have a 
negative urine pregnancy test at the entry to the study and to use 
effective contraception during the study period 
Exclusion criteria - had functional class IV using Steinbrocker’s criteria aspartate 
transaminase (AST), alanine transaminase (ALT) and serum 
creatinine C1.5-fold the upper limit of normal, were HBs antigen and/ 
or HCV antibody positive, had pulmonary fibrosis or active 
pulmonary disease, a history of serious adverse drug reaction to 
MTX, concomitant pleural effusion, ascites, varicella infection, or 
were excessive users of alcohol on a regular basis 
- had significant cardiac, blood, respiratory system, neurologic, 
endocrine, renal, hepatic, or gastrointestinal disease, or had an active 
infection requiring medication within 4 weeks before the first dose or 
medical history of a serious allergic reaction 
Therapy - Tocilizumab 8mg/kg every 4 weeks + MTX placebo 
- Tocilizumab placebo + Methotrexate 8mg/week 
Rescue therapy (number of 
patients) 
 
Follow-up time 24 weeks 
Primary endpoint ACR20 at week 24 
Secondary endpoint  
JADAD score 3 
Comment  
 
Table 39 Schiff 2008, abatacept 
Examination phase III, randomised, double-blind, double-dummy, placebo- and 
active (infliximab)-controlled multi-center study 
Number of patients 431 
Inclusion criteria - met the American College of Rheumatology (ACR) criteria for RA, 
were at least 18 years of age, had RA for at least 1 year,4 and had 
an inadequate response to MTX, as demonstrated by ongoing active 
disease (at randomisation> 10 swollen joints,> 12 tender joints, and 
C-reactive protein (CRP) levels> 1 mg/dl using a high sensitivity 
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assay (upper limit of the normal range, 0.5)) 
- had received MTX> 15 mg/week for> 3 months prior to 
randomisation (stable for at least 28 days) and washed out all 
DMARDs (> 28 days prior) except for MTX 
- no prior experience of abatacept or anti-TNF therapy was permitted 
Exclusion criteria  
Therapy - abatacept 10mg/kg + MTX 
- infliximab 3mg/kg every 8 weeks + MTX 
- placebo + MTX 
Rescue therapy (number of 
patients) 
0 
Follow-up time 52 weeks 
Primary endpoint DAS28 with abatacept vs. placebo 
Secondary endpoint DAS28 with infliximab vs. placebo; DAS28 with abatacept vs 
infliximab; EULAR; 6 low disease activity score (LDAS; DAS28 
(ESR), DAS28, (ESR)-defined remission (DAS28 (ESR); ACR 20, 50 
and 70 responses; HAQ-DI; response rates and mean changes in the 
physical and mental component summary (PCS and MCS, 
respectively) scores; and eight subscales of the SF-36 
JADAD score 5 
Comment  
 
Table 40 Smolen 2008, tocilizumab 
Examination phase III, three arm, randomised, double-blind, placebo-controlled, 
parallel group, international study 
Number of patients 623 
Inclusion criteria - adult patients with moderate to severe active rheumatoid arthritis 
(diagnosed according to American College of Rheumatology [ACR] 
criteria) of more than 6 months’duration who had an inadequate 
response to methotrexate were recruited 
- active disease was defi ned by a swollen joint count of 6 or more 
plus a tender joint count of 8 or more and C-reactive protein (CRP) 
over 10 mg/L or ESR of 28 mm/h or more 
- had to have received methotrexate for 12 weeks or longer before the 
start of the study (stable dose of 10–25 mg/week for 8 weeks or 
longer) 
- all other DMARDs were discontinued before the start of the study: 
lefl unomide for 12 weeks or more (or ≥4 weeks after 11 days of 
standard colestyramine washout), anakinra for 1 week or more, 
etanercept for 2 weeks or longer, and infl iximab or adalimumab for 8 
weeks or longer 
Exclusion criteria - other autoimmune diseases or significant systemic involvement 
secondary to rheumatoid arthritis (eg, vasculitis, pulmonary fi brosis, 
or Felty’s syndrome), functional class IV rheumatoid arthritis, 
previous or current infl ammatory joint disease other than rheumatoid 
arthritis, currently active or previous recurrent bacterial, viral, fungal, 
or other infections including, but not limited to, tuberculosis and 
atypical mycobacterial disease, clinically signifi cant abnormalities on 
chest radiograph, hepatitis B and C, and recurrent herpes zoster 
- had active liver disease, indicated by screening and baseline 
concentrations of alanine or aspartate aminotransferase of 1・5 times 
the upper limit of normal or more, or previous unsuccessful treatment 
with an anti-TNF agent (ie, lack of effi cacy or signifi cant safety 
issues; terminations due to cost or injection discomfort were not 
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excluded) 
Therapy - Tocilizumab 8mg/kg every 4 week + MTX (10-25mg) weekly 
- Tocilizumab 4mg/kg every 4 week + MTX (10-25mg) weekly 
- Placebo every 4 week + MTX (10-25mg) weekly 
Rescue therapy (number of 
patients) 
118 
Follow-up time 24 weeks 
Primary endpoint ACR20 at week 24 
Secondary endpoint ACR50, ACR70, DAS28, DAS (remission), EULAR at week 24 
JADAD score 5 
Comment  
 
Table 41 Smolen 2009, golimumab 
Examination a multicentre, randomised, double-blind, placebo-controlled, phase III 
trial 
Number of patients 461 
Inclusion criteria - aged 18 years or older, and had been diagnosed with active 
rheumatoid arthritis (persistent disease activity with at least four 
swollen and four tender joints), according to the criteria of the 
American College of Rheumatology (ACR), at least 3 months before 
screening 
- must have been treated with at least one dose of a TNFα inhibitor 
(etanercept, adalimumab, or infl iximab), the last dose of which must 
have been given at least 8 weeks (adalimumab or etanercept) or 12 
weeks (infl iximab) before the first dose of the study drug 
- patients receiving such drugs must have tolerated the dose for at 
least 12 weeks, and the dose must have been stable for 4 weeks before 
the first dose of study drug 
Exclusion criteria - had inflammatory diseases other than rheumatoid arthritis; had a 
serious adverse reaction to a previous TNFα inhibitor (judged by the 
investigator); had ever received natalizumab or rituximab; had 
received anakinra less than 4 weeks, or alefacept or efalizumab less 
than 3 months before the first dose of study drug; had ever received 
cytotoxic drugs; had a history of latent or active granulomatous 
infection, except latent tuberculosis, that was treated prophylactically 
in the past 3 years; had a BCG vaccination less than 12 months before 
screening; had an opportunistic infection less than 6 months before 
screening; had a serious infection (judged by the investigator) less 
than 2 months before screening; had a history of chronic infection, 
demyelinating disease, congestive heart failure, or severe, 
progressive, uncontrolled renal, hepatic, haematological, gastro 
intestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or 
cerebral disease; or had a transplanted organ or a malignancy in the 
past 5 years 
Therapy - Golimumab 100mg every 4 weeks 
- Golimumab 50mg every 4 weeks 
- Placebo every 4 weeks 
Rescue therapy (number of 
patients) 
113 
Follow-up time 24 weeks 
Primary endpoint ACR20, the number of tender (0–68) and swollen (0–66) joints, and 
at least three of either patient assessment of pain (0–10 cm, visual 
analogue scorepatient global assessment of disease activity (0–10 cm, 
VAS, 0 indicates no disease), physician global assessment of disease 
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activity (0–10 cm, VAS), patient assessment of physical function (0–
3, health assessment questionnaire disability index [HAQ-DI], 0 
indicates no disability),12 or C-reactive protein concentration (normal 
range according to the central laboratory 0–6 mg/L) at week 14 
Secondary endpoints ACR20 at week 24, ACR50 and ACR70 at weeks 14 and 24; numeric 
index of the ACR response18 at weeks 14 and 24; DAS28 at weeks 
14 and 24; HAQ-DI scores at weeks 14 and 24; fatigue score at weeks 
14 and 24; DAS28 response according to EULAR and DAS28 
remission 
JADAD score 5 
Comment  
 
Table 42 Smolen 2008, certolizumab 
Examination an international, multicentre, phase 3, randomised, double-blind, 
placebo-controlled study 
Number of patients 619 
Inclusion criteria - aged >18 years with a diagnosis of RA, defined by American 
College of Rheumatology (ACR) 1987 criteria,19 of >6 months’ 
duration but not longer than 15 years, with active disease at screening 
and baseline. Patients had to have received prior MTX for >6 months 
(stable dose >10 mg/week for >2 months before baseline) 
Exclusion criteria - had received any biological agent for RA within 6 months before 
enrolment (3 months for etanercept and anakinra), had received 
previous treatment with a biological agent resulting in a severe 
hypersensitivity or anaphylactic reaction, or had not initially 
responded to previous anti-TNF therapy 
- patients with history of, or positive chest x-ray findings for, 
tuberculosis, or a positive purified protein derivative (PPD) skin test 
(defined as positive indurations per local medical practice)  
Therapy - Certolizumab 400mg + MTX at weeks 0, 2, 4 
- Certolizumab 200mg + MTX 
- Placebo + MTX every 2 weeks 
Rescue therapy (number of 
patients) 
214 
Follow-up time 24 weeks 
Primary endpoint ACR20 at week 24 
Secondary endpoints ACR50, ACR70, mTSS and individual ACR core set variables at 
week 24 
JADAD score 3 
Comment  
 
 
Table 43 Tak 2011, rituximab 
Examination double-blind, randomized, controlled, phase III study 
Number of patients 748 
Inclusion criteria - aged 18–80 years with RA diagnosed according to the revised 1987 
American College of Rheumatology (ACR) criteria. Disease duration 
was ≥8 weeks but ≤4 years. Patients were not to have received 
previous treatment with MTX and were to have active disease defi 
ned as a swollen joint count (66 joints) and tender joint count (68 
joints) both ≥8 at screening and baseline, and C-reactive protein 
(CRP) ≥1.0 mg/dl 
Exclusion criteria  
Therapy - Rituximab 1000mg twice a week + MTX 
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- Rituximab 500mg twice a week + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
 
Follow-up time 52 weeks 
Primary endpoint change in total Sharp score from baseline to week 52 
Secondary endpoint  
JADAD score 5 
Comment  
 
Table 44 VandePutte 2004, adalimumab 
Examination double blind, placebo controlled, phase III trial 
Number of patients 544 
Inclusion criteria - met the diagnostic criteria for RA established by the American 
College of Rheumatology (ACR), treatment with at least one 
DMARD had previously failed, and they had active disease defined as 
>12 tender joints based on a 68 joint assessment, >10 swollen joints 
based on a 66 joint evaluation, and either an erythrocyte 
sedimentation rate (ESR) >28 mm/1st h or a serum C reactive protein 
(CRP) concentration >20 mg/l 
- negative pregnancy test and the use of a reliable contraceptive 
method were mandatory in women of childbearing potential 
Exclusion criteria - joint surgery within 2 months before screening or infection requiring 
admission to hospital or treatment with intravenous (iv) antibiotics 
within 1 month before screening 
- had received treatment with either an intra-articular or intramuscular 
corticosteroid within 1 month before the study or an investigational 
small molecule drug or biological agent within 2 months or 6 months 
before screening, respectively 
- patients with impaired renal or hepatic function, or a history of 
tuberculosis as shown by radiographs 
Therapy - Adalimumab 40mg weekly 
- Adalimumab 40mg every other week 
- Adalimumab 20mg weekly 
- Adalimumab 20mg every other week 
- Placebo 
Rescue therapy (number of 
patients) 
 
Follow-up time 26 weeks 
Primary endpoint ACR20 
Secondary endpoints ACR50, ACR70, EULAR, HAQ-DI and improvements in ACR core 
components (patient global assessment of disease activity, physician 
global assessment of disease activity, patient assessment of pain, the 
Disability Index of the Health Assessment Questionnaire (HAQ DI), 
and serum levels of CRP, changes in the disease activity score 28 
(DAS28), a composite score (score 2–10) defined by criteria 
established by the European League Against Rheumatism (EULAR) 
JADAD score 5 
Comment  
 
Table 45 Weinblatt 2006, abatacept 
Examination multinational, multicenter, randomized, double-blind, 2-arm, parallel-
dosing trial 
Number of patients 1441 
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Inclusion criteria - men and women at least 18 years of age who met the 1987 
American College of Rheumatology (ACR; formerly, the American 
Rheumatism Association) criteria for the diagnosis of RA and the 
1991 ACR criteria for RA functional classes I, II, III, or IV 
Patients had to have active disease despite receiving background 
DMARDs and/or biologic therapy, warranting additional therapy at 
the discretion of the investigator. 
- required to have been receiving 1 biologic and/or nonbiologic 
DMARD approved for RA for at least 3 months, and at a stable dose 
for at least 28 days prior to day 1 of the trial  
- patients with stable medical conditions such as congestive heart 
failure (CHF), asthma, chronic obstructive pulmonary disease 
(COPD), and diabetes mellitus were included 
Exclusion criteria - had unstable or uncontrolled renal, endocrine, hepatic, hematologic, 
gastrointestinal, pulmonary, cardiac, or neurologic diseases, or any 
autoimmune disorder other than RA as the main diagnosis 
- active or chronic recurrent bacterial infections unless treated and 
resolved, active herpes zoster infection within the previous 2 months, 
hepatitis B or hepatitis C virus infection, and active or latent 
tuberculosis (as assessed via chest radiography and tuberculin testing) 
unless appropriately treated 
- pregnant or nursing women 
Therapy - Abatacept 10mg/kg + DMARD 
- Placebo + DMARD 
Rescue therapy (number of 
patients) 
 
Follow-up time 1 year 
Primary endpoint evaluate the safety  
Secondary endpoints ACR20, ACR50, ACR70, HAQ, patient’s global assessment of 
disease activity, patient’s global assessment of pain, and physician’s 
global assessment of disease activity were all assessed using a 100-
mm VAS 
JADAD score 5 
Comment  
 
Table 46 Weinblatt 1999, etanercept 
Examination multicenter, randomized, double-blind trial 
Number of patients 89 
Inclusion criteria - at least 18 years of age and fulfilled the 1987 criteria for rheumatoid 
arthritis of the American Rheumatism 
Association were in functional class I, II, or III according to the 
revised criteria of the American College of Rheumatology (ACR) and 
had active disease, as manifested by at least six joints that were 
swollen and six that were tender at the time of enrollment. Before 
receiving the study drugs, all the patients had been taking 
methotrexate for at least six months, and at a stable dose of 15 to 25 
mg per week for the last four weeks (weekly doses as low as 10 mg 
were acceptable for patients who could not tolerate higher doses). All 
patients received folic acid or folinic acid to mitigate the toxic effects 
of methotrexate. 
- had platelet counts of at least 125,000 per cubic millimeter, serum 
creatinine levels of no more than 2 mg per deciliter (177 μmol per 
liter), white-cell counts of at least 3500 per cubic millimeter, serum 
aspartate and alanine aminotransferase levels no more than 1.2 times 
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the laboratory’s upper limit of normal, hemoglobin levels of at least 
8.5 g per deciliter, stable hemoglobin levels for at least six months in 
patients with levels of less than 10 g per deciliter, and negative 
serologic results on tests for hepatitis B surface antigen and hepatitis 
C antibody 
- patients discontinued therapy with sulfasalazine and 
hydroxychloroquine at least two weeks before starting to take the 
study drug and disease-modifying antirheumatic drugs other than 
methotrexate at least four weeks before 
Exclusion criteria  
Therapy - Etanercept 25mg twice weekly + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
 
Follow-up time 24 weeks 
Primary endpoint ACR20 at week 24 
Secondary endpoint ACR 20 at week12 and the proportions who met the ACR 50 and 
ACR70 at 12 and 24 weeks, individual measures of disease activity, 
such as numbers of swollen and tender joints and physician’s 
assessment, at 12 and 24 weeks 
JADAD score 3 
Comment  
 
Table 47 Weinblatt 2003, adalimumab 
Examination randomized, double-blind, placebo-controlled trial 
Number of patients 271 
Inclusion criteria - 18 years of age or older and had RA that was diagnosed according 
to the 1987 revised criteria of the American College of Rheumatology 
(ACR; formerly, the American Rheumatism Association)   
Active disease was defined as the presence of at least 9 tender joints 
(of 68 joints evaluated) and 6 swollen joints (of 66 joints evaluated). 
Additionally, participants must have been treated with MTX for a 
minimum of 6 months and must have been taking a stable weekly 
dose (12.5–25 mg, or 10 mg if intolerant to higher doses) for at least 4 
weeks before entering the study. 
- must have failed treatment with at least 1 DMARD besides MTX, 
but no more than 4 DMARDs 
Exclusion criteria - had received treatment with anti-CD4 therapy or TNF antagonists, 
had a history of active listeriosis or mycobacterial infection, and had a 
major episode of infection requiring hospitalization or treatment with 
intravenous antibiotics within 30 days or oral antibiotics within 14 
days prior to screening 
Therapy - Adalimumab 80mg every other week + MTX 
- Adalimumab 40mg every other week + MTX 
- Adalimumab 20mg every other week + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
 
Follow-up time 24 weeks 
Primary endpoint ACR20 
Secondary endpoint ACR50, ACR70, improvements in ACR core set of disease activity 
measures for RA clinical trials, as follows: tender joint count, swollen 
joint count, patient’s assessment of pain, patient’s global assessment 
of disease activity, HAQ-DI, and serum levels of C-reactive protein, 
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FACIT, proMMP-1and proMMP-3  
JADAD score 3 
Comment  
 
Table 48 Westhovens 2009, abatacept 
Examination multi-national, randomised, doubleblind 
Number of patients 509 
Inclusion criteria - 18 years of age or older, with RA for 2 years or less, at least 12 
tender and 10 swollen joints, C-reactive protein (CRP) 0.45 mg/dl or 
greater, RF and/or anti-CCP2 seropositivity and radiographic 
evidence of bone erosion of the hands/wrists/feet. Patients were either 
methotrexate-naive or had previous exposure of 10 mg/week or less 
for 3 weeks or less, with none administered for 3 months before 
providing informed consent (there were no requirements relating to 
the reason for discontinuation of previous methotrexate therapy) 
- required to practice effective contraceptive measures for the study 
duration 
Exclusion criteria - women who were pregnant or breastfeeding 
- had had active Mycobacterium tuberculosis (tuberculosis) requiring 
treatment within 3 years 
Therapy - Abatacept 10mg/kg + MTX 
- Placebo + MTX 
Rescue therapy (number of 
patients) 
 
Follow-up time 2 years 
Primary endpoint DAS28, Genant-modified Sharp score 
Secondary endpoint ACR50, DAS28, MCR, ACR70, Genant-modified Sharp erosion 
score, joint-space narrowing score, physical function, health-related 
quality of life (HRQoL)  
JADAD score 5 
Comment  
 
 
Table 49 Westhovens 2006, infliximab 
Examination Randomized, Placebo-Controlled Trial 
Number of patients 1084 
Inclusion criteria - had a diagnosis of RA according to the revised criteria of the 
American College of Rheumatology (ACR; formerly, the American 
Rheumatism Association), and had active disease despite receiving 
MTX; patients may or may not have been treated with other 
concomitant DMARDs. Active RA was defined as the presence of 6 
swollen joints and 6 tender joints. At screening, patients were 
required to have a chest radiograph that showed no evidence of 
malignancy, infection, fibrosis, or active tuberculosis 
- must have been receiving MTX for at least 3 months prior to 
randomization. The MTX dose must have been stable for at least 4 
weeks prior to randomization 
Exclusion criteria - had opportunistic infections, serious infections during the 2 months 
prior to screening, known human immunodeficiency virus infection, 
active tuberculosis or history of active tuberculosis with inadequate 
documentation of treatment, evidence of latent tuberculosis and an 
inability to receive prophylaxis with isoniazid, a history of 
lymphoproliferative disease or malignancy, or a diagnosis of 
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congestive heart failure 
- if had been treated with an investigational drug (within 3 months or 
5 half-lives from the time of screening, whichever was greater), with 
cyclophosphamide, nitrogen mustard, chlorambucil, or other 
alkylating agents, with more than 5 mg/kg of cyclosporine, or with 
any approved or investigational biologic agent (including infliximab) 
at any time prior to the study, with the exception of approved 
vaccines for the purpose of immunization 
Therapy - Infliximab 10mg/kg + MTX at weeks 0, 2, 6, and 14 
- Infliximab 3mg/kg + MTX at weeks 0, 2, 6, and 14 
- Placebo + MTX at weeks 0, 2, 6, and 14 
Rescue therapy (number of 
patients) 
 
Follow-up time 22 weeks 
Primary endpoint occurrence of serious infections as primary end point through week 
22 
Secondary endpoints ACR20, ACR50, ACR70, DAS28 
JADAD score 5 
Comment  
 
Table 50 Kim 2007 adalimumab 
Examination randomized, double-blind, placebo-controlled, phase III study 
Number of patients 128 
Inclusion criteria - 18 years of age or older 
- met American College of Rheumatology (ACR) criteria for 
diagnosis of active RA, and had ≥ 6 swollen joints and ≥ 9 tender 
joints at both screening and baseline visits 
- had to have received at least one prior DMARD other than MTX but 
could have had efficacy failures to no more than four standard 
DMARDs other than MTX 
- had to have been treated with MTX for at least 6 months and been 
receiving a stable dosage for at least 4 weeks prior to screening 
Exclusion criteria - acute inflammatory joint diseases other than RA, active Listeria or 
tuberculosis infection; positive serology for human 
immunodeficiency virus antibody, hepatitis B surface antigen, or 
hepatitis C antibody; calcified granuloma and/or pleural scarring on 
chest radiograph 
Therapy - Adalimumab 40 mg every other week 
- Placebo 
Rescue therapy (number of 
patients) 
27 
Follow-up time 24 weeks 
Primary endpoint ACR20 compared with the placebo group at week 24 
Secondary endpoint ACR50, ACR70, the percentage of patients achieving improvement in 
individual ACR core components, including tender joint count, 
swollen joint count, the Physician’s Global Assessment of Disease 
Activity, the Patient’s Global Assessment of Disease Activity, the 
Patient’s Global Assessment of Pain, Disability Index of the Korea 
Health Assessment Questionnaire (KHAQ), and C-reactive protein 
concentrations; and the percentage of patients reporting morning 
stiffness 
JADAD score 1 
Comment  
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Table 51 Yazici 2012 tocilizumab 
Examination randomised, double-blind, placebo-controlled, parallel-group, 
multicentre, phase IIIb clinical trial 
Number of patients 614 
Inclusion criteria - adults diagnosed with active RA for at least 6 months who were 
experiencing an inadequate clinical response to DMARD as 
determined by the investigator 
- had six or more swollen joints and six or more tender joints at 
screening and baseline, and either a C-reactive protein (CRP) level of 
95.24 nmol/l or greater or an erythrocyte sedimentation rate (ESR) of 
28 mm/h or greater at screening 
- discontinue previous biological therapy before randomisation 
Exclusion criteria  
Therapy - tocilizumab 8mg/kg every 4 weeks + DMARD 
- placebo every 4 weeks + DMARD 
Rescue therapy (number of 
patients) 
124 
Follow-up time 24 weeks 
Primary endpoint ACR50 
Secondary endpoint every 4 weeks to week 24: ACR20/50/70 responses; EULAR 
responses; DAS28, including proportions of patients with clinically 
meaningful improvement (change from baseline in DAS28 of ≥1.2) 
and patients achieving low disease activity (LDA, DAS28 ≤3.2) or 
clinical remission (DAS28 <2.6) ESR and CRP levels; functional 
assessment of chronic illness therapy fatigue (FACIT-F) and routine 
assessment of patient index data (RAPID3) scores (on a scale of 0–
10) derived from the multidimensional health assessment 
questionnaire (MDHAQ) 
JADAD score 3 
Comment  
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8.6 Detailed results from classical direct meta-analysis 
Forest plot of comparison: 5 Efficacy of biological + DMARD at six months in DMARD 
IR population, outcome: ACR20 
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Forest plot of comparison: Efficacy of biological + DMARD at six months in DMARD 
IR population, outcome: ACR50 
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Forest plot of comparison: 5 Efficacy of biological + DMARD at six months in DMARD 
IR population, outcome: ACR70 
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8.7 Literature search strategies for cost-utility articles 
Ovid MEDLINE(R) 1946 to Present with Daily Update, 23rd April, 2012 
Search strategy (number of hits): 
1     Arthritis, Rheumatoid/     (76115) 
2     (rheum$ adj (arthrit$ or arthropath$)).ti,ab.   (67563) 
3     1 or 2       (93337) 
4     (etanercept or enbrel or tnfr-fc).ti,ab,rn.   (4169) 
5     (infliximab or remicade).ti,ab,rn.    (6777) 
6     (adalimumab or humira or D2E7).ti,ab,rn.   (2281) 
7     (golimumab or simponi).ti,ab,rn.    (144) 
8     (tocilizumab or roactemra or ro-actemra).ti,ab,rn.  (417) 
9     (certolizumab or certolizumab pegol or cimzia).ti,ab,rn. (286) 
10     (rituximab or mabthera).ti,ab,rn.    (8305) 
11     (abatacept or orencia).ti,ab,rn.    (2102) 
12     4 or 5 or 6 or 7 or 8 or 9 or 10 or 11     (20282) 
13     3 and 12       (4211) 
14     economics/       (26255) 
15     exp "Costs and Cost Analysis"/    (163753) 
16     VALUE OF LIFE/      (5209) 
17     economics, dental/       (1837) 
18     exp economics, hospital/     (17845) 
19     economics, medical/     (8438) 
20     economics, nursing/      (3860) 
21     economics, pharmaceutical/      (2316) 
22     (econom$or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom$).ti,ab. 
          (129853) 
23     (expenditure$ not energy).ti,ab.    (14949) 
24     (value adj1 money).ti,ab.     (18) 
25     budget$.ti,ab.      (15206) 
26     14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 (301032) 
27     ((energy or oxygen) adj cost).ti,ab.     (2405) 
28     (metabolic adj cost).ti,ab.     (635) 
29     ((energy or oxygen) adj expenditure).ti,ab.   (13888) 
30     27 or 28 or 29      (16292) 
31     26 not 30       (300287) 
32     letter.pt.       (743838) 
33     editorial.pt.      (296310) 
34     historical article.pt.        (281817) 
35     32 or 33 or 34       (1308587) 
36     31 not 35        (278751) 
37     Animals/        (4916135) 
38     Humans/        (12224012) 
39     37 not (37 and 38) [Including Related Terms]   (17936) 
40     36 not 39        (278456) 
41     13 and 40         (196) 
42     limit 41 to yr="2008 -Current"     (85) 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <, 23rd April, 2012> 
Search Strategy (number of hits): 
1     (rheum$ adj (arthrit$ or arthropath$)).ti,ab.   (2856) 
2     (etanercept or enbrel or tnfr-fc).ti,ab,rn.   (267) 
3     (infliximab or remicade).ti,ab,rn.    (462) 
4     (adalimumab or humira or D2E7).ti,ab,rn.   (219) 
5     (golimumab or simponi).ti,ab,rn.    (20) 
6     (tocilizumab or roactemra or ro-actemra).ti,ab,rn.  (76) 
7     (certolizumab or certolizumab pegol or cimzia).ti,ab,rn.  (36) 
8     (rituximab or mabthera).ti,ab,rn.    (645) 
9     (abatacept or orencia).ti,ab,rn.     (36) 
10     2 or 3 or 4 or 5 or 6 or 7 or 8 or 9    (1439) 
11     1 and 10       (314) 
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12     (econom$or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom$).ti,ab. 
         (8466) 
13     (expenditure$ not energy).ti,ab.    (733) 
14     (value adj1 money).ti,ab.     (2) 
15     budget$.ti,ab.      (1456) 
16     12 or 13 or 14 or 15      (10213) 
17     11 and 16       (15) 
Web of knowledge, http://apps.webofknowledge.com, 23 rd April, 2012 
Number of hits and search strategy: 
# 7 250  
#5 NOT #6 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=2008-2012 
Lemmatization=On    
# 6 553,255  
TS=(animal or animals or dog or dogs or hamster* or mice or mouse or rat or rats or bovin or sheep 
or guinea*) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=2008-2012 
Lemmatization=On    
# 5 253  
#4 AND #3 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=2008-2012 
Lemmatization=On    
# 4 420,694  
TS=(econom* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom* 
or budget*) Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=2008-2012 
Lemmatization=On    
# 3 4,049  
#2 AND #1 Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=2008-2012 
Lemmatization=On    
# 2 15,363  
TS=(etanercept or enbrel tnfr-fc or infliximab or remicade or adalimumab or humira or D2E7 or 
golimumab or simponi or tocilizumab or roactemra or ro-actemra or certolizumab or certolizumab 
pegol or cimzia or rituximab or mabthera or abatacept or orencia) Databases=SCI-EXPANDED, 
SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=2008-2012 
Lemmatization=On    
# 1 27,503  
TS=((rheum* same arthrit*) or (rheum* same arthropath*)) Databases=SCI-EXPANDED, SSCI, 
A&HCI, CPCI-S, CPCI-SSH Timespan=2008-2012 Lemmatization=On     
Search http://www.crd.york.ac.uk/CRDWeb, 23rd April, 2012. 
Search strategy and number of hits: 
1 MeSH DESCRIPTOR Arthritis, Rheumatoid EXPLODE ALL TREES 400 
2 (((rheum* NEAR arthrit*) ) ) WHERE PD FROM 22/09/2008 TO 23/04/2012 368 
3 #1 OR #2         580 
4 ((etanercept OR enbrel OR infliximab OR remicade OR adalimumab OR humira OR D2E7 or 
tocilizumab OR roactemra OR ro-actemra OR certolizumab OR certolizumab pegol OR cimzia OR 
rituximab OR mabthera OR abatacept OR orencia)) WHERE PD FROM 22/09/2008 TO 23/04/2012 
255 
5 #3 AND #4         100 
 
8.8 Results of the health economic literature search (references and 
abstracts) 
 
See webpage: http://hecon.uni-corvinus.hu 
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